書籍詳細

序論 骨格系の分子制御機構の解明とその骨代謝学への応用

P.12 掲載の参考文献

• 1) Karp, S. J., Schipani, E., St-Jacques, B. et al.:Indian hedgehog coordinates endochondral bone growth and morphogenesis via parathyroid hormone related-protein-dependent and-independent pathways. Development 127:543-548, 2000
  pubmed

• 2) Pathi, S., Rutenberg, J. B., Johnson, R. L. et al.:Interaction of Ihh and BMP/Noggin signaling during cartilage differentiation. Dev. Biol. 209:239-253,1999
  pubmed

• 3) Zehentner, B. K., Dony, C., Burtsche, H.:The transcription factor Sox9 is involved in BMP-2 signaling. J. Bone Miner. Res. 14:1734-1741, 1999

• 4) Naski, M. C., Colvin, J. S., Coffin, J. d . et al:Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development 125:4977-4988, 1998
  pubmed

• 5) Inada, M., Yasui, T., Nomura, S. et al.:Maturational disturbance of chondrocytes in Cbfa1-deficient mice. Dev. Dyn. 214:279-290, 1999
  pubmed

• 6) 金谷直子, 上田千里, 岩本容泰ほか:Cbfa 1 トランスジェニックマウスにおける軟骨細胞の成熟と内軟骨性骨化の促進. 日本骨代謝学会雑誌 18:6, 2000

• 7) Takeda, S., Priemel, M., Amling, M. et al.:Ectopic bone formation in transgenic mice expressing Cbfa1 in chondrocytes. J. Bone Miner. Res. (Abstract) 15:S145(#1026), 2000

• 8) Yoshizawa, T., Handa, Y., Uematsu, Y. et al.:Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat. Genet. 16:391-396, 1997
  pubmed

• 9) Koyama, E., Golden, E. B., Kirsch, T. et al.:Retinoid signaling is required for chondrocyte maturation and endochondral bone formation during limb skeletogenesis. Dev. Biol. 208:375-391, 1999
  pubmed

• 10) Koyama, E., Iwamoto, M., Enomoto-Iwamoto, M. et al.:Regulation of indian hedgehog and Cbfa1 expression during chondrocyte maturation by retinoid signaling. J. Bone Miner. Res. (Abstract) 15:S145 (#1025), 2000

• 11) Komori, T., Yagi, H., Nomura, S. et al.:Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational-arrest of osteoblasts. Cell 89:755-764, 1997

• 12) Ducy, P., Zhang, R., Geoffroy, V. et al.:Osf2/Cbfa1:a transcriptional activator of osteoblast differentiation. Cell 89:747-754, 1997
  pubmed

• 13) Otto, F., Thornell, A. P., Crompton, T. et al.:Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89:765-771, 1997
  pubmed

• 14) Takeuchi, Y., Nakayama, K., Matsumoto, T.:Differentiation and cell surface expression of transforming growth factor-βreceptors are regulated by interaction with matrix collagen in murine osteoblastic cells. J. Biol. Chem. 271:3938-3944, 1996

• 15) Suzawa, M., Takeuchi, Y., Fukumoto, S. et al.:Extracellular matrix-associated bone morphogenetic proteins are essential for differentiation of murine osteoblastic cells in vitro. Endocrinology 140:2125-2133, 1999
  pubmed

• 16) Takeuchi, Y., Suzawa, M., Kikuchi, T. et al.:Differentiation and transforming growth factor-β receptor down-regulation by collagen-α2β1 integrin interaction is mediated by focal adhesion kinase and its downstream signals in murine osteoblastic cells. J. Biol. Chem. 272:29309-29316, 1997

• 17) Xiao, G., Jiang, D., Thomas, P. et al.:MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J. Biol. Chem. 275:4453-4459, 2000
  pubmed

• 18) 須澤美幸, 竹内靖博, 田村康博ほか:Ras/MAP キナーゼによる BMP/Smad1 を介する転写活性の促進作用. 日本骨代謝学会雑誌 16:24, 1998
  Medical*Online

• 19) 中山耕之介, 田村康博, 須澤美幸ほか:チロシンキナーゼ受容体-Ras-ERK シグナルによる BMP依存性 Smad6 プロモータ活性の抑制. 日本骨代謝学会雑誌 18:30, 2000

• 20) 井上大輔, 松本俊夫:骨吸収系における最近の知見. 日本臨床 56:1412-1418, 1998
  Medical*Online

• 21) Yasuda, H., Shima, N., Nakagawa, N. et al.:Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95:3597-3602, 1998
  pubmed

• 22) Lacey, D. L., Timms, E., Tan, H. L. et al.:Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176, 1998
  pubmed

• 23) Hsu, H., Lacey, d. L, Dunstan, C. R. et al.:Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96:3540-3545, 1999
  pubmed

• 24) Nakagawa, N., Kinosaki, M., Yamaguchi, K. et al.:RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun. 253:395-400, 1998
  pubmed

• 25) Simonet, W. S., Lacey, D. L., Dunstan, C. R. et al.:Osteoprotegerin:a novel secreted protein involved in the regulation of bone density. Cell 89:309-319, 1997
  pubmed

• 26) Yasuda, H., Shima, N., Nakagawa, N. et al.:Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG):a machanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329-1337, 1998

• 27) Kong, Y. Y., Yoshida, H., Sarosi, I. et al.:OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323, 1999
  pubmed

• 28) Li, j., Sarosi, I., Yan, X. Q. et al.:RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97:1566-1571, 2000
  pubmed

• 29) Dougall, W. C., Glaccum, M., Charrier, K. et al.:RANK is essential for osteoclast and lymph node development. Genes. Dev. 13:2412-2424, 1999
  pubmed

• 30) Kobayashi, K., Takahashi, N., Jimi, E. et al.:Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191:275-286, 2000

• 31) Jimi, E., Nakamura, I., Duong, L. T. et al.:Interleukin 1 induces multinucleation and bone resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp. Cell Res. 247:84-93, 1999
  pubmed

• 32) Kong, Y. Y., Feige, U., Sarosi, I. et al.:Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-309, 1999
  pubmed

• 33) Onoe, Y., Miyaura, C., Ohta, H. et al.:Expression of estrogen receptor β in rat bone. Endocrinology 138:4509-4512, 1997

• 34) Smith, E. P., Boyd, J., Frank, G. R. et al.:Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. N. Engl. J. Med. 331:1056-1061, 1994

• 35) Morishima, A., Grumbach, M. M., Simpson, E. R. et al.:Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J. Clin. Endocrinol. Metab. 80:3689-3698, 1995
  pubmed

• 36) Windahl, S. H., Vidal, O., Andersson, G. et al.:Increased cortical bone mineral content but unchanged trabacular bone mineral density in female ERβ (-/-) mice. J. Clin. Invest. 104:895-901, 1999

• 37) Vidal, O., Lindberg, M. K., Hollberg, K. et al.:Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice. Proc. Natl . Acad. Sci. USA 97:5474-5479, 2000
  pubmed

• 38) Kuro-o, M., Matsumura, Y., Aizawa, H. et al.:Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45-51, 1997
  pubmed

• 39) Kawaguchi, H., Manabe, N., Miyaura, C. et al.:Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia. J. Clin. Invest. 104:229-237, 1999
  pubmed

• 40) Kodama, Y., Takeuchi, Y., Suzawa, M. et al.:Reduced expression of interleukin-11 in bone marrow stromal cells of senescence-accelerated mice (SAMP6)-Relationship to osteopenia with enhanced adipogenesis-. J. Bone Miner. Res. 13:1370-1377, 1998
  pubmed

• 41) Weinstein, R. S., Jilka, R. L., Parfitt, A. M. et al.:Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects of bone. J. Clin. Invest. 102:274-282, 1998

• 42) Hofbauer, L. C., Gori, F., Riggs, B. L. et al.:Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells:potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140:4382-4389, 1999
  pubmed

• 43) Sakai, K., Mohtai, M., Shida, J. et al.:Fluid shear stress increases interleukin-11 expression in human osteoblast-like cells:its role in osteoclast induction. J. Bone Miner. Res. 14:2089-2098, 1999
  pubmed

• 44) Jensen, O. B., Bjarnason, N. H., Rosequist, C. et al.:Serum CrossLaps for monitoring the response anti-resorptive therapy in the individual patient. J. Bone Miner. Res. (Abstract) 14:S162 (#1119), 1999

• 45) Chapurlat, R. S., Garnero, P., Breart, G. et al.:Afternoon sampled serum CrossLaps predicts hip fracture in elderly women:The EPIDOS Study. J. Bone Miner. Res. 14:S162 (#1118), 1999

• 46) Nishi, Y., Atley, L., Eyre, D. E. et al.:Determination of bone markers in pycnodysostosis:Effects of cathepsin K deficiency on bone matrix degradation. J. Bone Miner. Res. (Abstract) 14:1902-1908, 1999

• 47) Ettinger, B., Black, D. M., Mitlak, B. H. et al.:Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene:results from a 3-year randomized Clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645, 1999
  pubmed

• 48) Cummings, S. R., Eckert, S., Krueger, K. A. et al.:The effect of raloxifene on risk of breast cancer in postmenopausal women:results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2819-2197, 1999

• 49) Walsh, B. W., Kuller, L. H., Wild, R. A. et al.:Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279:1445-1451, 1998
  pubmed

• 50) Roe, E. B., Sancez, S. D., del Puerto, G. A. et al.:Parathyroid hormone 1-34 (hPTH1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis-results from a placebo-controlled randomized trial. J. Bone Miner. Res. (Abstract) 14:S137 (#1019), 1999

第1章 骨・軟骨細胞の形成・分化の分子機構

P.49 掲載の参考文献

• 1) Poole, R.:関節軟骨と骨関節炎(藤沢隆一 訳). 蛋白質核酸酵素 40:56-67, 1995

• 2) 小澤英浩:骨. 軟骨の構造. 最新内科学体系 73:3-12, 1995

• 3) Schmidt, C., Christ, B., Patel, K. et al.:Experimental induction of BMP-4 expression leads to apoptosis in the paraxial and lateral plate mesoderm. Dev. Biol. 202(2):253-263, 1998
  pubmed

• 4) Macias, D., Ganan, Y., Sampath, T. K. et al.:Role of BMP-2 and OP-1 (BMP-7) in programmed cell death and skeletogenesis during chick limb development. Development 124(6):1109-1117, 199

• 5) Buckland, R. A., Collinson, J. M., Graham, E. et al.:Antagonistic effects of FGF 4 on BMP induction of apoptosis and chondrogenesis in the chick limb bud. Mech. Dev. 71(1-2):143-150, 1998

• 6) Zuniga, A., Haramis, A. P., McMahon, A. P. et al.:Signal relay by BMP antagonism controls the SHH/FGF4 feedback loop in vertebrate limb buds. Nature 401 (6753):598-602, 1997

• 7) Murtaugh, L. C., Chyung, J. H., Lassar, A. B.:Sonic hedgehog promotes somitic chondrogenesis by altering the cellular response to BMP signaling. Genes Dev. 13(2):225-237, 1999
  pubmed

• 8) Mo, R., Freer, A. M., Zinyk, D. L. et al.:Specific and redundant functions of Gli2 and Gli3 zinc finger genes in skeletal patterning and Development. Development 124(1):113-123, 1997
  pubmed

• 9) Rintala, M., Metsaranta, M., Saamanen, A. M. et al.:Abnormal craniofacial growth and early mandibular osteoarthritis in mice harbouring a mutant type II collagen transgene. J. Anat. 190:201-208, 1997
  pubmed

• 10) Saamanen, A. M., Tammi, M., Jurvelin, J. et al.:Proteoglycan alterations following immobilization and remobilization in the articular cartilage of young canine knee (stifle) joint. J. Orthopaedic Res. 8(6):863-873, 199

• 11) Kato, Y., Nomura, Y., Daikuhara, Y. et al.:Cartilage-derived factor (CDF) I. Stimulation of proteoglycan synthesis in rat and rabbit costal chondrocytes in culture. Exp. Cell Res. 130 (1):73-81, 1980
  pubmed

• 12) Kato, Y., Watanabe, R., Nomura, Y. et al.:Effect of bone-derived growth factor on DNA, RNA, and proteoglycan synthesis in cultures of rabbit costal chondrocytes. Metabol. Clin. Exp. 31 (8):812-815, 1982

• 13) Nakamura, H., Ozawa, H.:Immunohistochemical localization of heparan sulfate proteoglycan in rat tibiae. J. Bone Miner. Res. 9(8):1289-1299, 1994
  pubmed

• 14) Hiraki, Y., Tanaka, H., Inoue, H. et al.:Molecular cloning of a new class of cartilage-specific matrix, chondromodulin-I, which stimulates growth of cultured chondrocytes. Biochem. Biophys. Res. Commun. 175:971-977, 1991
  pubmed

• 15) Gerber, H. P., Vu, T. H., Ryan, A. M. et al.:VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 5(6):623-628, 1999
  pubmed

• 16) Vu, T. H., Shipley, J. M., Bergers, G. et al.:MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93(3):411-422, 1998
  pubmed

• 17) Simonet, W. S., Lacey, D. L., Dunstan, C. R. et al.:Osteoprotegerin:a novel secreted protein involved in the regulation of bone density. Cell 89(2):309-319, 1997
  pubmed

• 18) Ikeda, T., Nomura, S., Yamaguchi A. et al.:In situ hybridization of bone matrix proteins in undercalcified adult rat bone sections. J. Histochem. Cytochem. 40:1079-1088, 1992

• 19) Wuthier, R. E.:The role of phospholipids in biological calcification:distribution of phospholipase activity in calcifying epiphyseal cartilage. Clin. Orthop. Res. 90:191-200, 1973
  pubmed

• 20) Wuthier, R. E.:Proposed mechanism of matrix vesicle formation and vesicle-mediated mineralization. (Ascenzi A., Bonucci E., Bernard B. eds.:matrix vesicles) Wichting Editore srl., Milano, 1981, p.103

• 21) 須田立雄, 小澤英浩, 高橋栄明:骨の科学. 医歯薬出版, 1986

• 22) Fleish, H., Neuman, W. F.:Mechanisms of calcification:role of collagen, polyphosphates, and phosphate. Am. J. Physiol. 200:1296-1300, 1961
  pubmed

• 23) Arana-Chavez, V. E., Soares, A. M. V., Katchburian, E.:Junctions between early developing osteoblasts of rat calvaria as revealed by freeze-fracture and ultrathin section electron microscopy. Arch. Histol. Cytol. 58(3):285-292, 1995

• 24) Tsukita, S., Oishi, K., Akiyama, T. et al.:Specific proto-oncogenic tyrosine kinases of src family are enriched in cell-to-cell adherens junctions where the level of tyrosine phosphorylation is elevated. J. Cell Biol. 113:867-879, 1991
  pubmed

• 25) Lee, Y. S., Chuong, C. M.:Adhesion molecules in skeletogenesis:I. Transient expression of neural cell adhesion molecules (NCAM) in osteoblasts during endochondral and intramembranous ossification. J. Bone Miner. Res. 7:1435-1446, 1992
  pubmed

• 26) Nakamura, H., Kenmotsu, S., Sakai, H. et al.:Localization of CD 44, the hyaluronate receptor, on the plasma membrane of osteocytes and osteoclasts in rat tibiae. Cell. Tissue Res. 280:225-233, 1995

• 27) Clover, J., Dodds, R. A., Gowen, M.:Integrin subunit expression by human osteoblasts and osteoclasts in situ and in culture. J. Cell Sci. 103:267-271, 1992
  pubmed

• 28) Grzesik, W. J., Robey, P. G.:Bone Matrix RGD Glycoproteins:Immunolocalization and interaction with human primary osteoblastic bone cells in vitro. J. Bone Miner. Res. 9:487-496, 1994
  pubmed

• 29) Katagiri, T., Yamaguchi, A., Komaki, M. et al.:Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J. Cell Biol. 127(6):1755-1766, 1994
  pubmed

• 30) Wang, E. A., Israel, D. I., Kelly, S. et al.:Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 land 3T3 cells. Growth Factors 9(1):57-71, 1993

• 31) Winnier, G., Blessing, M., Labosky, P. A. et al.:Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. Genes Dev. 9(17):2105-2116, 1995
  pubmed

• 32) Tanaka, M., Amizuka, N. Kim, K. J. et al.:Histochemical Examination of Ectopic Bone Formation Induced in Rat Bone Marrow. J. Bone Miner. Metab. 15:67-76, 1997

• 33) Amizuka, N., Yamada, M., Watanabe, J. et al.:Morphological examination of bone synthesis via direct administration of basic fibroblast growth factor into rat bone marrow. Micro. Res. Tech. 41:313-322, 1998

• 34) Nagai, H., Tsukuda, R., Mayahara, H.:Effects of basic fibroblast growth factor (bFGF) on bone formation in growing rats. Bone 16:367-373, 1995

• 35) Peters, K., Ornitz, D., Werner, S. et al.:Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis. Dev. Biol. 155:423-430, 1993
  pubmed

• 36) Peters, K. G., Werner, S., Chen, C. et al.:Two FGF receptor genes are differentially expressed in epitheila and mesenchymal tissues during limb formation and organogenesis in the mouse. Develoment 114:233-243, 1992

• 37) Miles, R. R., Turner, C. H., Santerre, R. et al.:Analysis of differential gene expression in rat tibia after an osteogenic stimulus in vivo:mechanical loading regulates osteopontin and myeloperoxidase. J. Cell. Biochem. 68(3):355-365, 1998
  pubmed

• 38) Chow, J. W. M., Wilson, T. J., Chambers, T. J. et al.:Mechanical loading stimulates bone formation by reactivation of bone lining cells in 13-week-old rats. J. Bone Miner. Res. 13(11):1760-1767, 1998

• 39) Fitzsimmons, R. J., Ryaby, J. T., Magee, F. P. et al.:IGF-II receptor number is increased in TE-85 osteosarcoma cells by combined magnetic fields. J. Bone Miner. Res. 10(5):812-819, 1995
  pubmed

• 40) Shinar, D. M., Endo, N., Halperin, D. et al.:Differential expression of insulin like growth factor-I (IGF-I) and IGF-II messenger ribonucleic acid in growing rat bone. Endocrinology 132(3):1158-1167, 1993
  pubmed

• 41) Jackson, S. M., Demer. L. L.:Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Lett. 471(1):119-124, 2000
  pubmed

• 42) Hara, F., Fukuda, K., Ueno, M. et al.:Pertussis toxin-sensitive G proteins as mediators of stretch induced decrease in nitric-oxide release of osteoblast-like cells. J. Orthop. Res. 17(4):593-597, 1999

• 43) Sato, M., Ochi, T., Nakase, T. et al.:Mechanical tension-stress induces expression of bone morphogenetic protein (BMP)-2 and BMP-4, but not BMP-6, BMP-7, and GDF-5 mRNA, during distraction osteogenesis. J. Bone Miner. Res. 14(7):1084-1095, 1999

• 44) Ikegame, M., Ishibashi, O., Yoshizawa, T. et al.:Tensile stress induces bone morphogenetic protein 4 (BMP-4) in preosteoblastic and fibroblastic cells, which later differentiate into osteoblasts leading to osteogenesis in the mouse calvariae in organ culture. J. Bone Miner. Res. (in press)

• 45) Horiuchi, K., Amizuka, N., Takeshita, S. et al.:Identification and characterization of a novel protein, Periostin (OSF-2) with restricted expression to periosteum and periodontal ligament and increased expression by transforming factor. J. Bone Miner. Res. 14:1239-1249, 1999

• 46) Mark, M. P., Butler, W. T. et al.:Developmental expression of 44-kDa phosphoprotein (osteopontin) and boneγ-carboxyglutamic acid (Gla)-containin protein (osteocalcin) in calcifying tissues of rat. Differentiation 37:123-136, 1988

• 47) Bosky, A. L, Maresca, M., Ullrich, W. et al.:Osteopontin-hydroxyapatite interactions in vitro:Inhibition of hydroxyapatite formation and growth in a gelatin-gel. Bone Miner. 22:147-159, 1993

• 48) Nomura, S., Wills, A. J., Edwards, D. R. et al.:Developmental expression of 2ar (osteopontin) and SPARC (osteonectin) RNA as revealed by in situ hybridization. J. Cell Biol. 106:441-450, 1988
  pubmed

• 49) McKee, M. D., Nanci, A.:Post-embedding colloidal-gold immunocytochemistry of non-collagenous extracellualr matrix proteins in mineralized tissues. Microsc. Res. Tech. 31:44-62, 1995

• 50) McKee, M. D., Nanci, A.:Osteopontin at mineralized tissue interfaces in bone teeth and osteointegrated implants:Ultrastructural distribution and implications for mineralized tissue formation, turnover and repair. Microsc. Res. Tech. 33:141-164, 1996

• 51) Ducy, P., Desbois, C., Boyce, B. et al.:Increased bone formation in osteocalcin-deficient mice. Nature 382(6590):448-452, 1996
  pubmed

• 52) Luo, G., Ducy, P., McKee, M. D. et al.:Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386(6620):78-81, 1997
  pubmed

• 53) Yoshitake, H., Rittling, S. R., Denhardt, D.T. et al.:Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc. Natl. Acad. Sci. USA 96(14):8156-8160, 1999
  pubmed

• 54) Asou, Y., Amizuka, N., Yamashita, T. et al.:Osteopontin-deficient bone is defective in angiogenesis, osteoclast recruitment and ectopic resorption. J. Bone Miner. Res. 14:s133, 1999

• 55) McKee, M. D., Farach-Carson, M. C., Butler, W. T. et al.:Ultrastructural immunolocalization of non-collagenous (osteopontin and osteocalcin) and plasma (albumin and α2HS-glycoprotein) proteins in rat bone. J. Bone Miner. Res. 8:485-496, 1993

• 56) Hamilton, J. A., Lingelbach, S. R., Partridge, N. C. et al.:Stimulation of plasminogen activator in osteoblast-like cells by bone-resorbing hormones. Biochem. Biophys. Res. Commun. 122:230-236, 1984
  pubmed

• 57) Jilka, R. L., Weinstein, R. S., Bellido, T. et al.:Osteoblast programmed cell death (apoptosis):modulation by growth factors and cytokines. J. Bone Miner. Res. 13(5):793-802, 1998
  pubmed

• 58) Aarden, E. M., Wassenaar, A. M., Alblas, M. J. et al.:Immunocytochemical demonstration of extracellular matrix proteins in isolated osteocytes. Histochem. Cell Biol. 106(5):495-501, 1996
  pubmed

• 59) Aarden, E. M., Burger, E. H., Nijweide, P. J.:Function of osteocytes in bone. J. Cell. Biochem. 55(3):287-299, 1994

• 60) Doty, S. B.:Morphological evidence of gap junctions between bone cells. Calcif. Tissue Int. 33:509-512, 1981
  pubmed

• 61) Palumbo, C., Palazzini, S., Marotti, G.:Morphological study of intercellular junctions during osteocyte differentiation. Bone 11:401-406, 1990
  pubmed

• 62) Belanger, L. F.:Osteocytic osteolysis. Calcif. Tissues Res. 4:1-12, 1969
  pubmed

• 63) Pollak, M. R., Brown, E. M., Chou, Y. H. et al.:Mutations in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism Cell 75:1297-1303, 1993
  pubmed

• 64) Desfleurs, E., Wittner, M., Simeone, S. et al.:Calcium-sensing receptor:regulation of electrolyte transport in the thick ascending limb of Henle's loop. Kidney & Blood Pressure Research 21(6):401-412, 1998
  pubmed

• 65) 真野 博, 前島朋子, 久米川正好:骨細胞(osteocyte)を介するシグナリング, 骨形成 ・吸収のシグナリングと骨疾患. 実験医学 14(10):103-108, 1996

• 66) Chambers, T. J., Ali, N. N.:Inhibition of osteoclastic motility by prostaglandins I2, E1, E2 and 6-oxo-E1. J. Pathol. 139:383-389, 1983
  pubmed

• 67) Rawlinson, S. C., Mosley, J. R., Suswillo, R. F. et al.:Calvarial and limb bone cells in organ and monolayer culture do not show the same early responses to dynamic mechanical strain. J. Bone Miner. Res. 10:1225-1232, 1995
  pubmed

• 68) Rawlinson, S. C., Mohan, S., Baylink, D. J. et al.:Exogenous prostacyclin, but not prostaglandin E2, produces similar responses in both G6Pd activity and RNA production as mechanical loading, and increases IGF-II release, in adult cancellous bone in culture. Calcif. Tissue Int. 53:324-329, 1993

• 69) Lean, J. M., Mackay, A. G., Chow, J. W. et al.:Osteocytic expression of mRNA for c-fos and IGF-I:an immediate early gene response to an osteogenic stimulus. Am. J. Physiol. 270:E937-E945, 1996

• 70) Ypey, D. L., Weidema, A. F., Nijweide, P. J. et al.:Voltage, calcium, and stretch activated ionic channels and intracellular calcium in bone cells. J. Bone Miner. Res. 7 (Suppl.2):S377-S387, 1992

• 71) Resnick, N., Collins, T., Atkinson, W. et al.:Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element. Proc. Natl. Acad. Sci. USA 90:4591-4595, 1993
  pubmed

• 72) Drake, F. H., Dodds, R. A., James, I. E. et al.:Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J. Biol. Chem. 271(21):12511-12516, 1996

• 73) Minkin, C.:Bone acid phosphatase:tratrate resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int. 34:285-290, 1982

• 74) Salo, J., Lehenkari, P., Mulari, M. et al.:Removal of osteoclast bone resorption products by transcytosis. Science 276:270-273, 1997
  pubmed

• 75) Nesbitt, S. A., Horton, M. A.:Trafficking of matrix collagens through bone-resorbing osteoclasts. Science 276:266-269, 1997
  pubmed

• 76) Nakamura, H., Ozawa, H.:Ultrastructural, enzyme-, lectin-and imunohistochemical studies of the erosion zone in rat tibiae. J. Bone Miner. Res. 11:1158-1164, 1996

• 77) Nakamura, H., Kenmotsu, S., Sakai, H. et al:Localization of CD44, the hyaluronate receptor, on the plasma membrane of osteocytes and osteoclasts in rat tibiae. Cell. Tissue Res. 280:225-233, 1995
  pubmed

• 78) Nakamura, H., Moriyama, Y., Futai, M. et al.:Immunohistochemical localization of vacuolar H+-ATPase in osteoclasts of rat tibiae. Arch. Histol. Cytol. 57:535-539, 1994
  pubmed

• 79) Baron, R., Neff, L, Brown, W. et al.:Cell-mediated extracellular acidification and bone resorption:evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. J. Cell Biol. 101:2210-2222, 1985

• 80) Chambers, T. J., Revell, P. A., Fuller, K. et al.:Resorption of bone by isolated rabbit osteoclasts. J. Cell Sci. 66:383-399, 1984
  pubmed

• 81) Akatsu, T., Takahashi, N., Debari, K. et al.:Prostaglandins promote osteoclast like cell formation by a mechanism involving cyclic adenosine 3',5'-monophosphate in mouse bone marrow cell cultures. J. Bone Miner. Res. 4(1):29-35, 1989
  pubmed

• 82) Goto, T., Tsukuba, T., Kiyoshima, T. et al.:Immunohistochemical localization of cathepsins B, D and L in the rat osteoclast. Histochemistry 99(5):411-414, 1993
  pubmed

• 83) Kakudo, S., Mano, H., Shiokawa, M. et al.:Concanavalin A directly stimulates bone-resorbing activity of osteoclasts and their gene expression of cathepsin K/OC-2. Biochem. Biophys. Res. Commum. 234 (3):600-604, 1997

• 84) Horton, M. A., Nesbit, M. A., Helfrich, M. H.:Interaction of osteopontin with osteoclast integrins. Ann. N. Y. Acad. Sci. 760:190-200, 1995
  pubmed

• 85) Reponen, P., Sahlberg, C., Munaut, C. et al.:High expression of 92 kD type IV collagenase (gelatinasel B) in the osteoclast lineage during mouse development. J. Cell Biol. 124:1091-1103, 1994
  pubmed

• 86) Okada, Y., Naka, K., Kawamura, K. et al.:Localization of matrix metalloproteinase 9 (92= kilodalton gelatinase/type IV collagenase=gelatinase B) in osteoclasts:Implications for bone resorption. Lab. Invest. 72:311-323, 1995
  pubmed

• 87) Ejiri, S.:The preosteoclast and its cytodifferentiation into the osteoclast:ultrastructural and histochemical studies of rat fetal parietal bone. Arch. Histol. Jap. 46:533-577, 1983
  pubmed

• 88) Burger, E. H., van der Meer, J. W., Nijweide, P. J. et al.:Osteoclast fromation from mononuclear phagocytes:role of bone-forming cells. J. Cell Biol. 99:1901-1906, 1984

• 89) Fuller, K., Gallagher, A. C., Chambers, T. J.:Osteoclast resorption stimulating activity is associated with the osteoblast cell surface and/or the extracellular matrix. Biochem. Biophys. Res. Commun. 181:67-73, 1991
  pubmed

• 90) Yasuda, H., Shima, N., Nakagawa, N. et al.:Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95(7):3597-3602, 1998
  pubmed

• 91) Kodama, H., Nose, M., Niida, S. et al.:Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J. Exp. Med. 173:1291-1294, 1991
  pubmed

• 92) Ikegame, M., Ejiri, S., Ozawa, H.:Histochemical and autoradiographic studies on Elcatonin in internalization and intracellular movement in osteoclasts. J. Bone Miner. Res. 9(1):25-37, 1994
  pubmed

• 93) Warshawsky, H., Goltzman, D., Rouleau, M. F. et al.:Direct in vivo demonstration by radioautography of specific binding sites for calcitonin. J. Cell Biol. 85:682-694, 1980
  pubmed

• 94) Hughes, D. E, Wright, K. R., Uy, H. L et al.:Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 10 (10):1478-1487, 1995
  Medical*Online
  pubmed

• 95) Hara-Irie, F, Amizuka, N, Ozawa, H.:Immunohistochemical and ultrastructural localization of CGRP-positive nerve fibers at the distal trabecules facing the growth plate of rat femurs. Bone 18:29-39, 1996

• 96) Tran, V. P., Vignery, A., Baron, R.:An electron-microscopic study of the bone-remodeling sequence in the rat. Cell Tissue Res. 225 (2):283-292, 1982

• 97) Wu, C.-H., Hara, K., Ozawa, H.:Enhanced osteoinduction by intramuscular grafting of BMP-β-TCP-compound pellets into murine models. Arch. Histol. Cytol. 55:97-112, 1992

• 98) Okuda, K., Nakajima, Y., Irie, K. et al.:Transforming growth factoer β-1 coated β-tricalcium phosphate pellets are osteoinductive in experimental bone defects of rat calvaria. Oral Dis. 1:92-97, 1995

P.65 掲載の参考文献

• 1) 須田立雄:硬組織の形成と吸収のしくみ. 口腔生化学, 第二版. (早川太郎, 須田立雄 編)医歯薬出版, 1994, p.89-111

• 2) Suzuki, F., Yoneda, T., Shimomura, Y.:Calcitonin and parathyroid hormone stimulation of acid mucopolysaccharide synthesis in cultured chondrocytes isolated from growth cartilage. FEBS Lett. 70:155-158, 1976
  pubmed

• 3) Takigawa, M., Takano, T., Suzuki, F.:Effect of parathyroid hormone and cyclic AMP analogues on the activity of ornithine decarboxylase and expression of the differentiated phenotype of chondrocytes in culture. Cell. Physiol. 106:259-268, 1981
  pubmed

• 4) Takigawa, M., Ishida, H., Takano, T. et al.:Polyamine and differentiation:Induction of ornithine decarboxylase by parathyroid hormone is a good marker of differentiated chondrocytes. Proc. Natl. Acad. Sci. USA 77:1481-1485, 1980
  pubmed

• 5) 滝川正春, 鈴木不二男:軟骨細胞-細胞培養を中心に. 最新組織培養応用研究法, in vitro アッセイと有用物質生産. (山根績 編)ソフトサイエンス社, 1985, p.116-128

• 6) Kato, Y., Shimazu, A., Nakashima, K. et al.:Effect of parathyroid hormone and calcitonin on alkaline phosphatase activity and matrix calcificaton in rabbit growth-plate chondrocyte cultures. Endocrinol. 127:114-118, 1990

• 7) Enomoto, M., Kinoshita, A., Pan, H.-O. et al.:Demonstration of receptors for parathyroid hormone on cultured rabbit costal chondrocytes. Biochem. Biophys. Res. Commun. 162:1222-1229, 1989
  pubmed

• 8) Koike, T., Iwamoto, M., Shimazu, A. et al.:Potent mitogenic effects of parathyroid hormone (PTH) on embryomic chick and rabbit chondrocytes. J. Clin. Invest. 85:626-631, 1990

• 9) Juppner, H., Abou-Samra, A.-B., Freeman, M. et al:A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254:1024-1026, 1991

• 10) Abou-Samra, A.-B., Juppner, H., Force, T. et al.:Expression cloning of common receptor for parathyriod hormone and parathyroid hormone-related peptide from rat osteoblast-like cells:A single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proc. Natl. Acad. Sci. USA 89:2732-2736, 1992

• 11) Urena, P., Kong, X.-F., Abou-Samra, A.-B. et al.:Parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acids are widely distributed in rat tissues. Endocrinol. 133:617-623, 1993

• 12) Lee, C., Gardella, T. J., Abou-Samra, A.-B. et al.:Role of the extracellular regions of the parathyriod hormone (PTH)/PTH-related peptide receptor in hormone binding. Endocrinol. 135:1488-1495, 1994

• 13) Schipani, E., Kruse, K., Juppner, H.:Aconstitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 268:98-100, 1995
  pubmed

• 14) Lanske, B., Karaplis, A., Luz, A. et al.:Characterization of mice heterozygous for the parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor gene knockout. Bone 16:86S, 1995

• 15) Takahashi, O. K., Okamoto, T., Krane, S. M. et al.:Stimulation by glycocorticoids of the differentiated phenotype of chondrocytes and the proliferation of rabbit costal chondrocytes in culture. Bone 16:87S, 1995

• 16) Takigawa, M., Enomoto, M., Shirai, E. et al.:differential effects of 1α, 25-dihydroxycholecalciferol and 24R, 25-dihydroxycholecalciferol on the proliferation and the differential phenotype of rabbit costal chondrocytes in culture. Endocrinol. 122:831-839, 1988

• 17) Yoshizawa, T., Handa, Y., Uematsu, Y. et al.:Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat. Genet. 16:391-396, 1997
  pubmed

• 18) 滝川正春:ヒト軟骨肉腫由来の軟骨培養細胞株(HCS-2/8). The Bone 12:37-43, 1990

• 19) Enomoto, M., Takigawa, M.:Regulation of tumor-derived and immortalized chondrocytes. Biological Regulation of the Chondrocyte. (Adolphe, M. ed. ) CRC press, Boca Raton, Florida, 1992, p.321-338

• 20) 高橋浩二郎, 滝川正春:軟骨と成長の制御. CLINICAL CALCIUM 5:29-32, 1995

• 21) Enomoto, M., Pan, H.-O., Suzuki, F. et al:Physiological role of vitamin A in growth cartilage cells:Low concentrations of retinoic acid strongly promote the proliferation of rabbit costal growth cartilage cell in culture. J. Biochem. 107:743-748, 1990

• 22) Iwamoto, M., Golden, E. B., Adams, S. L. et al.:Responsiveness to retinoic acid changes during chondrocyte maturation. Exp. Cell Res. 205:213-224, 1993
  pubmed

• 23) 野地澄晴, 吉岡秀文, 谷口茂彦:発生分化とレチノイン酸レセプター. 実験医学 10:2368-2369, 1992

• 24) Saitou, M., Sugai, S., Tanaka, T. et al.:Inhibition of skin development by targeted expression of adominant-negative retinoic acid receptor. Nature 374:159-162, 1995

• 25) Trippel, S. T.:Role of IGF in the regulation of chondrocyte. Biological Regulation of the Chondrocyte. (Adolphe, M. ed.) CRC Press, Boca Raton, Florida, 1992, p.161-190

• 26) Klangsbrun, M., Langer, R., Levenson, R. et al.:The stimulation of DNA and cell division in chondrocytes and 3T3 cells by a growth factor isolated from cartilage. Exp. Cell Res. 105:99-108, 1977

• 27) Lobb, R., Sasse, J., Sullivan, R. et al.:Purification and characterization of heparine-binding endothelial cell growth factors. J. Biol. Chem. 261:1924-1928, 1986
  pubmed

• 28) Kato, Y., Iwamoto, M.:Fibroblast growth factor is an inhibitor of chondrocyte terminal Differentiation. J. Biol. Chem. 265:5903-5909, 1990
  pubmed

• 29) Iwamoto, M., Shimazu, A., Nakashima, K. et al.:Reduction of basic fibroblast growth factor receptor is coupled with terminal differentiation of chondrocytes. J. Biol. Chem. 266:461-467, 1991
  pubmed

• 30) Erlebacher, A., Filvaroff, E. H., Gitelman, S. E. et al.:Toward a molecular understanding of skeletal development. Cell 80:371-378, 1995

• 31) Noda, M., Camilliere, J. J.:In vivo stimulation of bone formation by transforming growth factor-β. Endocrinol. 24:2991-2994, 1989

• 32) Gitelman, S. E., Kobrin, M. S. Ye, J.-Q. et al.:Recombinant Vgr-1/BMP-6-expressing tumors induce fibrosis and endochondral bone in vivo. J. Cell Biol. 126:1595-1609, 1994
  pubmed

• 33) Chang, S. C., Hoang, B., Thomas, J. T. et al.:Cartilage-delived morphogenetic proteins (new members of the transforming growth factor-β superfamily predominantly expressed in long bones during human embryonic development) J. Biol. Chem. 269:28227-28234, 1994

• 34) Tsumaki, N., Tanaka, K., Arikawa-Hirasawa, E. et al.:Role of CDMP-1 in skeletal morphogenesis:promotion of mesenchymal cell recruitment and chondrocyte differentiation. J. Cell Biol. 144:161-173, 1999
  pubmed

• 35) Nakanishi, T., Kimura, Y., Tamura, T. et al.:Cloning of a mRNA preferentially expressed in chondrocytes by differential display-PCR from a human chondrocytic cell line that is identical with connective tissue growth factor (CTGF) mRNA. Biochem. Biophys. Res. Commun. 234:206-210, 1997
  pubmed

• 36) 中西徹, 滝川正春:結合組織成長因子CTGF/Hcs 24の生理機能-内軟骨性骨化における役割. 生化学 71:429-432, 1999

• 37) Nakanishi, T., Nishida, T., Shimo, T. et al.:Effects of CTGF/Hcs24, a product of a hypertrophic chondrocyte-specific gene, on the proliferation and differentiation of chondrocytes in culture. Endocrinol. 141:264-273, 2000

• 38) Shimo, T., Nakanishi, T., Nishida, T. et al.:Connective tissue growth factor induces the proliferation, migration and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. J. Biochem. 126:137-145, 1999
  pubmed

• 39) Gerber, H. P., Vu, T. H., Ryan, A. M. et al.:VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 5:623-628, 1999
  pubmed

• 40) Takigawa, M., Nishida, Y., Suzuki, F. et al.:Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP and TIMP-2) . Biochem. Biophys. Res. Commun. 171:1264-1271, 1990
  pubmed

• 41) Takigawa, M., Shirai, E., Enomoto, M. et al.:Cartilage-derived anti-tumor factor (CATF):Partial purification and correlation of inhibitory activity against tumor growth with anti-angiogenic activity. J. Bone Miner. Metabol. 6:83-92, 1988

• 42) Takigawa, M., Pan, H.-O., Enomoto, M. et al.:Aclonal human chondrosarcoma cell line produces an anti-angiogenic antitumor factor. Anticancer Res. 10:311-316, 1990

• 43) Ohba, Y., Goto, Y., Kimura, Y. et al.:Purification of an angiogenesis inhibitor from culture medium conditioned by a human chondrosarcoma-derived chondrocytic cell line, HCS-2/8. Biochim. Biophys. Acta 1245:1-8, 1995
  pubmed

• 44) Vortkamp, A., Lee, K., Lanske, B. et al.:Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science 273:613-622, 1996
  pubmed

• 45) St Jacques, B., Hammerschmidt, M., McMahon, A. P.:Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev. 13:2072-2086, 1999
  pubmed

• 46) Karp, S. J., Schipani, E., St Jacques, B. et al.:Indian hedgehog coordinates endochondral bone growth and morphogenesis via parathyroid hormone related-protein-dependent and-independent pathways. Development 127:543-548, 2000
  pubmed

• 47) Kimata, K., Barrach, H. J., Brown, K. S. et al.:Absence of proteoglycan core protein in cartilage from the cmd/cmd (cartilage matrix deficiency) mouse. J. Biol. Chem. 256:6961-6968, 1981
  pubmed

• 48) Sandell, L. J., Morris, N., Robbins, J. R. et al.:Alternative speliced type II procollagen mRNAs define distrct populations of cells during vertebral development:Differential expression of the amino-propeptide. J. Cell Biol. 114:1307, 1991

• 49) Tuckwell, D. S., Ayad, S., Grant, M. E. et al.:Conformation dependence of integrin-type II collagen binding, Inability of collagen peptides to support α2β1 binding, and mediation of adhesion to denatured collagen by a novel α5β1-fibronectine bridge. J. Cell Sci. 107:993-1005, 1994

• 50) Chan, D., Cole, W. G., Chow, C. W. et al.:ACOL2A1 mutation in achondrogenesis type II results in the replacement of type II collagen by type I and III collagens in cartilage. J. Biol. Chem. 270:1714-1753, 1995

• 51) Rosati, R., Horan, G. S. B., Pinero, G. J. et al.:Normal long bone growth and development in type X collagen-null mice. Nat. Genet. 8:129-135, 1994

• 52) Li, Y., Lacerda, D. A., Warman, M. L. et al.:A fibrillar collagen gene, Col11a1, is essential for skeletal morphogenesis. Cell 80:423-430, 1995
  pubmed

• 53) Vikkula, M., Mariman, E. C. M., Lui, V. C. H. et al.:Autosomal dominant and recessive osteochondrodysplasias associated with the COL11A2 locus. Cell 80:431-437, 1995

• 54) Lefebvre, V., de Crombrugghe, B.:Toward understanding SOX9 function in chondrocyte differentiation. Matrix Biol. 16:529-540, 1998
  pubmed

• 55) Lefebvre, V., Li, P., de Crombrugghe, B.:A new long form of Sox5 (L-Sox5), Sox6 and Sox9 are coexpressed in chondrogenesis and cooperatively activate the type II collagen gene. EMBO J. 17:5718-5733, 1998
  pubmed

• 56) Asp, J., Thornemo, M., Inerot, S. et al.:The helix-loop-helix transcription factors Id1 and Id3 have a functional role in control of cell division in human normal and neoplastic chondrocytes. FEBS Lett. 438:85-90, 1998
  pubmed

• 57) Nakazawa, M., Hasunuma, T., Ohshima, T. et al.:CBP:Atarget molecule of HTLV-1 Tax in synoviocyte activation. Biochem. Biophys. Res. Commun. 269:584-590, 2000

• 58) Enomoto, H., Enomoto-Iwamoto, M., Iwamoto, M. et al.:Cbfa 1 is a positive regulatory factor in chondrocyte maturation. J.Biol. Chem. 275:8685-8702, 2000

• 59) Takigawa, M., Tajima, K., Pan, H.-O. et al.:Establishment of a clonal human chondrosarcoma cell line with cartilage phenotypes. Cancer Res. 49:3996-4002, 1989
  pubmed

• 60) 滝川正春:HCS-2/8, バイオテクノロジー素材としての培養細胞. 骨代謝(I). (久米川正好 編) 蛋白質核酸酵素 34:898-900, 1989

• 61) 滝川正春:軟骨培養細胞株の樹立. 組織培養 15:165-169, 1989

• 62) Zhu, J., Pan, H.-O., Suzuki, F. et al.:Proto-oncogene expression in a human chondrosarcoma cell line:HCS-2/8. Jpn. J. Cancer Res. 85:364-371, 1994

P.77 掲載の参考文献

• 1) Cooper, E. L., Klempau, A. E., Ramirez, J. A. et al.:Source of stem cells in evolution. In:development and differentiation of vertebrate lymphocytes. (Horton, J. D. ed. ) Elsevier/North-Holland, Amsterdam, 1980, p.3-14

• 2) Kurokawa, K.:The kidney and calcium homeostasis. Kidney Int. 45:97-105, 1994

• 3) Medvinsky, A., Dzierzak, E.:definitive hematopoiesis is autonomously initiated by the AGM region. Cell 86:897-906, 1996
  pubmed

• 4) Yoder, M. C., Hiatt, K., Mukherjee, P.:In vivo repopulating hematopoietic stem cells are present in the murine yolk sac at day 9.0 postcoitus. Proc. Natl. Acad. Sci. USA 94:6776-6780, 1997

• 5) Yoder, M. C., Hiatt, K., Dutt, P. et al.:Characterization of definitive lymphohematopoietic stem cells in the day 9 murine yolk sac. Immunity 7:335-344, 1997
  pubmed

• 6) Godin, I., Dieterlen-Lievre, F., Cumano, A.:Emergence of multipotent hemopoietic cells in the yolk sac and paraaortic splanchnopleura in mouse embryos, beginning at 8.5 day postcoitus. Proc. Natl. Acad. Sci. USA 92:773-777, 1995

• 7) Cumano, A., Franise Dieterlen-Lievre, F., Godin, I.:Lymphoid potential, probed before circulation in mouse, is restricted to caudal intraembryonic splanchnopleura. Cell 86:907-916, 1996
  pubmed

• 8) Gerber, H.-P., Vu, T. H., Ryan, A. M. et al.:VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nature Med. 5:623-628, 1999
  pubmed

• 9) Ash, P., Loutit, J. F., Townsend, K. M.:Osteoclasts derived from haematopoietic stem cells. Nature 283:669-670, 1980
  pubmed

• 10) Scheven, B. A., Visser, J. W., Nijweide, P. J.:In vitro osteoclast generation from different bone marrow fractions, including a highly enriched haematopoietic stem cell population. Nature 321:79-81, 1986
  pubmed

• 11) Kurihara, N., Chenu, C., Miller, M. et al.:Identification of committed mononuclear precursors for osteoclast-like cells formed in long term human marrow cultures. Endocrinology 126:2733-2741, 1990
  pubmed

• 12) Takahashi, N., Akatsu, T., Udagawa, N. et al.:Osteoblastic cells are involved in osteoclast formation. Endocrinology 123:2600-2602, 1988
  pubmed

• 13) Udagawa, N., Takahashi, N., Akatsu, T. et al.:The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology 125:1805-1813, 1989
  pubmed

• 14) Tanaka, S., Takahashi, N., Udagawa, N. et al.:Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J. Clin. Invest. 91:257-263, 1993
  pubmed

• 15) Yoshida, H., Hayashi, S., Kunisada, T. et al.:The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345:442-444, 1990
  pubmed

• 16) Hofstetter, W., Wetterwald, A., Cecchini, M. C. et al.:detection of transcripts for the receptor for macrophage colony-stimulating factor, c-fms, in murine osteoclasts. Proc. Natl. Acad. Sci. USA 89:9637-9641, 1992
  pubmed

• 17) Lacey, D. L, Timms, E., Tan, H. L. et al.:Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176, 1998
  pubmed

• 18) Yasuda, H., Shima, N., Nakagawa, N. et al.:Osteoclast differeritiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95:3597-3602, 1998
  pubmed

• 19) Anderson, D. M., Maraskovsky, E., Billingsley, W. L. et al.:A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179, 1997
  pubmed

• 20) Wong, B. R., Rho, J., Arron, J. et al.:TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272:25190-25194, 1997

• 21) Yeh, W. C., Shahinian, A., Speiser, D. et al.:Early lethality, functional NF-B activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 7:715-725, 1997

• 22) Galibert, L, Tometsko, M. E., Anderson, D. M. et al.:The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-B, a member of the TNFR superfamily. J. Biol. Chem. 273:34120-34127, 1998

• 23) Wong, B. R., Josien, R., Lee, S. Y. et al.:The TRAF family of signal transducers mediates NF-B activation by the TRANCE receptor. J. . Biol. Chem. 273:28355-28359, 1998
  pubmed

• 24) Hsu, H., Lacey, D. L., Dunstan, C. R. et al.:Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96:3540-3545, 1999
  pubmed

• 25) Lomaga, M. A., Wen-Chen, W. Y., Sarosi, I. et al.:TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13:1015-1024, 1999

• 26) Iotsova, V., Caamano, J., Loy, J. et al.:Osteopetrosis in mice lacking NF-B1 and NF-B2. Nature Med. 3:1285-1289, 1997

• 27) Franzoso, G., Carlson, L., Xing, L. et al.:Requirement for NF-B in osteoclast and B-cell development. Genes Dev. 11:3482-3496, 1997

• 28) Kong, Y. Y., Yoshida, H., Sarosi, I. et al.:OPGL is a key regulator of osteoclastogenesis, lyrnphocyte development and lymph-node organogenesis. Nature 397:315-323, 1999
  pubmed

• 29) Dougall, W. C., Glaccum, M., Charrier, K. et al.:RANK is essential for osteoclast and lymph node development. Genes Dev. 13:2412-2424, 1999
  pubmed

• 30) Spangrude, G. J., Heimfeld, S., Weissman, I. L.:Purification and characterization of mouse hematopoietic stem cells. Science 241:58-62, 1988
  pubmed

• 31) Okada, S., Nakauchi, H., Nagayoshi, K. et al.:In vivo and in vitro stem cell function of c-kit-and Sca-1-positive murine hematopoietic cells. Blood 80:3044-3050, 1992
  pubmed

• 32) Morrison, S. J., Hemmati, H. D., Wandycz, A. M. et al.:The purification and characterization of fetal liver hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 92:10302-10306, 1995
  pubmed

• 33) Sariban, E., Mitchell, T., Kufe, D.:Expression of the c-fms proto-oncogene during human monocytic differentiation. Nature 316:64-66, 1985

• 34) Arai, F., Miyamoto, T., Ohneda, O. et al.:Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor B (RANK) receptors. J. Exp. Med. 190:1741-1754, 1999

• 35) Begg, S. K., Bertoncello, I.:The hematopoietic deficiencies in osteopetrotic (op/op) mice are not permanent, but progressively correct with age. Exp. Hematol. 21:493-495, 1993a
  pubmed

• 36) Begg, S. K., Radley, J. M., Pollard, J. W. et al.:Delayed hematopoietic development in osteopetrotic (op/op) mice. J. Exp. Med. 177:237-242, 1993b

• 37) Lagasse, E., Weissman, I. L.:Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice. Cell 89:1021-1031, 1997
  pubmed

• 38) Scott, E. W., Simon, M. C., Anastasi, J. et al.:Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 265:1573-1577, 1994
  pubmed

• 39) Grigoriadis, A. E., Wang, Z. Q., Cecchini, M. G. et al.:c-Fos:a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266:443-448, 1994
  pubmed

• 40) Hodgkinson, C. A., Moore, K. J., Nakayama, A. et al.:Mutation at the mouse micropthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 74:395-404, 1993

• 41) Baldwin, A. S. Jr.:The NF-xB and IxB proteins:New discoveries and insights. Annu. Rev. Immunol. 14:649-683, 1996

P.89 掲載の参考文献

• 1) Takahashi, N., Akatsu, T., Udagawa, N. et al.:Osteoblastic cells are involved in osteoclast differentiation. Endocrinology 123:2600-2602, 1988
  pubmed

• 2) Udagawa, N., Takahashi, N., Akatsu, T. et al.:Origin of osteoclasts:mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc. Natl. Acad. Sci. USA 87:7260-7264, 1990

• 3) Suda, T., Takahashi, N., Suda, T. et al.:Modulation of osteoclast differentiation. Endocr. Rev. 13:66-80, 1992
  pubmed

• 4) Takeda, S., Yoshizawa, T., Nagai, Y. et al.:Stimulation of osteoclast formation by 1, 25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells:studies using VDR knockout mice. Endocrinology 140:1005-1008, 1999
  pubmed

• 5) Liu, B. Y., Guo, J., Lanske, B. et al.:Conditionally immortalized murine bone marrow stromal cells mediate parathyroid hormone-dependent osteoclastogenesis in vitro. Endocrinology 139:1952-1964, 1998
  pubmed

• 6) Sakuma, Y., Tanaka, K., Suda, M. et al.:Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast fomation by proinflammatory cytokines and lipopolysaccharide. J. Bone Miner. Res. 15:218-227, 2000

• 7) Udagawa, N., Takahashi, N., Katagiri, T. et al.:Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast Progenitors. J. Exp. Med. 182:1461-1468, 1995

• 8) Jimi, E., Nakamura, I., Amano, H. et al.:Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology 137:2187-2190, 1996

• 9) Suda, T., Nakamura, I., Jimi, E. et al.:Regulation of osteoclast function. J. Bone Miner. Res. 12:869-879, 1997
  pubmed

• 10) Suda, T., Takahashi, N., Udagawa, N. et al.:Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20:345-357, 1999
  pubmed

• 11) Yoshida, H., Hayashi, S., Kunisada, T. et al.:The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 31:442-444, 1990

• 12) Kodama, H., Yamasaki, A., Nose, M. et al.:Congenital osteoclast deficiency in osteopetrotic (op/op) mice is cured by injections of macrophage colony-stimulating factor. J. Exp. Med. 173:269-272, 1991
  pubmed

• 13) Felix, R., Cecchini, M. G., Fleisch, H.:Macrophage colony stimulating factor restores in in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology 127:2592-2594, 1990
  pubmed

• 14) Takahashi, N., Udagawa, N., Akatsu, T. et al.:Deficiency of osteoclasts in osteopetrotic mice is due to a defect in the local microenvironment provided by osteoblastic cells. Endocrinology 128:1792-1796, 1991
  pubmed

• 15) Tanaka, S., Takahashi, N., Udagawa, N. et al.:Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J. Clin. Invest. 91:257-263, 1993
  pubmed

• 16) Yasuda, H., Shima, N., Nakagawa, N. et al.:Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG):a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329-1337, 1998
  pubmed

• 17) Simonet, W. S., Lacey, d. L., Dunstan, C. R. et al.:Osteoprotegerin:a novel secreted protein involved in the regulation of bone density. Cell 18:309-319, 1997

• 18) Kwon, B. S, Wang, S., Udagawa, N. et al.:TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J. 12:845-854, 1998
  pubmed

• 19) The American Society for Bone and Mineral Research President's Committee on Nomenclature.:Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. J. Bone Miner. Res. 2000 (in press)

• 20) Yasuda, H., Shima, N, Nakagawa, N. et al.:Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95:3597-3602, 1998
  pubmed

• 21) Anderson, D. M., Maraskovsky, E., Billingsley, W. L. et al.:Ahomologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179, 1997
  pubmed

• 22) Wong, B. R., Rho, J., Arron, J. et al.:TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272:25190-25194, 1997

• 23) Lacey, D. L., Timms, E., Tan, H. L. et al.:Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176, 1998
  pubmed

• 24) Matsuzaki, K., Udagawa, N., Takahashi, N. et al.:Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem. Biophys. Res. Commun. 246:199-204, 1998
  pubmed

• 25) Quinn, J. M., Elliott, J., Gillespie, M. T. et al.:A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 139:4424-4427, 1998
  pubmed

• 26) Nakagawa, N., Kinosaki, M., Yamaguchi, K. et al.:RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun. 253:395-400, 1998
  pubmed

• 27) 高橋直之, 宇田川信之, 須田立雄:破骨細胞の分化と機能を調節する新規の TNF 様因子(破骨細胞分化因子)の役割. 生化学 71:241-253, 1999

• 28) 保田尚孝, 後藤雅昭:破骨細胞形成抑制因子 (Osteoclastogenesis inhibitory factor, OCIF) と破骨細胞分化因子 (Osteoclast differentiation factor, ODF):破骨細胞の分化 ・成熟を調節するメカニズム. 日本骨代謝学会雑誌 17:10-18, 1999
  Medical*Online

• 29) Kobayashi, K., Takahashi, N., Jimi, E. et al.:Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191:275-286, 2000

• 30) Azuma, Y., Kaji, K., Katogi, R. et al.:Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem. 275:4858-4864, 2000

• 31) 小林幹一郎, 宇田川信之, 高橋直之:骨吸収を調節する TNF 関連サイトカインの作用とシグナル伝達. 実験医学 18:348-353, 2000
  Medical*Online

• 32) Jimi, E., Nakamura, I., Duong, L. T. et al.:Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp. Cell Res. 247:84-93, 1999
  pubmed

• 33) Kong, Y. Y., Yoshida, H., Sarosi, I. et al.:OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323, 1999
  pubmed

• 34) Dougall, W. C., Glaccum, M., Charrier, K. et al.:RANK is essential for osteoclast and lymph node development. Genes. Dev. 13:2412-2424, 1999
  pubmed

• 35) Li, J., Sarosi, I., Yan, X. Q. et al.:RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97:1566-1571, 2000
  pubmed

• 36) Hughes, A. E., Ralston, S. H., Marken, J. et al.:Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat. Genet. 24:45-48, 2000
  pubmed

• 37) Mizuno, A., Amizuka, N., Irie, K. et al.:Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 247:610-615, 1998
  pubmed

• 38) Bucay, N., Sarosi, I., Dunstan, C. R. et al.:Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12:1260-1268, 1998
  pubmed

• 39) Udagawa, N., Takahashi, N., Yasuda, H. et al.:Osteoprotegerin (OPG) produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141:3478-3484, 2000
  pubmed

• 40) Takami, M., Woo, J. T., Nagai, K.:Osteoblastic cells induce fusion and activation of osteoclasts through a mechanism independent of macrophage-colony-stimulating factor production. Cell Tissue Res. 298:327-334, 1999
  pubmed

• 41) Jimi, E., Akiyama, S., Tsurukai, T. et al.:Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J. Immunol. 163:434-442, 1999
  pubmed

• 42) Udagawa, N., Takahashi, N., Jimi, E.:Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor:receptor activator of NF-B ligand. Bone 25:517-523, 1999
  pubmed

• 43) Lomaga, M. A., Yeh, W. C., Sarosi, I. et al.:TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13:1015-1024, 1999
  pubmed

• 44) Naito, A., Azuma, S., Tanaka, S. et al.:Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells. 4:353-362, 1999
  pubmed

• 45) Wong, B. R., Besser, D., Kim, N. et al.:TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Genes Cells 4:1041-1049, 1999

• 46) Kotake, S., Udagawa, N., Takahashi, N. et al.:IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103:1345-1352, 1999
  pubmed

• 47) Romas, E., Bakharevski, O., Hards, D. K. et al.:Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum. 43:821-826, 2000
  pubmed

• 48) Horwood, N. J., Kartsogiannis, V., Quinn, J. M. et al.:Activated T lymphocytes support osteoclast formation in vitro. Biochem. Biophys. Res. Commun. 265:144-150, 1999
  pubmed

• 49) Kong, Y. Y., Feige, U., Sarosi, I. et al.:Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-309, 1999
  pubmed

• 50) 小竹茂, 宇田川信之, 須田立雄:関節病変における破骨細胞. リウマチ科 21:182-187, 1999

• 51) Koide, M., Murase, Y., Yamato, K. et al.:Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1α through upregulation of osteoclast differentiation factor and cyclooxygenase-2. Biochem. Biophys. Res. Commun. 259:97-102, 1999

• 52) Sells Galvin, R. J., Gatlin, C. L., Horn, J. W. et al.:TGF-β enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF. Biochem. Biophys. Res. Commun. 265:233-239, 1999

• 53) Fuller, K., Bayley, K. E., Chambers, T. J.:Activin A is an essential cofactor for osteoclast induction. Biochem. Biophys. Res. Commun. 268:2-7, 2000
  pubmed

• 54) 伊藤雅波, 宇田川信之, 片桐岳信ほか:日本骨代謝学会雑誌18(抄):141, 2000

• 55) Hsu, H., Lacey, D. L., Dunstan, C. R. et al.:Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96:3540-3545, 1999
  pubmed

• 56) Iotsova, V., Caamano, J., Loy, J. et al.:Osteopetrosis in mice lacking NF-B1 and NF-B2 Nat. Med. 3:1285-1289, 199

• 57) Franzoso, G., Carlson, L., Xing, L. et al.:Required and nonessential functions of nuclear factor-B in bone cells. Genes Dev. 11:3482-3496, 1997

P.100 掲載の参考文献

• 1) Scimeca, J. C., Franchi, A., Trojani, C. et al.:The gene encoding the mouse homologue of the human osteoclast-specific 116-kda V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants Bone 26:207-213, 2000

• 2) Gowen, M., Lazner, F., dodds, R. et al.:Cathepsin K knockout mice develop osteopetrosis due to adeficit in matrix degradation but not demineralization. J. Bone Miner. Res. 14:1654-1663, 1998

• 3) Saftig, P., Hunziker, E., Wehmeyer, O. et al.:Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. USA 95:13453-13458, 1998
  pubmed

• 4) Gelb, B.D., Shi, G. P., Chapman, H.A. et al.:Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:1236-1238, 1996
  pubmed

• 5) McHugh, K.P., Hodivala-Dilke, K., Zheng, M.H. et al.:Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J. Clin. Invest. 105:433-440, 2000
  pubmed

• 6) Soriano, P., Montgomery, C., Geske, R. et al.:Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64:693-702, 1991

• 7) Lowe, C., Yoneda, T., Boyce, B. F. et al.:Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc. Natl. Acad. Sci. USA 90:4485-4489;1993

• 8) Horne, W.C., Neff, L., Chatterjee, d. et al.:Osteoclasts express high levels of pp60c-src in association with intracellular membranes. J. Cell Biol. 119:1003-1013, 1992
  pubmed

• 9) Tanaka, S., Takahashi, N., Udagawa, N. et al.:Osteoclasts express high levels of p60c-src, preferentially on ruffled border membranes. FEBS Lett. 313:85-89, 1992
  pubmed

• 10) Stein, P.L., Vogel, H., Soriano, P.:Combined deficiencies of Src, Fyn, and Yes tyrosine kinases in mutant mice. Genes Dev. 8:1999-2007, 1994
  pubmed

• 11) Lowell, C.A., Niwa, M., Soriano, P. et al.:Deficiency of the Hck and Src tyrosine kinases results in extreme levels of extramedullary hematopoiesis. Blood 87:1780-1792, 1996
  pubmed

• 12) Tanaka, S., Amling, M., Neff, L. et al.:c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption. Nature 383:528-531, 1996

• 13) Langdon, W. Y.:The cbl oncogene:a novel substrate of protein tyrosine kinases. . Aust. N. Z. J. Med. 25:859-864, 1995
  pubmed

• 14) Murphy, M. A., Schnall, R. G., Venter, D. J. et al.:Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice. Mol. Cell. Biol. 18:4872-4882, 1998

• 15) Yokouchi, M., Kondo, T., Houghton, A. et al.:Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7. J. Biol. Chem. 274:31707-31712, 1999

• 16) Schwartzberg, P.L., Xing, L., Hoffmann, O. et al.:Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src mutant mice. Genes Dev. 11:2835-2844, 1997
  pubmed

• 17) Schwartzberg, P.L:The many faces of Src:multiple functions of a prototypical tyrosine kinase. Oncogene 17:1463-1468, 1998
  pubmed

• 18) Miyazaki, T., Takayanagi, H., Isshiki, M. et al.:In vitro and in vitro suppression of osteoclast function by adenovirus vector-induced csk gene. J. Bone Miner. Res. 15:41-51, 2000

• 19) Takayanagi, H., Juji, T., Miyazaki, T. et al.:Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts. J. Clin. Invest. 104:137-146, 1999
  pubmed

• 20) Hughes, D.E., Dai, A., Tiffee, J.C. et al.:Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat.L Med. 2:1132-1136, 1996

• 21) Ullrich, A., Schlessinger, J.:Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212, 1990
  pubmed

• 22) Miyazaki, T., Katagiri, H., Kanegae, Y. et al.:Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J. Cell. Biol. 148:333-342, 2000
  pubmed

• 23) Jimi, E., Nakamura, I., Ikebe, T. et al.:Activation of NF-kappaB is involved in the survival of osteoclasts promoted by interleukin-1. J. Biol. Chem. 273:8799-8805, 1998
  pubmed

• 24) Lomaga, M. A., Yeh, W. C., Sarosi, I. et al.:TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes. Dev. 13:1015-1024, 1999
  pubmed

• 25) Wong, B.R., Besser, D., Kim, N. et al.:TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell. 4:1041-1049, 1999

• 26) Naito, A., Azuma, S., Tanaka, S. et al.:Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells. 4:353-362, 1999
  pubmed

P.109 掲載の参考文献

• 1) Aubin, J. E., Turksen, K., Heersche, J. N. M.:Osteoblastic lineage, in Cellular and Molecular Biology of Bone. (Noda, M. ed. ) Academic Press, London, 1993, p.1-45

• 2) Komori, T., Yagi, H., Nomura, S. et al.:Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 89:755-764, 1997

• 3) Otto, F., Thornell, A. P., Crompton, T. et al.:Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell. 89:765-771, 1997
  pubmed

• 4) Komori, T., Kishimoto, T.:Cbfa1 in bone development. Curr. Opin. Genet. Dev. 8:494-499, 1998
  pubmed

• 5) Weimin, B., Jian, M. D., Zhaoping, Z. et al.:Sox9 is required for cartilage formation. Nat. Genet. 22:85-89, 1999

• 6) Ogawa, E., Maruyama, M., Kagoshima, H. et al.:PEBP2/PEA2 represents a new family of transcription factor homologous to the products of the drosophila runt and the human AMLI gene. Proc. Natl. Acad. Sci. USA 90:6859-6863, 1993

• 7) Bae, S. C., Yamaguchi-Iwai, Y., Ogawa, E. et al.:Isolation of PEBP2αB cDNA representing the mouse homolog of human acute myeloid leukemia gene, AML1. Oncogene 8:809-814, 1993

• 8) Bae, S. C., Takahashi, E., Zhang, Y. W. et al.:Cloning, mapping and expression of PEBP2αC a third gene encoding the mammalian Runt domain. Gene 159:245-248, 1995

• 9) Ogawa, E., Inuzaka, M., Maruyama, M. et al.:Molecular cloning and characterization of PEBP2β, the heterodimeric partner of a novel dorosophila runt-related DNA binding protein PEBP2α. Virology 194:314-331, 1993

• 10) Wang, S., Wang, Q., Crute, B. E. et al:Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol. Cell. Biol. 13:3324-3339, 1993

• 11) Okuda, T., van Deursen, J., Hiebert, S. W. et al.:AML1, the target of multiple chromosomal translocation in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84:321-330, 1996
  pubmed

• 12) Wang, Q., Stancy, T., Binder, M.:Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc. Natl. Acad. Sci. USA 93:3444-3449, 1996

• 13) Sasaki, K, Yagi, H., Bronson, R. T. et al:Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor β. Proc. Natl. Acad. Sci. USA 93:12359-12363, 1996

• 14) Wang, Q., Stacy, T., Miller, J. d. et al.:The CBFβsubunit is essential for CBFα2 (AML1) function in vivo. Cell 87:697-708, 1996

• 15) Niki, M., Okada, H., Takano, H. et al.:Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding subunit of the transcriptional factor, polyomavirus enhancer binding protein 2/core binding factor. Proc. Natl. Acad. Sci. USA 94:5697-5702, 1997
  pubmed

• 16) Thirunavukkarasu, K., Mahajan, M., Mclarren, K. W. et al.:Two domains unique to osteoblastspecific transcription factor Osf2/Cbfa1 contribute to its transactivation function and its inability to heterodimerize with Cbfβ. Mol. Cell. Biol. 18:4197-4208, 1998

• 17) Harada, H., Tagashira, S., Fujiwara, M. et al.:Cbfa1 isoforms exert functional differences in osteoblast differentiation. J. Biol. Chem. 274:6972-6978, 1999
  pubmed

• 18) Fujiwara, M., Tagashira, S., Harada, H. et al.:Isolation and characterization of the distal promoter region of mouse Cbfa1. Biochim. Biophys. Acta. 1446:265-272, 1999
  pubmed

• 19) Stewart, M., Terry, A., Hu, M. et al.:Proviral insertions induce the expression of bone-specific isoforms of PEBP2αA (CBFA1):evidence for a new myc collaborating oncogene. Proc. Natl. Acad. Sci. USA 94:8646-8651, 1997

• 20) Ducy, P., Zhang, R., Geoffroy, V. et al.:Osf2/Cbfa1:atranscriptional activator of osteoblast differentiation. Cell 89:747-754, 1997

• 21) Tsuji, K., Ito, Y., Noda, M. et al.:Expression of the PEBP2αA/AML3/CBFA1 gene is regulated by BMP4/7 heterodimer and its overexpression suppresses type I collagen and osteocalcin gene expression in osteoblastic and nonosteoblastic mesenchymal cells. Bone 22:87-92, 1998

• 22) Li, J., Tsuju, K., Komori, T. et al.:Smad2 overexpression enhances Smad4 gene expression and suppresses CBFA1 gene expression in osteoblastic osteosarcoma ROSI7/2.8 cells. J. Biol. Chem. 273:31009-31015, 1998

• 23) Xiao, G., Jiang, D., Thomas, P. et al.:MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J. Biol. Chem. 275:4453-4459, 2000
  pubmed

• 24) Selvamurugan, N., Pulimati, M. R., Tyson, D. R. et al.:Parathyroid hormone regulation of the rat collagenase-3 promoter by protein kinase A-dependent transactivation of core binding factorα1.J. Biol. Chem. 275:5037-5042, 2000

• 25) Levanon, D., Goldstein R. E., Bernstein, Y. et al.:Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors. Proc. Natl. Acad. Sci. USA 95:11590-11595, 1998
  pubmed

• 26) McLarren, K. W., Lo, R., Grbavec, D. et al.:The mammalian basic helix loop helix protein HES-1 binds to and modulates the transactivating function of the runt-related factor Cbfa1. J. Biol. Chem. 275:530-538, 2000
  pubmed

• 27) Matsue, M., Kageyama, R., Denhardt, D. T. et al.:Helix-Loop-Helix-Type transcription factor (HES-1) is expressed in osteoblastic cells, suppressed by 1,25 (OH)2 vitamin D3, and modulates 1, 25 (OH)2 vitamin D3 enhancement of osteopontin gene expression. Bone 20:329-334, 1997
  pubmed

• 28) Tintut, Y., Parhami, F., Le, V. et al.:Inhibition of osteoblast-specific transcription factor Cbfa1 by the cAMP pathway in osteoblastic cells. J. Biol. Chem. 274:28875-28879, 1999

• 29) Inada, M., Yasui, T., Nomura, S. et al.:Maturational disturbance of chondrocytes in Cbfa 1-deficient mice. Dev. Dyn. 214:279-290, 1999

• 30) Kim, I.S., Otto, F., Zabel, B. et al.:Regulation of chondrocyte differentiation by Cbfa1. Mech. Dev. 80:159-170, 1999
  pubmed

• 31) Hoshi, K., Komori, T., Ozawa, H.:Morphological Characterization of Skeletal Cells in Cbfa1-Deficient Mice. . Bone 25:639-651, 1999
  pubmed

• 32) Ducy, P., Starbuck, M., Priemel, M. et al.:A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev. 13:1025-1036, 1999
  pubmed

• 33) Sato, M., Morii, E., Komori, T. et al.:Transcriptional regulation of osteopontin gene in vivo by PEBP2αA/CBFA1 and ETS1 in the skeletal tissues. Oncogene 17:1517-1525, 1998

• 34) Sasaki-lwaoka, H., Maruyama, K., Endoh, H. et al.:A trans-acting enhancer modulates estrogen-mediated transcription of reporter genes in osteoblasts. J. Bone Miner. Res. 14:248-255, 1999

• 35) Hanai, J., Chen, L. F., Kanno, T. et al.:Interaction and functional cooperation of PEBP2/CBF with Smads. J. Biol. Chem. 274:31577-31582, 1999
  pubmed

• 36) Kobayashi, H., Gao, Y. H., Ueta, C. et al.:Multilineage differentiation of Cbfa1-deficient calvarial cells in vitro. Biochem. Biophys. Res. Commun. 273:630-636, 2000
  pubmed

• 37) Jimenez, M. G., Balbin, M., Lopez, J. M. et al.:Collagenase-3 is a target of Cbfa1, a transcription factor of the runt gene family involved in bone formation. Mol. Cell. Biol. 19:4431-4442, 1999

• 38) Enomoto, H., Enomoto-Iwamoto, M., Iwamoto, M. et al.:Cbfa1 is a positive regulatory factor in chondrocyte maturation. J. Biol. Chem. 275:8695-8702, 2000
  pubmed

• 39) Gao, Y. H., Shinki, T., Yuasa, T. et al.:Potential role of Cbfa1, an essential transcription factor for osteoblast differentiation, in osteogenesis:regulation of mRNA expression of osteoclast differentiation factor (ODF). Biochem. Biophys. Res. Commun. 252:687-702, 1998

P.119 掲載の参考文献

• 1) Komori, T., Yagi, H., Nomura, S. et al.:Target disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755-764, 1997

• 2) Ducy, P., Zhang, R., Geoffroy, V. et al.:Cbfa1/Osf2:Atranscriptional activator of osteoblast differentiation. Cell 89:747-754, 1997

• 3) Otto, F., Thornell, A. P., Crompton, T. et al.:Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89:765-771, 1997
  pubmed

• 4) Yamaguchi, A., Komori, T., Suda, T.:Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs and Cbfa1. Endocr. Rev. 21:393-411, 2000
  pubmed

• 5) Geoffroy, V., Ducy, P., Karsenty, G.:APEBP2α/AML-1-related factor increases osteocalcin promoter activity through its binding to an osteoblast-specific cis-acting element. J. Biol. Chem. 270:30973-30979, 1995

• 6) Ducy, P., Karsenty, G.:Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol. Cell Biol. 15:1858-1869, 1995
  pubmed

• 7) Banerjee, C., Hiebert, S. W., Stein, J. L. et al.:An AML-1 consensus sequence binds an osteoblast-specific complex and transcriptionally activates the osteocalcin gene. Proc. Natl. Acad. Sci. USA 12:4968-4973, 1996

• 8) Hanai, J., Chen, L. F., Kanno, T.:Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline C α promoter. J. Biol. Chem. 274:31577-31582, 1999

• 9) Schinke, T., Karsenty, G.:Characterization of Osf1, an osteoblast-specific transcription factor binding to a critical cis-acting element in the mouse Osteocalcin promoters. J. Biol. Chem. 274:30182-30189, 1999
  pubmed

• 10) Katagiri, T., Yamaguchi, A., Ikeda, T. et al.:The non-osteogenic mouse pluripotent cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by recombinant human bone morphogenetic protein-2. Biochem. Biophys. Res. Commun. 172:295-299, 1990
  pubmed

• 11) Wang, E. A., Israel, D. I., Kelly, S. et al:Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells. Growth Factors 9:57-71, 1993
  pubmed

• 12) Asahina, I., Sampath, T. K., Hauschka, P. V.:Human osteogenic protein-1 induces chondroblastic, osteoblastic, and/or adipocytic differentiation of clonal murine target cells. Exp. Cell. Res. 222:38-47, 1996

• 13) Yamaguchi, A., Katagiri, T., Ikeda, T. et al.:Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J. Cell Biol. 113:681-687, 1991
  pubmed

• 14) Thies, R. S., Bauduy, M., Ashton, B. A. et al.:Recombinant human bone morphogenetic protein-2 induces osteoblastic differentiation in W-20-17 stromal cells. Endocrinology 130:1318-1324, 1992

• 15) Yamaguchi, A., Ishizuya, T., Kintou, N. et al.:Effects of BMP-2, BMP-4 and BMP-6 on osteoblast differentiation of bone marrow-derived stromal cell lines, ST2 and MC3T3-G2/PA6. Biochem. Biophys. Res. Commun. 220:366-371, 1996
  pubmed

• 16) Katagiri, T., Yamaguchi, A., Komaki, M. et al.:Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J. Cell Biol. 127:1755-1766, 1994
  pubmed

• 17) Chen, D., Ji, X., Marris, M. A. et al.:Differential roles for bone morphogenetic protein (BMP) receptor type I B and I A in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages. J. Cell Biol. 142:295-305, 1998

• 18) Gimble, J. M., Morgan, C., Kelly, K. et al.:Morphogenetic proteins inhibit adipocyte differentiation by bone marrow stromal cells. J. Cell Biochem. 58:393-402, 1995
  pubmed

• 19) Lecka-Czernik, B., Gubrij, I., Moerman, E. J.:Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2. J. Cell. Biochem. 74:357-371, 1999

• 20) Chiang, C., Litingtung, Y., Lee, E. et al.:Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. Nature 383:407-413, 1996
  pubmed

• 21) Vortkamp, A., Lee, K., Lanske, B. et al.:Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science 273:613-622, 1996
  pubmed

• 22) Lanske, B., Karaplis, A. C., Lee, K. et al:PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science 273:663-666, 1996
  pubmed

• 23) St-Jacques, B., Hammerschmidt, M., McMahon, A. P.:Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev. 13:2072-2086, 1999
  pubmed

• 24) Vortkamp, A., Pathi, S., Peretti, G. M. et al:Recapitulation of signals regulating embryonic bone formation during postnatal growth and in fracture repair. Mech. Dev. 71:65-76, 1998
  pubmed

• 25) Ferguson, C., Alpern, E., Miclau, T. et al.:Does adult fracture repair recapitulate embryonic skeletal formation? Mech. Dev. 87:57-66, 1999
  pubmed

• 26) Ito, H., Akiyama, H., Shigeno, C. et al.:Hedgehog signaling molecules in bone marrow cells at the initial stage of fracture repair. Biochem. Biophys. Res. Commun. 262:443-451, 1999
  pubmed

• 27) Kinto, N., Iwamoto, M., Enomoto-Iwamoto, M. et al.:Fibroblasts expressing Sonic hedgehog induce osteoblast differentiation and ectopic bone formation. FEBS Lett. 404:319-323, 1997

• 28) Nakamura, T., Aikawa, T., Iwamono-Enomoto, M. et al.:Induction of osteogenic differentiation by hedgehog proteins. Biochem. Biophys. Res. Commun. 237:465-469, 1997

• 29) Bitgood, M. J., McMahon, A. P.:Hedgehog and Bmp genes are coexpressed at many diverse sites of cell-cell interaction in the mouse embryo. Dev. Biol. 172:126-138, 1995
  pubmed

• 30) Murtaugh, L. C., Chyung, J. H., Lassar, A. B.:Sonic hedgehog promotes somitic chondrogenesis by altering the cellular response to BMP signaling. Genes Dev. 13:225-237, 1999
  pubmed

• 31) Pathi, S., Rutenberg, J. B., Johnson, R. L. et al.:Interaction of Ihh and BMP/Noggin signaling during cartilage differentiation. Dev. Biol. 209:239-253, 1999
  pubmed

• 32) Enomoto-Iwamoto, M., Nakamura, T., Aikawa, T. et al.:Hedgehog proteins stimulate chondrogenic cell differentiation and cartilage formation. J. Bone Miner. Res. 15:1659-1668, 2000
  pubmed

• 33) McCarthy, T. L., Centrella, M., Canalis, E.:Regulatory effects of insulin-like growth factors I and II on bone collagen synthesis in rat calvarial cultures. Endocrinology 124:301-309, 1989

• 34) Canalis, E., Rydziel, S., Delany, A. M. et al.:Insulin-like growth factors inhibit interstitial collagenase synthesis in bone cell cultures. Endocrinology 136:1348-1354, 1995
  pubmed

• 35) Rydziel, S., Delany, A. M., Canalis, E.:Insulin-like growth factor I inhibits the transcription of collagenase 3 in osteoblast cultures. J. Cell. Biochem. 167:176-183, 1997

• 36) Birnbaum, R. S., Wiren, K. M.:Changes in insulin-like growth factor-binding protein expression and secretion during the proliferation, differentiation, and mineralization of primary cultures of rat osteoblasts. Endocrinology 135:223-230, 1994
  pubmed

• 37) Hill, P. A., Tumber, A., Meikle, M. C.:Multiple extracellular signals promote osteoblast survival and apoptosis. Endocrinology 138:3849-3858, 1997
  pubmed

• 38) Shinar, D. M., Endo, N., Halperin, D. et al.:differential expression of insulin-like growth factor-I (IGF-I) and IGF-II messenger ribonucleic acid in growing rat bone. Endocrinology 132:1158-1167, 1993
  pubmed

• 39) Turner, R. T., Backup, P., Sherman, P. J. et al.:Mechanism of action of estrogen on intramembranous bone formation:regulation of osteoblast differentiation and activity. Endocrinology 13:883-889, 1992

• 40) Lean, J. M., Jagger, C. J., Chambers, T. J. et al.:Increased insulin-like growth factor I mRNA expression in rat osteocytes in response to mechanical stimulation. Am. J. Physiol. 268 (2 Pt 1):E318-E327, 1995

• 41) Watson, P., Lazowski, D., Han, V. et al.:Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor I gene expression in ovariectomized rats. Bone 16:357-365, 1995
  pubmed

• 42) Ishizuya, T., Yokose, S., Hori, M. et al.:Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J. Clin. Invest. 99:2961-2970, 1997

• 43) Zhao, G., Monier-Faugere, M. C., Langub, M. C. et al.:Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice:increased trabecular bone volume without increased osteoblast proliferation. Endocrinology 141:2674-2682, 2000
  pubmed

• 44) Globus, R. K., Patterson-Buckendahl, P., Gospodarowicz, D.:Regulation of bovine bone cell proliferation by fibroblast growth factor and transforming growth factor β. Endocrinology 123:98-105, 1988

• 45) Rodan, S. B., Wesolowski, G., Yoon, K. et al.:Opposing effects of fibroblast growth factor and pertussis toxin on alkaline phosphatase, osteopontin, osteocalcin, and type I collagen mRNA levels in ROS 17/2. 8 cells. J. Biol. Chem. 264:19934-19941, 1989

• 46) Canalis, E., Centrella, M., McCarthy, T.:Effects of basic fibroblast growth factor on bone formation in vitro. J. Clin. Invest. 81:1572-1577, 1988

• 47) Hurley, M. M., Abreu, C, Harrison, J. R. et al.:Basic fibroblast growth factor inhibits type I collagen gene expression in osteoblastic MC3T3-E1 cells. J. Biol. Chem. 268:5588-5593, 1993

• 48) Aspenberg, P., Lohmander, L. S.:Fibroblast growth factor stimulates bone formation. Bone induction studied in rats. Acta Orthop. Scand. 60:473-476, 1989
  pubmed

• 49) Aspenberg, P., Thorngren, K. G., Lohmander, L. S.:dose-dependent stimulation of bone induction by basic fibroblast growth factor in rats. Acta Orthop. Scand. 62:481-484, 1991
  pubmed

• 50) Mayahara, H., Ito, T., Nagai, H. et al.:In vivo stimulation of endosteal bone formation by basic fibroblast growth factor in rats. Growth Factors 9:73-80, 1993
  pubmed

• 51) Nagai, H., Tsukuda, R., Mayahara, H.:Effects of basic fibroblast growth factor (bFGF) on bone formation in growing rats. Bone 16:367-373, 1995

• 52) Nakamura, T., Hanada, K., Tamura, M. et al.:Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats. Endocrinology 136:1276-1284, 1995
  pubmed

• 53) Liang, H., Pun, S., Wronski, T. J.:Bone anabolic effects of basic fibroblast growth factor in ovariectomized rats. Endocrinology 140:5780-5788, 1999
  pubmed

• 54) Kawaguchi, H., Kurokawa, T., Hanada, K. et al.:Stimulation of fracture repair by recombinant human basic fibroblast growth factor in normal and streptozotocin-diabetic rats. Endocrinology 135:774-781, 1994
  pubmed

• 55) Kuroda, S., Kasugai, S., Oida, S. et al.:Anabolic effect of aminoterminally truncated fibroblast growth factor 4 (FGF4) on bone. Bone 25:431-437, 1999

• 56) Nakamura, K., Kurokawa, T., Kawaguchi, H. et al.:Stimulation of endosteal bone formation by local intraosseous application of basic fibroblast growth factor in rats. Rev. Rhum. Engl. Ed. 64:101-105, 1997
  pubmed

P.129 掲載の参考文献

• 1) Lian, J. B., Stein, G. S., Stewart, C. et al.:Osteocalcin:characterization and regulated expression of the rat gene. Connect. Tissue Res. 21 (1-4):61-68, 1989
  pubmed

• 2) Binkley, N. C., Suttie, J. W.:Vitamin K nutrition and osteoporosis. J. Nutr. 125 (7):1812-1821, 1995

• 3) Price, P. A., Rice, J. S., Williamson, M. K.:Conserved phosphorylation of serines in the Ser-X-Glu /Ser (P) sequences of the vitamin K-dependent matrix Gla protein from shark, lamb, rat, cow, and human. Protein Sci. 3 (5):822-830, 1994

• 4) Hart, S. M., Eastell, R.:Biochemical markers of bone turnover. Curr. Opin. Nephrol. Hypertens. 8 (4):421-427, 1999
  pubmed

• 5) Power, M. J., Fottrell, P. F.:Osteocalcin:diagnostic methods and Clinical applications. Crit. Rev. Clin. Lab. Sci. 28 (4):287-335, 1991
  pubmed

• 6) Lian, J. B., Stein, G. S., Stein, J. L. et al.:Osteocalcin gene promoter:unlocking the secrets for regulation of osteoblast growth and differentiation. J. Cell. Biol. (Suppl1.) 30-31:62-72, 1998

• 7) Stein, G. S., Lian, J. B., Stein, J. L. et al.:Transcriptional control of osteoblast growth and differentiation. Physiol. Rev. 76 (2):593-629, 1996
  pubmed

• 8) Ducy, P., Zhang, R., Geoffroy, V. et al.:Osf 2/Cbfa1:atranscriptional activator of osteoblast differentiation. cell 89 (5):747-754, 1997

• 9) Ducy, P., Desbois, C., Boyce, B. et al.:Increased bone formation in osteocalcin-deficient mice. Nature 382:448-452, 1996
  pubmed

• 10) Motamed, K.:SPARC (osteonectin/BM-40) . [Review][19 refs]Int. J. Biochem. Cell Biol. 31 (12):1363-1366, 1999

• 11) Yan, Q., Sage, E. H.:SPARC, a matricellular glycoprotein with important biological functions. J. Histochem. Cytochem. 47 (12):1495-1506, 1999
  pubmed

• 12) Withold, W.:Monitoring of bone turnover biological, preanalytical and technical criteria in the assessment of biochemical markers. Eur. J. Clin. Chem. Clin. Biochem. 34 (10):785-799, 1996
  pubmed

• 13) Kato, Y., Sakai, N., Baba, M. et al.:Stimulation of motility of human renal cell carcinoma by SPARC/Osteonectin/BM-40 associated with type IV collagen. Invasion Metastasis 18 (2):105-114, 1998-1999

• 14) Lecrone, V., Li, W., Devoll, R. E. et al:Calcium signals in prostate cancer cells:specific activation by bone-matrix proteins. Cell Calcium 27 (1):35-42, 2000
  pubmed

• 15) Gilles, C., Bassuk, J. A., Pulyaeva, H. et al.:SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res. 58 (23):5529-5536, 1998
  pubmed

• 16) lkemoto, M., Takita, M., Imamura, T. et al.:Increased sensitivity to the stimulant effects of morphine conferred by anti-adhesive glycoprotein SPARC in amygdala. Nat. Med. 6:910-915, 2000

• 17) Lane, T. F., Irueia-Arispe, M. L., Johnson, R. S. et al.:SPARC is a source of copper-binding peptides that stimulate angiogenesis. J. Cell Biol. 125 (4):929-943, 1994

• 18) Lane, T. F., Sage, E. H.:The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J:8 (2):163-173, 1994
  pubmed

• 19) Fedarko, N. S., Robey, P. G., Vetter, U. K.:Extracellular matrix stoichiometry in osteoblasts from patients with osteogenesis imperfecta. J. Bone Miner. Res. 10 (7):1122-1129, 1995
  pubmed

• 20) Muriel, M. P., Bonaventure, J., Stanescu, R. et al.:Morphological and biochemical studies of a mouse mutant (fro/fro) with bone fragility. Bone 12 (4):241-248, 1991
  pubmed

• 21) Norose, K., Clark, J. I., Syed, N. A. et al.:SPARC deficiency leads to early-onset cataractogenesis. Invest. Opthalmol. Vis. Sci. 39 (13):2674-2680, 1998

• 22) Strandjord, T. P., Madtes, d. K., Weiss, d. J. et al.:Collagen accumulation is decreased in SPARC-null mice with bleomycin-induced pulmonary fibrosis. Am. J. Physiol. 277 (3 Pt 1):1628-1635, 1999

• 23) Bradshaw, A. D., Francki, A., Motamed, K. et al.:Primary mesenchymal cells isolated from SPARC
  pubmed

• 24) Delany, A. M., Amling, M., Priemel, M. et al.:Osteopenia and decreased bone formation in osteonectin-deficient mice. J. Clin. Invest. 105:915-923, 2000
  pubmed

• 25) Gorski, J. P.:Is all bone the same? Distinctive distributions and properties of non-collagenous matrix proteins in lamellar vs. woven bone imply the existence of different underlying osteogenic mechanisms. Crit. Rev. Oral Biol. Med. 9 (2):201-223, 1998
  pubmed

• 26) Binkley, N. C., Suttie, J. W.:Vitamin K nutrition and osteoporosis. J. Nutr. 125 (7):1812-1821, 1995

• 27) Howe, A. M., Webster, W. S.:Vitamin K-its essential role in craniofacial development. A review of the literature regarding vitamin K and craniofacial development. Aust. Dent. J. 39 (2):88-92, 1994
  pubmed

• 28) Schinke, T., McKee, M. D., Kiviranta, R. et al.:Molecular determinants of arterial calcification. Ann. Med. 30 (6):538-541, 1998
  pubmed

• 29) Shanahan, C. M., Proudfoot, D., Farzaneh-Far, A. et al.:The role of Gla proteins in vascular calcification. Crit. Rev. Eukaryot. Gene Expr. 8 (3-4):357-375, 1998

• 30) Lawton, d. M., Andrew, J. G., Marsh, d. R. et al.:Expression of the gene encoding the matrix gla protein by mature osteoblasts in human fracture non-unions. Mol. Pa thol. 52 (2):92-96, 1999

• 31) Yagami, K., Suh, J. Y., Enomoto-Iwamoto, M. et al.:Matrix GLA protein is a developmental regulator of chondrocyte mineralization and, when constitutively expressed, blocks endochondral and intramembranous ossification in the limb. J. Cell Biol. 147 (5):1097-1108, 1999

• 32) Luo, G., dugy, P., Mckee, M. d. et al.:Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386:78-81, 2000

• 33) Bonin, L. R., Madden, K., Shera, K. et al.:Generation and characterization of human smooth muscle celllines derived from atherosclerotic plaque. Arterioscler. Thromb. Vasc. Biol. 19 (3):575-587, 1999

• 34) Wallin, R., Cain, D., Sane, d. C.:Matrix Gla protein synthesis and γ-carboxylation in the aortic vessel wall and proliferating vascular smooth muscle cells-a cell system which resembles the system in bone cells. Thromb. Haemost. 82 (6):1764-1767, 1999

• 35) Tsukamoto, K., Orimo, H., Hosoi, T. et al:Association of bone mineral density with polymorphism of the human matrix Gla protein locus in elderly women. J. Bone Miner. Metab. 18 (1):27-30, 2000
  pubmed

• 36) Munroe, P. B., Olgunturk, R. O., Fryns, J. P. et al:Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome. Nat. Genet. 21 (1):142-144, 1999
  pubmed

• 37) Yasui, T., Fujita, K., Sasaki, S. et al.:Expression of bone matrix proteins in urolithiasis model rats. Urol. Res. 27 (4):255-261, 1999
  pubmed

• 38) Hocking, A. M., Shinomura, T., McQuillan, d. J.:Leucine-rich repeat glycoproteins of the extracellular martrix. Matrix Biol. 17 (1):1-19, 1998

• 39) Hall, R. C., Embery G.:The use of immunohistochemistry in understanding the structure and function of the extracellular matrix of dental tissues. Adv. Dental Res. 11 (4):478-486, 1997
  pubmed

• 40) Kresse, H., Hausser, H., Schonherr, E. et al.:Biosynthesis and interactions of small chondroitin/ dermatan sulphate proteoglycans. Eur. J. Clin. Chem. Clin. Biochem. 32 (4):259-264, 1994
  pubmed

• 41) Matsushima, N., Ohyanagi, T., Tanaka, T. et al.:Super-motifs and evolution of tandem leucinerich repeats within the small proteoglycans-biglycan, decorin, lumican, fibromodulin, PRELP, keratocan, osteoadherin, epiphycan, and osteoglycin. Proteins 38 (2):210-225, 2000
  pubmed

• 42) Krishnan, P., Hocking, A. M., Scholtz, J. M. et al.:distinct secondary structures of the leucine-rich repeat proteoglycans decorin and biglycan. Glycosylation-dependent conformational stability. J. Biol. Chem. 274 (16):10945-10950, 1999
  pubmed

• 43) Tianshun, Xu., Paolo, B., Larry, W. et al:Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat. Genet. 20:78-82, 1998

• 44) Inoue, A., Hayakawa, T., Otsuka, E. et al:Correlation between induction of expression of biglycan and mineralization by C-type natriuretic peptide in osteoblastic cells. J. Biochem. 125 (1):103-108, 1999

• 45) Edwin, A. C., Todd, R. G., Eric, S. et al.:Genomic analysis of metastasis reveals an essential role for Rho C. Nature 406:532-535, 2000

• 46) McCormick, C., duncan, G., Tufaro, F.:New perspectives on the molecular basis of hereditary bone tumours. Mol. Med. Today 5 (11):481-486, 1999
  pubmed

• 47) Bowe, M. A., Mendis, d. B., Fallon, J. R.:The small leucine-rich repeat proteoglycan biglycan binds to α-dystroglycan and is upregulated in dystrophic muscle. J. Cell Biol. 148(4):801-810, 2000

• 48) Stokes, M. B., Holler, S., Cui, Y. et al.:Expression of decorin, biglycan, and collagen type I in human renal fibrosing disease. Kidney Int. 57 (2):487-498, 2000
  pubmed

• 49) Kavanagh, E., Ashhurst, d. E.:development and aging of the articular cartilage of the rabbit knee joint:distribution of biglycan, decorin, and matrilin-1. J. Histochem. Cytochem. 47 (12):1603-1616, 1999
  pubmed

• 50) Eddy, A. A.:Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J. Am. Soc. Nephrol. 5 (6):1273-1287, 1994
  pubmed

• 51) Patarca, R., Saavedra, R. A., Cantor, H.:Molecular and cellular basis of genetic resistance to bacterial infection:the role of the early T-lymphocyte activation-1/osteopontin gene. Crit. Rev. Immunol. 13 (3-4):225-246, 1993

• 52) Chambers, A. F., Tuck, A. B.:Ras-responsive genes and tumor metastasis. Crit. Rev. Oncogene. 4 (2):95-114, 1993
  pubmed

• 53) Baik, M. G., Lee, M. J., Choi, Y. J.:Gene expression during involution of mammary gland. Int. J. Mol. Med. 2 (1):39-44, 1998
  pubmed

• 54) Denhardt, d. T., Noda, M.:Osteopontin expression and function:role in bone remodeling. J. Cell. Biochem. (Suppl. ) 30-31:92-102, 1998

• 55) Rittling, S. R., Denhardt, d. T.:Osteopontin function in pathology:lessons from osteopontindeficient mice. Exp. Nephrol. 7 (2):103-113, 1999
  pubmed

• 56) McKee, M. D., Nanci, A.:Osteopontin:an interfacial extracellular matrix protein in mineralized tissues. Connect. Tissue Res. 35 (1-4):197-205, 1996

• 57) Nanci, A.:Content and distribution of noncollagenous matrix proteins in bone and cementum:relationship to speed of formation and collagen packing density. J. Struct. Biol. 126 (3):256-269, 1999
  pubmed

• 58) Noda, M., Yoon, K., Prince, C. W. et al.:Transcriptional regulation of osteopontin production in rat osteosarcoma cells by type β transforming growth factor. J. Biol. Chem. 263:13916-13921, 1988

• 59) Noda, M., Rodan, G. A.:Transcriptional regulation of osteopontin production in rat osteoblast-like cells by parathyroid hormone. J. Cell Biol. 108 (2):713-718, 1989
  pubmed

• 60) Heymann, D., Guicheux, J., Gouin, F. et al.:Cytokines, growth factors and osteoclasts. Cytokine 10 (3):155-168, 1998
  pubmed

• 61) Rittling, S. R., Matsumoto, H. N., McKee, M. d. et al.:Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J. Bone Miner. Res. 13 (7):1101-1111, 1998
  pubmed

• 62) Liaw, L, Birk, d. E., Ballas, C. B. et al:Altered wound healing in mice lacking a functional osteopontin gene (spp1) . J. Clin. Invest. 101 (7):1468-1478, 1998
  pubmed

• 63) Crawford, H. C., Matrisian, L. M., Liaw, L.:distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res. 58 (22):5206-5215, 1998
  pubmed

• 64) Yoshitake, H., Susan, R., Rittling, D. T. et al.:Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc. Natl. Acad. Sci. USA 96:8156-8160, 1999

• 65) Asou, Y., Rittling, S. R., Yoshitake, H. et al.:Osteopontin facilitates angiogenesis, accumulation of osteoclasts and resorption in ectopic bone. Endocrinology 142:(in press), 2001

• 66) Ihara, H., Denhardt, d. T., Furuya, K. et al.:Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin. J. Biol. Chem. 276:(in press), 2001
  pubmed

• 67) Benson, M. D., Bargeon, J. L, Xiao, G. et al:Identification of a homeodomain binding element in the bone sialoprotein gene promoter that is required for its osteoblast-selective expression. J. Biol. Chem. 275 (18):13907-13917, 2000
  pubmed

• 68) Bellahcene, A., Bonjean, K., Fohr, B. et al.:Bone sialoprotein mediates human endothelial cell attachment and migration and promotes angiogenesis. Circ. Res. 86 (8):885-891, 2000
  pubmed

P.142 掲載の参考文献

• 1) Stein, G. S., Lian, J. B.:Molecular mechanisms mediating proliferation/differentiation inter-relationships during progressive development of the osteoblast phenotype. Endocr. Rev. 14:424-442, 1993

• 2) ducy, P., Karsenty, G.:Genetic control of cell differentiation in the skeleton. Curr. Opin. Cell Biol. 10:614-619, 1998
  pubmed

• 3) Ibaraki, K., Termine, J. D., Whitson, W. et al.:Bone matrix mRNA expression in differentiating fetal bovine osteoblasts. J. Bone Miner. Res. 7:743-754, 1992

• 4) Harris, S., Bonewald, L. F., Harris, M. A. et al.:Effects of transforming growth factor β on bone nodule formation and expression of bone morphogenetic protein 2, Osteocalcin, osteopontin, alkaline phosphatase, and type I collagen mRNA in long-term cultures of fetal rat calvarial osteoblasts. J. Bone Miner. Res. 9:855-863, 1994

• 5) Wrana, J. L:Regulation of Smad activity. Cell 100:189-192, 2000
  pubmed

• 6) ducy, P., Zhang, R., Geoffroy, V. et al:Osf2/Cbfa1:Atranscriptional activator of osteoblast differentiation. Cell 89:747-754, 1997

• 7) Young, M. F., Kerr, J. M., Ibaraki, K. et al:Structure, expression and regulation of the major noncollagenous matrix proteins of bone. Clin. Orthop. 281:275-294, 1992
  pubmed

• 8) Raines, E. W., Lane, T. F., Iruela-Arispe, M. L. et al:The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PdGF)-AB and-BB and inhibits the binding of PdGF to its receptors. Proc. Natl Acad. Sci. USA 89:1281-1285, 1992
  pubmed

• 9) Takeuchi, Y., Kodama, Y., Matsumoto, T.:Bone matrix decorin binds transforming growth factor-β and enhances its bioactivity. J. Biol. Chem. 269:32634-32638, 1994

• 10) 久保木芳徳:骨と軟骨の有機成分-コラーゲン. BONE SCIENCE骨形成と骨吸収及びそれらの調節因子. (須田立雄 編)廣川書店, 1995, p. 59-75

• 11) Rossert, J., Eberspaecher, H., de Crombrugghe, B.:Separate cis-acting dNA elements of the mouse pro-α1 (I) collagen promoter direct expression of reporter genes to different type I collagen-producing cells in transgenic mice. J. Cell Biol. 129:1421-1432, 1995

• 12) Pavlin, D., Lichtler, A. C., Bedalov, A. et al.:differential utilization of regulatory domains within the α1 (d collagen promoter in osseous and fibroblastic cells. J. Cell Biol. 116:227-236, 1992

• 13) Rossert, J. A., Chen, S. S., Eberspaecher, H. et al.:Identification of a minimal sequence of the mouse pro-α1 (d collagen promoter that confers high-level osteoblast expression in transgenic mice and that binds a protein selectively present in osteoblasts. Proc. Natl. Acad. Sci. USA 93:1027-1031, 1996

• 14) Jimenez, S. A., Varga, J., Olsen, A. et al.:Functional analysis of human α1(I) procollagen gene promoter:differential activity in collagen-producing and-nonproducing cells and response to transforming growth factor b1. J. Biol. Chem. 269:12684-12691, 1994

• 15) Nakamura, T., Hanada, K., Tamura, M. et al.:Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats. Endocrinology 136:1276-1284, 1995
  pubmed

• 16) Cosman, F., Lindsay, R.:Is parathyroid hormone a therapeutic option for osteoporosis? A review of the Clinical evidence. Calcif. Tissue Int. 62:475-480, 1998
  pubmed

• 17) Komori, T., Yagi, S., Nomura, S. et al.:Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755-764, 1997

• 18) Ducy, P., Starbuck, M., Priemel, M. et al.:A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes. Dev. 13:1025-1036, 1999
  pubmed

• 19) Ducy, P., Desbois, C., Boyce, B. et al.:Increased bone formation in osteocalcin-deficient mice. Nature 382:448-452, 1996
  pubmed

• 20) Delany, A. M., Amling, M., Priemel, M. et al.:Osteopenia and decreased bone formation in osteonectin-deficient mice. J. Clin.Invest. 105:915-923, 2000
  pubmed

• 21) Yoshitake, H., Rittling, S. R., Denhardt, D. T. et al.:Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc. Natl. . Acad. Sci. USA 96:8156-8160, 1999
  pubmed

• 22) Xu, T., Bianco, P., Fisher, L. W. et al.:Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat. Genet. 20:78-82, 1998

• 23) Zhao, W., Byrne, M. H., Boyce, B. F. et al.:Bone resorption induced by parathyroid hormone is strikingly diminished in collagenase-resistant mutant mice. J. Clin. Invest. 103:517-524, 1999
  pubmed

• 24) Franceschi, R., Iyer, B. S., Cui, Y.:Effects of ascorbic acid on collagen matrix formation and osteoblast differentiation in murine MC3T3-E1 cells. J. Bone Miner. Res. 9:843-854, 1994

• 25) Schiro, J. A., Chan, B. M. C., Roswit, W. T. et al:Integrinα2β1 (VLA-2) mediates reorganization and contraction of collagen matrices by human cells. Cell 67:403-410, 1991

• 26) Takeuchi, Y., Nakayama, K, Matsumoto, T.:differentiation and cell surface expression of transforming growth factor-β receptors are regulated by interaction with matrix collagen in murine osteoblastic cells. J. Biol. Chem. 271:3938-3944, 1996

• 27) Riikonen, T., Koivisto, L., Vihinen, P. et al.:Transforming growth factor-β regulates collagen gel contraction by increasing α2 β1 integrin expression in osteogenic cells. J. Biol. Chem. 270:376-382, 1995

• 28) Jikko, A., Harris, S. E., Chen, d. et al.:Collagen. integrin receptors regulate early osteoblast differentiation induced by BMP-2. J. Bone Miner. JRes. 14:1075-1083, 1999

• 29) Xiao, G., Wang, D., Benson, M. d. et al.:Role of the α2-integrin in osteoblast-specific gene expression and activation of the Osf2 transcription factor. J. Biol. Chem. 273:32988-32994, 1998

• 30) Clark, E. A., Brugger, J. S.:Integrins and signal transduction pathways:the road taken. Science 268:233-239, 1995

• 31) Takeuchi, Y., Suzawa, M., Kikuchi, T. et al.:differentiation and transforming growth factor-β receptor down-regulation by collagen-α2βi integrin interaction is mediated by focal adhesion kinase and its downstream signals in murine osteoblastic cells. J. Biol. Chem. 272:29309-29316, 1997

• 32) Xiao, G., Jiang, D., Thomas, P. et al.:MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J. Biol. Chem. 275:4453-4459, 2000
  pubmed

• 33) Kretzschmar, M., Doody, J., Massague, J.:Opposing BMP and EGF signalling pathways converge on the TGF-β family mediator Smad1. Nature 389:618-622, 1997

• 34) Suzawa, M., Takeuchi, Y., Fukumoto, S. et al:Extracellular matrix-associated bone morphogenetic proteins are essential for differentiation of murine osteoblastic cells in vitro. Endocrinology 140:2125-2133, 1999
  pubmed

• 35) Wu, L. N. Y., Sauer, G. R., Wuthier, R. E.:Induction of mineral deposition by primary cultures of chicken growth plate chondrocytes in ascorbate-containing media:evidence of an association between matrix vesicles and collagen. J. Biol. Chem. 264:10917-10921, 1989

• 36) Matsumoto, T., Kawanobe, Y., Morita, K. et al:Effect of 1,25-dihydroxyvitamin D3 on phospholipid metabolism in a clonal osteoblast-like rat osteogenic sarcoma cell line. J. Biol. Chem. 260:13704-13709, 1985

• 37) Scott, J. E.:Proteoglycan-fibrillar collagen interactions. Biochem. J. 252:313-323, 1988
  pubmed

• 38) Hoshi, K., Kemmotsu, S., Takeuchi, Y. et al.:The primary calcification in bones follows removal of decorin and fusion of collagen fibrils. J. Bone Miner. Res. 14:273-280, 1999
  pubmed

• 39) Takeuchi, Y., Matsumoto, T., Ogata, E. et al.:1,25-dihydroxyvitamin D, inhibits synthesis and enhances degradation of proteoglycans in osteoblastic cells. J. Biol. Chem. 264:18407-18413, 1989

• 40) 佐々木 哲:石灰化の機構. BONE SCIENCE骨形成と骨吸収及びそれらの調節因子. (須田立雄 編)廣川書店, 1995, p.149-159

• 41) Waymire, K. G., Mahuren, J. D., Jaje, J. M. et al.:Mice lacking tissue non-specific alkaline phosphatase die from seizures due to defective metabolism of vitamin B-6. Nat. Genet. 11:45-51, 1995
  pubmed

• 42) Heath, J. K., Suva, L. J., Yoon, K. et al:Retinoic acid stimulates transcriptional activity from the alkaline phosphatase promoter in the immortalized rat calvarial cell line, RCT-1. Mol. Endocrinol. 6:636-646, 1992
  pubmed

P.154 掲載の参考文献

• 1) Parfitt, A. M.:The cellular basis of bone turnover and bone loss:arebuttal of the osteocytic resorption-bone flow theory. Clin. Orthop. 127:236-247, 1977
  pubmed

• 2) Doty, S. B.:Morphological evidence of gap junctions between bone cells. Calcif. Tissue Int. 33:509-512, 1981
  pubmed

• 3) Ilvesaro, J., Vaananen, K., Tuukkanen, J.:Bone-resorbing osteoclasts contain gap-junctional connexin-43 [In Process Citation]. J. Bone Miner. Res. 15:919-926, 2000

• 4) Palazzini, S., Palumbo, C., Ferretti, M. et al.:Stromal cell structure and relationships in perimedullary spaces of chick embryo shaft bones. Anat. Embryol. (Berl.) 197:349-357, 1998
  pubmed

• 5) Eriksen, E. F., Mosekilde, L, Melsen, F.:Kinetics of trabecular bone resorption and formation in hypothyroidism:evidence for a positive balance per remodeling cycle. Bone 7:101-108, 1986
  pubmed

• 6) Palumbo, C., Palazzini, S., Marotti, G.:Morphological study of intercellular junctions during osteocyte differentiation. Bone 11:401-406, 1990
  pubmed

• 7) Marotti, G.:The structure of bone tissues and the cellular control of their deposition. Ital. J. Anat. Embryol. 101:25-79, 1996
  pubmed

• 8) Nefussi, J. R., Sautier, J. M., Forest, N.:Cell culture model and concept of bone surface. C. R. Seances Soc. Biol. Fil. 187:620-632, 1993
  pubmed

• 9) Mikuni-Takagaki, Y., Suzuki, Y., Kawase, T. et al.:distinct responses of different populations of bone cells to mechanical stress. Endocrinology 137:2028-2035, 1996
  pubmed

• 10) Martin, R. B.:Does osteocyte formation cause the nonlinear refilling of osteons? Bone 26:71-78, 2000
  pubmed

• 11) Dunstan, C. R., Somers, N. M., Evans, R. A.:Osteocyte death and hip fracture. Calcif. Tissue Int. 53 (Suppl.1):S113-S116, 1993

• 12) Frost, H. M.:In vivo osteocyte death. J. Bone Joint Surg. 42A:138-143, 1960 13) Vaughan, J. M.:The effects of radiation on bone. The Biochemisry and Physiology of Bone. (Bourne, G. H. ed. ) New York, Academic Press, 1956, p. 729-766

• 14) Ham, A. W., Harris, W. R.:Repair and transplantation of bone. The Biochemisry and Physiology of Bone. (Bourne, G. H. ed. ) New York, Academic Press, 1956, p. 475-506

• 15) Wong, S. Y., Evans, R. A., Needs, C. et al.:The pathogenesis of osteoarthritis of the hip. Evidence for primary osteocyte death. Clin. Orthop 214:305-312, 1987
  pubmed

• 16) Tomkinson, A., Reeve, J., Shaw, R. W. et al.:The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J. Clin. Endocrinol. Metab. 82:3128-3135, 1997

• 17) Tomkinson, A., Gevers, E. F, Wit, J. M. et al.:The role of estrogen in the control of rat osteocyte apotosis. J.Bone Miner. Res. 13:1243-1250, 1998

• 18) Stevens, H. Y., Reeve, J., Noble, B. S.:Bcl-2, tissue transglutaminase and p53 protein expression in the apoptotic cascade in ribs of premature infants. J. Anat. 196 (Pt 2):181-191, 2000

• 19) Weinstein, R. S., Jilka, R. L., Parfitt, A. M. et al.:Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102:274-282, 1998

• 20) Jilka, R. L., Weinstein, R. S., Bellido, T. et al.:Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone[see comments]. J. Clin. Invest. 104:439-446, 1999

• 21) Plotkin, L. I., Weinstein, R. S., Parfitt, A. M. et al.:Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J. Clin. Invest. 104:1363-1374, 1999
  pubmed

• 22) Marotti, G., Farneti, D., Remaggi, F. et al:Morphometric investigation on osteocytes in human auditory ossicles. Anat. Anz. 180:449-453, 1998

• 23) Migliaccio, A., Piccolo, D., Castoria, G. et al.:Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 17:2008-2018, 1998
  pubmed

• 24) Wolff, J. L.:1986 The Law of Bone Remodeling (das Gesetz der Transformation der Knochen, 1892) . (Translated by Maquet, P., Furlong, R. ) . Springer-Verlag, Berlin

• 25) Pead, M. J., Suswillo, R. S., Skerry, T. M. et al.:Increased 3H-uridine levels in osteocytes following asingle short period of dynamic loading in vivo. Calcif. Tissue Int. 43:92-96, 1988

• 26) Skerry, T. M., Bitensky, L, Chayen, J. et al.:Early strain-related changes in enzyme activity in osetocytes following bone loading in vivo. J. Bone Miner. Res. 4:783-788, 1989
  pubmed

• 27) Rawlinson, S. C., El-Haj, A. J., Minter, S. L. et al.:Loading-related increases in prostaglandin production in cores of adult canine cancellous bone in vitro:arole for prostacyclin in adaptive bone remodeling? J. Bone Miner. Res. 6:1345-1351, 1991

• 28) Cowin, S. C., Moss-Salentijn, L, Moss, M. L:Candidates for the mechanosensory system in bone. J. Biomed. Eng. 113:191-197, 1991

• 29) Van der Plas, A., Nijweide, P. J.:Isolation and purification of osteocytes. J. Bone Miner. .Res. 7:389-396, 1992

• 30) Mikuni-Takagaki, Y., Kakai, Y., Satoyoshi, M. et al.:Matrix mineralization and the differentiation of osteocyte-like cells in culture. J. Bone Miner. Res. 10:231-242, 1995
  pubmed

• 31) Klein-Nulend, J., Semeins, C. M., Ajubi, N. E. et al.:Pulsating fluid flow increases nitric oxide (NO) synthesis by osteocytes but not periosteal fibroblasts-correlation with prostaglandin upregulation. Biochem. Biophys. Res. Commun. 217:640-648, 1995

• 32) Lean, J. M., Mackay, A. G., Chow, J. W. et al.:Osteocytic expression of mRNA for c-fos and IGF-I:an immediate early gene response to an osteogenic stimulus. Am. J. Physiol. 270:E937-E945, 1996

• 33) Kawata, A., Mikuni-Takagaki, Y.:Mechanotransduction in stretched osteocytes-temporal expres sion of immediate early and other genes. Biochem. Biophys. Res. Commun. 246:404-408, 1998

• 34) Maejima-Ikeda, A., Aoki, M., Tsuritani, K. et al.:Chick osteocyte derived protein inhibits osteoclastic bone resorption. Biochem. J. 322:245-250, 1997
  pubmed

• 35) Rubin, C., Sun, Y. Q., Hadjiargyrou, M. et al.:Increased expression of matrix metalloproteinaselin osteocytes precedes bone resorption as stimulated by disuse:evidence for autoregulation of the cell:s mechanical environment? J. Orthop. Res. 17:354-361, 1999
  pubmed

• 36) Resnick, N., Collins, T., Atkinson, W. et al.:Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element. Proc. Natl. Acad. Sci. USA 90:4591-4595, 1993
  pubmed

• 37) Khachigian, L. M., Resnick, N., Gimbrone, M. A. Jr. et al.:Nuclear factor-xB interacts functionally with the platelet-derived growth factor B-chain shear-stress response element in vascular endothelial cells exposed to fluid shear stress. J. Clin. Invest. 96:1169-1175, 1995

• 38) Chien, S., Li, S., Shyy, Y. J.:Effects of mechanical forces on signal transduction and gene expression in endothelial cells. Hypertension 31:162-169, 1998
  pubmed

• 39) 安藤譲二 編:シェアストレスと内皮細胞. メディカルレビュー社

• 40) Reich, K. M., Frangos, J. A.:Effect of flow on prostaglandin E2 and inositol triphosphate levels in osteoblasts. Am. J. Physiol. 261:c428-c432, 1991

• 41) Klein-Nulend, J., Burger, E. H., Semeins, C. M. et al:Pulsating fluid flow stimulates prostaglandin release and inducible prostaglandin G/H synthase mRNA expression in primary mouse bone cells. J. Bone Miner. Res. 12:45-51, 1997

• 42) Zaman, G., Pitsillides, A. A., Rawlinson, S. C. et al.:Mechanical strain stimulates nitric oxide production by rapid activation of endothelial nitric oxide synthase in osteocytes. J. Bone Miner. Res. 14:1123-1131, 1999
  pubmed

• 43) McAllister, T. N., Frangos, J. A.:Steady and transient fluid shear stress stimulate NO release in osteoblasts through distinct biochemical pathways. J. Bone Miner. Res. 14:930-936, 1999
  pubmed

• 44) McAllister, T. N., du, T., Frangos, J. A.:Fluid shear stress stimulates prostaglandin and nitric oxide release in bone marrow-derived preosteoclast-like cells. Biochem. Biophys. Res. Commun. 270:643-648, 2000
  pubmed

• 45) Shen, J., Luscinskas, F. W., Gimbrone, M. A. Jr. et al.:Fluid flow modulates vascular endothelial cytosolic calcium responses to adenine nucleotides. Microcirculation 1:67-78, 1994
  pubmed

• 46) Naemsch, L. N., Weidema, A. F., Sims, S. M. et al.:P2X (4) purinoceptors mediate an ATP-activated, non-selective cation current in rabbit osteoclasts. J. Cell. Sci. 112:4425-4435, 1999
  pubmed

• 47) Yao, X., Kwan, H. Y., Chan, F. L. et al:Aprotein kinase G-sensitive channel mediates flow-induced Ca (2+) entry into vascular endothelial cells. FASEB J. 14:932-938, 2000

• 48) Hirooka, K., Kourennyi, d. E., Barnes, S.:Calcium channel activation facilitated by nitric oxide in retinal ganglion cells. J. Neurophysiol. 83:198-206, 2000
  pubmed

• 49) Westbroek, I., Ajubi, N. E, Alblas, M. J. et al:differential stimulation of prostaglandin G/H synthase-2 in osteocytes and other osteogenic cells by pulsating fluid flow. Biochem. Biophys. Res. Commun. 268:414-419, 2000
  pubmed

• 50) Sakai, K., Mohtai, M., Iwamoto, Y.:Fluid shear stress increases transforming growth factor β1 expression in human osteoblast-like cells:modulation by cation channel blockades. Calcif Tissue Int. 63:515-520, 1998

• 51) Owan, I., Burr, d. B., Turner, C. H. et al:Mechanotransduction in bone:osteoblasts are more responsive to fluid forces than mechanical strain. Am. J. Physiol. 273:C810-C815, 1997
  pubmed

• 52) Chow, J. W., Fox, S., Jagger, C. J. et al.:Role for parathyroid hormone in mechanical responsiveness of rat bone. Am. J. Physiol. 274:E146-E154, 1998
  pubmed

• 53) Sekiya, H., Mikuni-Takagaki, Y., Kondoh, T. et al.:Synergistic effect of PTH on the mechanical responses of human alveolar osteocytes. Biochem. Biophys. Res. Commun. 264:719-723, 1999
  pubmed

• 54) Miyauchi, A., Notoya, K., Mikuni-Takagaki, Y. et al.:Parathyroid hormone-activated volume-sensitive calcium influx pathways in mechanically loaded osteocytes. J. Biol. Chem. 275:3335-3342, 2000
  pubmed

• 55) Chow, J. W., Chambers, T. J.:Indomethacin has distinct early and late actions on bone formation induced by mechanical stimulation. Am. J. Physiol. 267:E287-E292, 1994

• 56) 曽我部正博, 千 文可, 威 智ほか:伸展活性化Ca2+透過チャネル. カルシウムイオンとシグナル伝達. 蛋白質核酸酵素43:1628-1635, 1998

• 57) Corey, d. P., Garcia-Anoveros, J.:Mechanosensation and the DEG/ENaC ion channels. Science 273:323-324, 1996
  pubmed

• 58) Trussell, L.:Mutant ion channel in cochlear hair cells causes deafness. Proc. Natl. Acad. Sci. USA97:3786-3788, 2000

• 59) Okabe, K., Okamoto, F., Kajiya, H. et al.:Multiple Ionic Channels Play the Role of Mechano-Receptor in Stretched Rat Osteocytes. J. Bone Miner. Res. 14:S480, 1999

• 60) Mikuni-Takagaki, Y., Kawata, A., Kawase, T. et al.:Mechanosensitive Ion Channels Specific to Osteocytes. J. Bone. Miner. Res. 14:S206, 1999

• 61) Laketic-Ljubojevic, I., Suva, L. J., Maathuis, F. J. et al.:Related Articles Functional characterization of N-methyl-D-aspartic acid-gated channels in bone cells. Bone 25:631-637, 1999

• 62) Maingret, F., Fosset, M., Lesage, F. et al.:TRAAK is a mammalian neuronal mechano-gated K+ channel. J. Biol. Chem. 274:1381-1387, 1999

• 63) Duan, D., Winter, C., Cowley, S. et al.:Molecular identification of a volume-regulated chloride channel. Nature 390:417-421, 1997
  pubmed

• 64) Suzuki, M., Sato, J., Kutsuwada, K. et al.:Cloning of a stretch-inhibitable nonselective cation channel. J. Biol. Chem. 274:6330-6335, 1999

• 65) Sukharev, S. I., Blount, P., Martinac, B. et al.:A large-conductance mechanosensitive channel in E. coli encoded by MscL alone. Nature 368:265-268, 1994

• 66) Kanzaki, M., Nagasawa, M., Kojima, I. et al.:Related Articles Molecular identification of a eukaryotic, stretch-activated nonselective cation channel. Science 285:882-886, 1999

• 67) Mikuni-Takagaki, Y.:Mechanical responses and signal transduction pathways in stretched osteocytes. J. Bone Miner. Metab. 17:57-60, 1999
  pubmed

• 68) Langton, P. d.:Calcium channel currents recorded from isolated myocytes of rat basilar artery are stretch sensitive. J. Physiol. (Lond. ) 471:1-11, 1993
  pubmed

• 69) Duncan, R. L., Kizer, N., Barry, E. L. et al.:Antisense oligodeoxynucleotide inhibition of a swelling-activated cation channel in osteoblast-like osteosarcoma cells. Proc. Natl. Acad. Sci. USA 93:1864-1869, 1996
  pubmed

第2章 骨代謝調節因子の分子作用機構

P.170 掲載の参考文献

• 1) Mangelsdorf, J., Thummel, C., Beato, M. et al.:The nuclear receptor superfamily the second decade. Cell 83:835-839, 1995

• 2) Beato, M., Herrlich, P., Schutz, G.:Steroid hormone receptors. Many actors in search of a plot. Cell 83:851-857, 1995
  pubmed

• 3) Tontonoz, P., Nagy, L., Alvarez, J. et al.:PPARγpromotes monocyte/macrophage differentiation and uptake of oxidized. LDL. Cell 93:241-252, 1998

• 4) Makishima, M., Okamoto, A., Repa, J. et al:Identification of a Nuclear Receptor for Bile Acids. Science 284:1362-1365, 1999
  pubmed

• 5) Beato, M., Heerrlich, P., Chambon, P.:Steroid hormone receptors. many actors in search of plot. Cell 83:851-857, 1995

• 6) Tasset, D., Tora, L., Fromental, C. et al.:distinct classes of transcriptional activating domains function by different mechanisms. Cell 62:1177-1187, 1990
  pubmed

• 7) Kato, S., Endo, H., Masuhiro, Y. et al.:Activation of the estrogen receptor through phosphorilation by mitogen-activated protein kinase. Science 270:1491-1494, 1995

• 8) Umesono, K., Murakami, K., Thompson, C. et al.:direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell 65:1255-1266, 1991
  pubmed

• 9) Bjorklund, S., Almouzni, G., Davidson, I. et al.:Global transcription regulators of eukaryotes. Cell 96:759-767, 1999
  pubmed

• 10) Freedman, P.:Increasing the complexity of coactivation in nuclear receptor signaling. Cell 97:5-8, 1999

• 11) Wurtz, M., Bourguet, W., Renaud, P. et al:Acanonical structure for the ligand-binding domain of nuclear receptors. Nature Structural Biology 3:87-94, 1996

• 12) Shiau, A., Barstad, D., Loria, P. et al:The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937, 1998
  pubmed

• 13) Kobayashi, Y., Kitamoto, T., Masuhiro, Y. et al.:p300 mediates functional synergims between AF-1 and AF-2 of estrogen receptor α and β by interacting directly with the N-terminal A/B domains. J. Boil. Chem. 275:15645-15651, 2000

• 14) Tora, L., White, J., Brou, C. et al.:The human estrogen receptor has two independent non-acidic transcriptional activation functions. Cell 59:477-487, 1989

• 15) Cavailles, V., Dauvois, S., Danielian, P. S. et al.:Interaction of proteins with transcriptionally active estrogen receptors. Proc. Natl. Acad. 91:10009-10013, 1994
  pubmed

• 16) Halachmi, S., Marden, E., Martin, G. et al.:Estrogen receptor-associated proteins:possible mediators of hormone-induced transcription. Science 264:1455-1458, 1994
  pubmed

• 17) Onate, A., Tsai, Y., Tsai, J. et al.:Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 27e:1354-1357, 1995

• 18) Heery, d. M., Kalkhoven, E., Hoare, S. et al:Asignature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733-736, 1997
  pubmed

• 19) Rachez, C., Lemon, D., Suldan, Z. et al.:Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 398:824-828, 1999

• 20) Takeyama, K., Masuhiro, Y., Fuse, H. et al.:Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Mol. Cell. Biol. 19:1049-1055, 1999

• 21) Kamei, Y., Xu, L., Heinzel, T. et al.:A CBP integrator complex mediates transcriptional activation and AP-l inhibition by nuclear receptors. Cell 85:403-414, 1996

• 22) Kalkhoven, E., Valentine, J. E, Heery, d. M. et al.:Isoforms of steroid receptor co-activator l differ in their ability to potentiate transcription by the oestrogen receptor. EMBO J. 17:232-243, 1998

• 23) Lanz, B., McKenna, J., Onate, A. et al:As teroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-l complex. Cell 97:17-27, 1999

• 24) Gu, W., Malik, S., Ito, M. et al.:Anovel human SRB/MEd-containing cofactor complex, SMCC, involved in transcription regulation. Mol. Cell 3:97-108, 1999

• 25) Spencer, T. E., Jenster, G., Burcin, M. M. et al.:Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389:194-198, 1997
  pubmed

• 26) Chen, H., Lin, R. J., Xie, W. et al.:Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell 98:675-686, 1999

• 27) Nagy, L., Kao, Y., Chakravarti, d. et al.:Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89:373-380, 1997

• 28) Wu, Z., Puigserver, P., Andersson, U. et al.:Mechanisms Controlling Mitochondrial Biogenesis and Respiration through the Thermogenic Coactivator PGC-1. Cell 98:115-124, 1999
  pubmed

• 29) Endoh, H., Maruyama, K., Masuhiro, Y. et al.:Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function l of human estrogen receptor α. Mol. Cell. Biol. 19:5363-5372, 1999

P.182 掲載の参考文献

• 1) Evans, R. M.:The steroid and thyroid hormone receptor superfamily. Science 240:889-895, 1988
  pubmed

• 2) Kuiper, G. G., Enmark, E., Pelto-Huikko, M. et al:Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci USA 93:5925-5930, 1996
  pubmed

• 3) Ogawa, S., Inoue, S., Watanabe, T. et al.:The complete primary structure of human estrogen receptor β (hERβ) and its heterodimerization with ERαin vivo and in vitro. Biochem. Biophys. Res. Commun. 243:122-126, 1998

• 4) Hiroi, H., Inoue, S., Watanabe, T. et al.:Differential immunolocalization of estrogen receptor α and β in rat ovary and uterus. J. Mol. Endocrinol. 22 (1):37-44, 1999

• 5) Watanabe, T., Inoue, S., Ogawa, S. et al.:Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype:functional difference between estrogen receptors α and β. Biochem. Biophys. Res. Commun. 236:140-145, 1997

• 6) Onoe, Y., Miyaura, C., Ohta, H. et al:Expression of estrogen receptor β in rat bone. Endocrinology I38:4509-4512, 1997

• 7) Arts, J., Kuiper, G. G., Janssen, J. M. et al:differential expression of estrogen receptors α and β mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology 138:5067-5070, 1997

• 8) Kameda, T., Mano, H., Yuasa, T. et al.:Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J. . Exp. Med. 186:489-495, 1997
  pubmed

• 9) Windahl, S. H., Norgard, M., Kuiper, G. G. et al.:Cellular distribution of estrogen receptor β in neonatal rat bone. Bone 26 (2):117-121, 2000

• 10) Vidal, O., Kindblom, L. G., Ohlsson, C.:Expression and localization of estrogen receptor-β in murine and human bone. J. Bone Miner. Res. 14 (6):923-929, 1999

• 11) Paech, K., Webb, P., Kuiper, G. G. et al.:differential ligand activation of estrogen receptors ERα and ERβ at API sites. Science 277 (5331):1508-1510, 1997

• 12) Brzozowski, A. M., Pike, A. C., Dauter, Z. et al.:Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (6652):753-758, 1997
  pubmed

• 13) Smith, E. P., Boyd, J., Frank, G. R. et al.:Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 331:1056-1061, 1994

• 14) Sudhir, K., Chou, T. M., Chatterjee, K. et al.:Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation 96:3774-3777, 1997

• 15) Lubahn, d. B., Moyer, J. S., Golding, T. S. et al.:Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc. Natl. Acad. Sci. USA 90:11162-11166, 1993

• 16) Krege, J. H., Hodgin, J. B., Couse, J. F. et al.:Generation and reproductive phenotypes of mice lacking estrogen receptorβ. Proc. Natl. Acad. Sci. USA 95 (26):15677-15682, 1998

• 17) Windahl, S. H., Vidal, O., Andersson, G. et al.:Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERβ (-/-) mice. J. Clin. .Invest. 104 (7):895-901, 1999

• 18) Karas, R. H., Hodgin, J. B., Kwoun, M. et al.:Estrogen inhibits the vascular injury response in estrogen receptorβ-deficient female mice. Proc. Natl. Acad. Sci. USA 96 (26):15133-15136, 1999

• 19) Simpson, E. R.:Genetic mutations resulting in estrogen insufficiency in the male. Mol. Cell. Endocrinol. 145:55-59, 1998
  pubmed

• 20) Fisher, C. R., Graves, K. H., Parlow, A. F. et al.:Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp 19 gene. Proc. Natl. Acad. Sci. USA 95:6965-6970, 1998
  pubmed

• 21) Couse, J. F., Korach, K. S.:Estrogen receptor null mice:what have we learned and where will they lead us? Endocr. Rev. 20 (3):358-417, 1999
  pubmed

• 22) Couse, J. F., Hewitt, S. C., Bunch, D. O. et al.:Postnatal sex reversal of the ovaries in mice lacking estrogen receptors α and β. Science 286 (5448):2328-2331, 1999

• 23) Ogawa, S., Inoue, S., Orimo, A. et al.:Cross-inhibition of both estrogen receptor α and β pathways by each dominant negative mutant. FEBS Lett. 423:129-132, 1998

• 24) Ogawa, S., Fujita, M., Ishii, Y. et al.:Impaired estrogen sensitivity in bone by inhibiting both estrogen receptor α and β pathways. J. Biol. Chem. 275 (28):21372-21379, 2000

• 25) Inoue, S., Kondo, S., Hashimoto, M. et al.:Isolation of estrogen receptor-binding sites in human genomic DNA. Nucleic. . Acids. Res. 19 (15):4091-4096, 1991

• 26) Inoue, S., Kondo, S., Muramatsu, M.:Identification of target genes for a transcription factor by genomic binding site (GBS) cloning (1998) Transcription Factors-A Practical Approach, 2nd Edition (Latchman, d. S. ed. ) IRL press, 1998, p. 165-178

• 27) Inoue, S., Orimo, A., Hosoi, T. et al.:Genomic binding-site cloning reveals an estrogen-responsive gene that encodes a RING finger protein. Proc. Natl. Acad. Sci. USA 90:11117-11121, 1993
  pubmed

• 28) Orimo, A., Inoue, S., Ikeda, K. et al.:Molecular cloning, structure, and expression of mouse estrogen-responsive finger protein Efp. Co-localization with estrogen receptor mRNA in target organs. J. Biol. Chem. 270:24406-24413, 1995
  pubmed

• 29) Ikeda, K., Orimo, A., Higashi, Y. et al.:Efp as a primary estrogen-responsive gene in human breast cancer. FEBS Lett. 472 (1):9-13, 2000
  pubmed

• 30) Orimo, A., Inoue, S., Minowa, O. et al.:Underdeveloped uterus and reduced estrogen responsiveness in mice with disruption of the estrogen-responsive finger protein gene, which is a direct target of estrogen receptor α. Proc. Natl. Acad. Sci. USA 96 (21):12027-12032, 1999

• 31) Inoue, S., Urano, S., Ogawa, S. et al.:Molecular cloning of rat efp:expression and regulation in primary osteoblasts. Biochem. Biophys. Res. Commun. 261:412-418, 1999

• 32) Muramatsu, M., Inoue, S.:Estrogen receptors:How do they control reproductive and nonreproductive functions. Biochem. Biophys. Res. Commun. 270 (1):1-10, 2000
  pubmed

P.195 掲載の参考文献

• 1) Baker, A. R., Mcdonnell, D. P., Hughes, M. et al.:Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc. Natl. Acad. Sci. USA 85:3294-3298, 1988
  pubmed

• 2) Kamei, Y., Kawada, T., Fukuwatari, T. et al.:Cloning and sequencing of the gene encoding the mouse vitamin D receptor. Gene 152:281-282, 1995
  pubmed

• 3) Burmester, J. K., Maeda, N., deLuca, H. F.:Isolation and expression of rat 1,25-dihydroxyvitamin D3 receptor cDNA. Proc. Natl. Acad. Sci. USA 85:1005-1009, 1988
  pubmed

• 4) Neibergs, H. L, Bosworth, B. T., Reinhardt, T. A.:Nucleotide sequence of the bovine vitamin D3 receptor. J. Dairy Sci. 79:1313-1315, 1996
  pubmed

• 5) Lu, Z., Hanson, K., deLuca, H. F.:Cloning and origin of the two forms of chicken vitamin D receptor. Arch. Biochem. Biophys. 339:99-106, 1997
  pubmed

• 6) Elaroussi, M. A., Prahl, J. M., deLuca, H. F.:The avian vitamin D receptors:primary structures and their origins. Proc. Natl. Acad. Sci. USA 91:11596-11600, 1994
  pubmed

• 7) Hughes, S., Zelus, D., Mouchiroud, d.:Warm-blooded isochore structure in Nile crocodile and turtle. Mol Biol. Evol. 16:1521-1527, 1999
  pubmed

• 8) Li, Y. C., Bergwitz, C., Juppner, H. et al.:Cloning and characterization of the vitamin D receptor from Xenopus laevis. Endocrinology 138:2347-2353, 1997
  pubmed

• 9) Suzuki, T., Suzuki, N., Srivastava, A. S. et al.:Identification of cDNAs encoding two subtypes of vitamin D receptor in flounder, Paralichthys olivaceus. Biochem. Biophys. Res. Commun. 270:40-45, 2000

• 10) Fisk, G. J., Thummel, C. S.:Isolation, regulation, and DNA-binding properties of three Drosophila nuclear hormone receptor superfamily members. Proc. Natl. Acad. Sci. USA 92:10604-10608, 1995
  pubmed

• 11) Waterston, R., Martin, C., Craxton, M. et al.:A survey of expressed genes in Caenorhabditis elegans. Nat. Genet. 1:114-123, 1992

• 12) Michigami, T., Suga, A., Yamazaki, M. et al:Identification of amino acid sequence in the hinge region of human vitamin D receptor that transfers a cytosolic protein to the nucleus. J. Biol. Chem. 274:33531-33538, 1999

• 13) Kliewer, S. A., Umesono, K., Mangelsdorf, d. J. et al.:Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 355:446-449, 1992
  pubmed

• 14) Kurokawa, R., Yu, V. C., Naar, A. et al.:differential orientations of the dNA-binding domain and carboxy-terminal dimerization interface regulate binding site selection by nuclear receptor heterodimers. Genes. dev. 7:1423-1435, 1993
  pubmed

• 15) Solomon, C., White, J. H., Kremer, R.:Mitogen-activated protein kinase inhibits 1,25-dihydroxyvitamin D3-dependent signal transduction by phosphorylating human retinoid X receptor α. J. Clin. Invest. 103:1729-1735, 1999

• 16) Hsieh, J. C., Whitfield, G. K., Oza, A. K. et al.:Characterization of unique DNA-binding and transcriptional-activation functions in the carboxyl-terminal extension of the zinc finger region in the human vitamin D receptor. Biochemistry 38:16347-16358, 1999
  pubmed

• 17) Nakajima, S., Hsieh, J. C, Macdonald, P. N. et al.:The C-terminal region of the vitamin D receptor is essential to form a complex with a receptor auxiliary factor required for high affinity binding to the vitamin D-responsive element. Mol. Endocrinol. 8:159-172, 1994

• 18) Whitfield, G. K., Hsieh, J. C., Nakajima, S. et al.:A highly conserved region in the hormonebinding domain of the human vitamin D receptor contains residues vital for heterodimerization with retinoid X receptor and for transcriptional activation [published erratum appears in Mol. Endocrinol. 1995 Nov;9 (11):1509]. Mol. Endocrinol. 9:1166-1179, 1995

• 19) Ebihara, K., Masuhiro, Y., Kitamoto, T. et al.:Intron retention generates a novel isoform of the murine vitamin D receptor that acts in a dominant negative way on the vitamin D signaling pathway. Mol. Cell. Biol. 16:3393-3400, 1996

• 20) Umesono, K., Murakami, K. K, Thompson, C. C. et al:direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors α 1165:1255-1266, 1991

• 21) Schrader, M., Nayeri, S., Kahlen, J. P. et al.:Natural vitamin D3 response elements formed by inverted palindromes:polarity-directed ligand sensitivity of vitamin D3 receptor-retinoid X receptor heterodimer-mediated transactivation. Moll. Cell. Biol. 15:1154-1161, 1995

• 22) Mackey, S. L., Heymont, J. L, Kronellberg, H. M. et al.:vitamin D receptor binding to the negative human parathyroid hormone vitamin D response element does not require the retinoid X receptor. Mol. Endocrinol. 10:298-305, 1996

• 23) Liu, S. M., Koszewski, N., Lupez, M. et al.:Characterization of a response element in the 5'-flanking region of the avian (chicken) PTH gene that mediates negative regulation of gene transcription by 1,25-dihydroxyvitamin D3 and binds the vitamin D3 receptor. Mol. Endocrinol. 10:206-215, 1996
  pubmed

• 24) Kurokawa, R., diRenzo, J., Boehm, M. et al:Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding. Nature 371:528-531, 1994
  pubmed

• 25) Nishishita, T., Okazaki, T., Ishikawa, T. et al:A negative vitamin D response DNA element in the human parathyroid hormone-related peptide gene binds to vitamin D receptor along with Ku antigen to mediate negative gene regulation by vitamin D. J. Biol. Chem. 273:10901-10907, 1998
  pubmed

• 26) Towers, T. L, Freedman, L. P.:Granulocyte-macrophage colony-stimulating factor gene transcription is directly repressed by the vitamin D3 receptor. Implications for allosteric influences on nuclear receptor structure and function by a DNA element. J. Biol. Chem. 273:10338-10348, 1998
  pubmed

• 27) Towers, T. L., Staeva, T. P., Freedman, L. P.:A two-hit mechanism for vitamin D3-mediated transcriptional repression of the granulocyte-macrophage colony-stimulating factor gene:vitamin D receptor competes for DNA binding with NFATI and stabilizes c-Jun. Mol. Cell. Biol. 19:4191-4199, 1999

• 28) Alroy, I., Towers, T. L, Freedman, L. P.:Transcriptional repression of the interleukin-2 gene by vitamin D3:direct inhibition of NFATp/AP-l complex formation by a nuclear hormone receptor. Mol. Cell. Biol. 15:5789-5799, 1995

• 29) Takeuchi, A., Reddy, G. S., Kobayashi, T. et al.:Nuclear factor of activated T cells (NFAT) as a molecular target for 1α, 25-dihydroxyvitamin D3-mediated effects. J. Immunol. 160:209-218, 1998

• 30) Chrivia, J. C., Kwok, R. P., Lamb, N. et al.:Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 365:855-859, 1993

• 31) Yang, X. J., Ogryzko, V. V., Nishikawa, J. et al.:A p300/CBP-associated factor that competes with the adenoviral oncoprotein EIA. Nature 382:319-324, 1996

• 32) Torchia, J., Rose, d. W., Inostroza, J. et al.:The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387:677-684, 1997
  pubmed

• 33) Kurokawa, R., Kalafus, D., Ogliastro, M. H. et al.:Differential use of CREB binding protein-coactivator complexes. Science 279:700-703, 1998
  pubmed

• 34) Kamei, Y., Xu, L., Heinzel, T. et al.:A CBP integrator complex mediates transcriptional activation and AP-l inhibition by nuclear receptors. Cell 85:403-414, 1996

• 35) diamond, M. I., Miner, J. N., Yoshinaga, S. K. et al.:Transcription factor interactions:selectors of positive or negative regulation from a single DNA element. Science 249:1266-1272, 1990
  pubmed

• 36) Nagy, L., Kao, H. Y., Chakravarti, d. et al.:Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89:373-380, 1997
  pubmed

• 37) Heinzel, T., Lavinsky, R. M., Mullen, T. M. et al.:Acomplex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387:43-48, 1997

• 38) Ogryzko, V. V., Schiltz, R. L, Russanova, V. et al.:The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87:953-959, 1996
  pubmed

• 39) Minucci, S., Horn, Y., Bhattacharyya, N. et al.:A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. Proc. Natl. Acad. Sci. USA 94:11295-11300, 1997

• 40) Glass, C. K., Rosenfeld, M. G.:The coregulator exchange in transcriptional functions of nuclear receptors. Genes. . Dev. 14:121-141, 2000
  pubmed

• 41) Baudino, T. A., Kraichely, d. M., Jefcoat, S. C. Jr. et al.:Isolation and characterization of a novel coactivator protein, NCoA-62, involved in vitamin D-mediated transcription. J. Biol. Chem. 273:16434-16441, 1998
  pubmed

• 42) Leo, C., Li, H., Chen, J. d.:Differential mechanisms of nuclear receptor regulation by receptor-associated coactivator 3. J. Biol. Chem. 275:5976-5982, 2000

• 43) Rachez, C., Lemon, B. D., Suldan, Z. et al.:Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 398:824-828, 1999
  pubmed

• 44) Rachez, C., Suldan, Z., Ward, J. et al.:A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. Genes. Dev. 12:1787-1800, 1998

• 45) Ito, M., Yuan, C. X., Malik, S. et al.:Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators. Mol. Cell 3:361-370, 1999
  pubmed

• 46) Naar, A. M., Beaurang, P. A., Zhou, S. et al.:Composite co-activator ARC mediates chromatin-directed transcriptional activation. Nature 398:828-832, 1999
  pubmed

• 47) Cooney, A. J., Leng, X., Tsai, S. Y. et al:Multiple mechanisms of chicken ovalbumin upstream promoter transcription factor-dependent repression of transactivation by the vitamin D, thyroid hormone, and retinoic acid receptors. J. Biol. Chem. 268:4152-4160, 1993
  pubmed

• 48) Lee, Y.-F., Young, W.-J., Lin, W.-J. et al.:Differential regulation of direct repeat 3 vitamin D3 and direct repeat 4 thyroid hormone signaling pathways by the human TR4 orphan receptor. J. Biol. Chem. 274:16198-16205, 1999
  pubmed

• 49) Nakajima, S., Yamagata, M., Sakai, N. et al.:Effect of cyclic adenosine 3', 5:-monophosphate and protein kinase A on ligand-dependent transactivation via the vitamin D receptor. Mol. Cell. Endocrinol. 159:45-51, 2000
  pubmed

• 50) Yanagisawa, J., Yanagi, Y., Masuhiro, Y. et al.:Convergence of transforming growth factor-β and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 283:1317-1321, 1999

• 51) Okano, T., Tsugawa, N., Masuda, S. et al.:Regulatory activities of 2β-(3-hydroxypropoxy)-1α, 25-dihydroxyvitamin D3, a novel synthetic vitamin D3 derivative, on calcium metabolism. Biochem. Biophys. Res. Commun. 163:1444-1449, 1989

• 52) Ono, Y., Kawase, A., Watanabe, H. et al.:Syntheses and preventive effects of analogues related to 1α, 25-dihydroxy-2β-(3-hydroxypropoxy) vitamin D3, (ED-71) on bone mineral loss in ovariectomized rats. Bioorg. Med. Chem. 6:2517-2523, 1998

• 53) Song, L. N., Cheng, T.:Effects of 1,25-dihydroxyvitamin D3 analogue l, 24 (OH) 2-22-ene-24-cyclopropyl D3 on proliferation and differentiation of a human megakaryoblastic Leukemia cell line. Biochem. Pharmacol. 43:2292-2295, 1992

• 54) Colston, K. W., Chander, S. K., Mackay, A. G. et al.:Effects of synthetic vitamin D analogues on breast cancer cells proliferation in vivo and in vitro. Biochem. Pharmacol. 44:693-702, 1992
  pubmed

• 55) Hickish, T., Cunningham, D., Colston, K. et al.:The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. Br. J. Cancer 68:668-672, 1993
  pubmed

• 56) Binderup, L., Latini, S., Binderup, E. et al:20-epi-vitamin D3 analogues:a novel class of potent regulators of cell growth and immune responses. Biochem. Pharmacol. 42:1569-1575, 1991
  pubmed

• 57) Blutt, S. E., Mcdonnell, T. J., Polek, T. C. et al.:Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141:10-17, 2000
  pubmed

• 58) Kiriyama, T., Okamoto, S., Ejima, E. et al.:Effect of a highly potent fluoro analog of 1,25-dihydroxyvitamin D3 on human bone-derived cells. Endocrinology 128:81-86, 1991
  pubmed

• 59) Asou, H., Koike, M., Elstner, E. et al.:19-nor vitamin-d analogs:a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. Blood 92:2441-2449, 1998

• 60) Inoue, D., Matsumoto, T., Ogata, E. et al:22-Oxacalcitriol, a noncalcemia analogue of calcitriol, suppresses both cell proliferation and parathytoid hormone-related peptide gene expression in human T cell lymphotrophic virus, type I-infected T cells. J. Biol. Chem. 268:16730-16736, 1993

• 61) Kanatani, M., Sugimoto, T., Kaji, H. et al:Effects of 22-oxacalcitriol on bone metabolism in vitro:comparison with calcitriol-effects of 22-oxacalcitriol on osteoclast-like cell formation and boneresorbing activity. Eur. J. Endocrinol. 133:618-625, 1995

• 62) Takeyama, K., Masuhiro, Y., Fuse, H. et al.:Selective interaction of vitamin D receptor with transcriptional coactivator by a vitamin D analog. Mol. Cell. Biol. 19:1049-1055, 1999

• 63) Yang, W., Freedman, L. P.:20-Epi analogues of 1,25-dihydroxyvitamin D3 are highly potent inducers of DRIP coactivator complex binding to the vitamin D3 receptor. J. Biol. Chem. 274:16838-16845, 1999

• 64) Rochel, N., Wurtz, J. M., Mitschler, A. et al.:The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol. Cell. 5:173-179, 2000
  pubmed

• 65) Ozono, K., Saito, M., Miura, d. et al.:Analysis of the molecular mechanism for the antagonistic action of a novel 1α, 25-dihydroxyvitamin D(3) analogue toward vitamin D receptor function. J. Biol. Chem. 274:32376-32381, 1999

• 66) Miura, D., Manabe, K., Ozono, K. et al.:Antagonistic action of novel 1α, 25-dihydroxyvitamin D3-26, 23-lactone analogs on differentiation of human leukemia cells (HL-60) induced by 1α, 25-dihydroxyvitamin D3. J. Biol. Chem. 274:16392-16399, 1999

• 67) Yoshizawa, T., Handa, Y., Uematsu, Y. et al.:Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat. Genet. 16:391-396, 1997
  pubmed

• 68) Takeyama, K., Kitanaka, S., Sato, T. et al.:25-Hydroxyvitamin D3 1α-hydroxylase and vitamin D synthesis. Science 277:1827-1830, 1997

P.212 掲載の参考文献

• 1) Anderson, A., Davis, d. L., Dahlback, H. et al.:Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J. Biol. Chem. 264:8222-8229, 1989

• 2) Masumoto, O., Ohyama, Y., Okuda, K.:Purification and characterization of vitamin D 25-hydroxylase from rat liver mitochondria. J. Biol. Chem. 263:14256-14260, 1988
  pubmed

• 3) Usui, E., Noshiro, M., Okuda, K.:Molecular cloning of cDNA for vitamin D3 25-hydroxylase from rat liver mitochondria. FEBS. Lett. 262:135-138, 1990
  pubmed

• 4) Ohyama, Y., Hayashi, S., Okuda, K.:Purification of 25-hydroxyvitamin D3 24-hydroxylase from rat kidney mitochondria. FEBS. Lett. 255 (2):405-408, 1989
  pubmed

• 5) Ohyama, Y., Noshiro, M., Okuda, K.:Cloning and expression of cDNA encoding 25-hydroxyvitamin D3 24-hydroxylase. FEBS. Lett. 278:195-198, 1991
  pubmed

• 6) Shinki, T., Shimada, H., Wakino, S. et al:Cloning and expression of rat 25-hydroxyvitamin D3-1α-hydroxylase cDNA. Proc. Natl. Acad. Sci. USA 94:12920-12925, 1997

• 7) Fu, G. K., Lin, D., Zhang, M. Y. H. et al:Cloning of human 25-hydroxyvitamin D3-1α-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol. Endocrinol. 11 (13):1961-1970, 1997

• 8) St-Arnaud, R., Messerian, S., Moir, J. M. et al.:The 25-hydroxyvitamin D3-1α-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J. Bone. Miner. Res. 12 (10):1552-1559, 1997

• 9) Takeyama, K., Kitanaka, S., Sato, T. et al:25-Hydroxyvitamin D3-1α-hydroxylase and vitamin D synthesis. Science・277 (5333):1827-1830, 1997

• 10) Monkawa, T., Yoshida, T., Wakino, S. et al.:Molecular cloning of cDNA and genomic DNA for human 25-hydroxyvitamin D3-1α-hydroxylase. Biochem. Biophys. Res. Commun. 239:527-533, 1997

• 11) Yoshida, T., Yoshida, N., Nakamura, A. et al.:Cloning of porcine 25-hydroxyvitamin D3-1α-hydroxylase and its regulation by cAMP in LLC-PKI cells. J. Am. Soc. Nephrol. 10:963-970, 1999

• 12) DeLuca, H. F.:The vitamin D story:a collaborative effort of basic science and Clinical medicine. FASSEB J. 2:224-236, 1988

• 13) Suda, T., Shinki, T., Kurokawa, K.:The mechanisms of regulation of vitamin D metabolism in the kidney. Curr. Opin. Nephrol. Hypertens. 3:59-64, 1994
  pubmed

• 14) Boyle, L T., Gray, R. W., DeLuca, H. F.:Regulation by calcium of in vivo synthesis of 1,25-dihydroxycholecalciferol and 21, 25-dihydroxycholecalciferol. Proc. Natl. Acad. Sci. USA 68:2131-2134, 1971

• 15) Garabedian, M., Holick, M. F., DeLuca, H. F. et al.:Control of 25-hydroxycholecalciferol metabolism by parathyroid glands. Proc. Natl. Acad. Sci. USA 69:1673-1676, 1972
  pubmed

• 16) Horiuchi, N., Suda, T., Sasaki, S. et al.:Absence of regulatory effects of 1α, 25-dihydroxyvitamin D3 on 25-hydroxyvitamin D3 metabolism in rats constantly infused with parathyroid hormone. Biochem. Biophys. Res. Commun. 73 (4):869-875, 1976

• 17) Horiuchi, N., Suda, T., Takahashi, H. et al.:In vivo evidence for the intermediary role of 3', 5:-cyclic AMP in parathyroid hormone-induced stimulation of 1α, 25-dihydroxyvitamin D3 synthesis in rats. Endocrinology 101:969-974, 1977

• 18) Tanaka, Y., Chen, T. C., Deluca, H. F.:dependence of 25-hydroxycholecalciferol-l-hydroxylase regulation on RNA and protein synthesis. Arch. Biochem. . Biophys. 152 (1):291-298, 1972

• 19) Shinki, T., Ueno, Y., deLuca, H. F. et al.:Calcitonin is a major regulator for the expression of renal 25-hydroxyvitamin D3-1α-hydroxylase gene in normocalcemic rats. Proc. Natl. Acad. Sci. USA 96:8253-8258, 1999

• 20) Brenza, H. L., Kimmel-Jehan, C., Jehan, F. et al:Parathyroid hormone activation of the 25-hydroxyvitamin D3-1α-hydroxylase gene promotor. Proc. Natl. Acad. Sci. USA 95:1387-1391, 1998

• 21) Kong, X. F, Zhu, X. H., Pei, Y. L. et al.:Molecular cloning, characterization, and promoter analysis of the human 25-hydroxyvitamin D3-1α-hydroxylase gene. Proc. Natl. Acad. Sci. USA 96:6988-6993, 1999

• 22) Murayama, A., Takeyama, K., Kitanaka, S. et al.:The promoter of the human 25-hydroxyvitamin D3-1α-hydroxylase gene confers positive and negative responsiveness to PTH, calcitonin, and 1α, 25(OH)2 D3. Biochem. Biophys. Res. Commun. 249 (1):11-16, 1998

• 23) Murayama, A., Takeyama, K, Kitanaka, S. et al.:Positive and negative regulations of the renal 25-hydroxyvitamin D3-1α-hydroxylase gene by parathyroid hormone, calcitonin, and 1α, 25(OH)2 D3 in intact animals. Endocrinology 140 (5):2224-2231, 1999

• 24) Galante, L., Colston, K. W., MacAuley, S. J. et al.:Effect of calcitonin on vitamin D metabolism. Nature 238:271-273, 1972
  pubmed

• 25) Lorenc, R., Tanaka, Y., DeLuca, H. F. et al.:Lack of effect of calcitonin on the regulation of vitamin D metabolism in the rat. Endocrinology 10:468-472, 1977

• 26) Kawashima, H., Torikai, S., Kurokawa, K.:Localization of 25-hydroxyvitamin D3-1α-hydroxylase and 24-hydroxylase along the rat nephron. Proc. Natl. Acad. Sci. USA 78:1199-1203, 1981

• 27) Morel, F.:Sites of hormone action in the mammalian nephron. Am. J. Physiol. 240:F159-F164, 1981
  pubmed

• 28) Kawashima, H., Torikai, S., Kurokawa, K. et al.:Calcitonin selectively stimulates 25-hydroxyvitamin D3-1α-hydroxylase in proxmal straight tubule of rat kidney. Nature 291:327-329, 1981

• 29) Yoshida, N., Yoshida, T., Nakamura, A. et al.:Calcitonin induces 25-hydroxyvitamin D31α-hydroxylase mRNA expression via protein kinase C pathway in LLC-PKI cells. J. Am. Soc. Nephrol. 10:2474-2479, 1999

• 30) Iida, K., Shinki, T., Yamaguchi, A. et al.:A possible role of vitamin D receptors in regulating vitamin D activation in the kidney. Proc. Natl. Acad. Sci. USA 92:6112-6116, 1995

• 31) Bland, R., Walker, E. A., Hughes, S. V. et al.:Constitutive expression of 25-hydroxyvitamin D3-1α-hydroxylase in a transformed human proximal tubule cell line:evidence for direct regulation of vitamin D metabolism by calcium. Endocrinology 140 (5):2027-2034, 1999

• 32) Akeno, N., Matsunuma, A., Maeda, T. et al.:Regulation of vitamin D-1α-hydroxylase and-24-hydroxylase expression by dexamethasone in mouse kidney. J. Endocrinology 164:339-348, 2000

P.227 掲載の参考文献

• 1) Juppner, H., Abou-Samra, A. B., Freeman, M. W. et al.:AG protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254:1024-1026, 1991

• 2) Usdin, T. B., Cruber, C., Bonner, T. I.:Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor. J. Biol. Chem. 270:15455-15458, 1995

• 3) Rubin, D., Juppner, H.:Zebrafish express the common parathyroid hormone/parathyroid hormone-related peptide receptor (PTH1R) and a novel receptor (PTH3R) that is preferentially activated by mammalian and fugufish parathyroid hormone-related peptide. J. Biol. Chem. 274:28185-28190, 1999

• 4) Senior, P. V., Heath, D. A., Beck, F.:Expression of parathyroid hormone-related protein mRNA in the rat before birth:demonstration by hybridization histochemistry. J. Mol. Endocrinol. 6:281, 1990

• 5) Kramer, S., Reynolds, F. H. Jr., Castillo, M. et al:Immunological identification and distribution of parathyroid hormone-like protein polypeptides in normal and malignant tissues. Endocrinology 128:1927, 1991
  pubmed

• 6) Karaplis, A. C., Luz, A., Glowacki, J. et al.:Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes. dev. 8:277-289, 1994
  pubmed

• 7) Amizuka, N., Henderson, J. E., Warshawsky, H. et al:Parathyroid hormone-related peptide (PTHrP)-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation. J. Cell Biol. 126:1611-1623, 1994
  pubmed

• 8) Amizuka, N., Henderson, J. E., Hoshi, K. et al.:Programmed cell death of chondrocytes and aberrant chondrogenesis in mice homozygous for parathyroid hormone-related peptide (PTHrP) gene deletion. Endocrinology 137:5055-5067, 1996
  pubmed

• 9) Amizuka, N., Karaplis, A. C., Henderson, J. E. et al.:Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal post-natal bone development. Develop. Biol. 175:166-176, 1996

• 10) Weir, E., Philbrick, W., Neff, L. et al.:Targeted over-expression of parathyroid hormone-related peptide in chondrocytes causes skeletal dysplasia and delayed osteogenesis. Proc. Natl. Acad. Sci. USA 93:10240, 1996

• 11) Lanske, B., Karaplis, A. C., Luz, A. et al.:Characterization of mice homozygous for the PTH/ PTHrP receptor gene null mutation. Science 273:663-666, 1996

• 12) Vortkamp, A., Lee, K., Lanske, B. et al.:Regulation of rate of cartilage differentiation by indian hedgehog and PTH-related peptide. Science 273:613, 1996

• 13) McCuaig, K. A., Clarke, J. C., White, J. H.:Molecular cloning of the gene encoding the mouse parathyroid hormone/parathyroid hormone-related peptide receptor. Proc. Natl. Acad. Sci. USA 91:5051-5055, 1994
  pubmed

• 14) McCuaig, K. A., Lee, H., Clarke, J. C. et al.:Parathyroid hormone/parathyroid hormone related peptide receptor gene transcripts are expressed from tissue-specific and ubiquitous promoters. Nucleic. Acids. Res. 23:1948-1955, 1995
  pubmed

• 15) Amizuka, N., Lee, H. S., Kwan, M. Y. et al.:Cell-specific expression of the parathyroid hormone (PTH) /PTH-related peptide receptor gene in rat kidney from kidney-specific and ubiquitous promoters. Endocrinology 138:469-481, 1997

• 16) Maren, D., Palmer, G., Bonjour, J. P. et al.:Sequence and activity of parathyroid hormone/ parathyroid hormone-related protein receptor promoter region in human osteoblast-like cells. Gene 218:49-56, 1998

• 17) Amizuka, N., Kwan, M., Goltzman, d. et al.:vitamin D3 differentially regulates parathyroid hormone/parathyroid hormone-related peptide receptor expression in bone and cartilage. J. Clin. Invest. 103:373-381, 1999
  pubmed

• 18) Fukumoto, S., Suzawa, M., Kikuchi, T. et al.:Cloning and characterization of kidney-specific promoter of human PTH/PTHrP receptor gene:Absence of mutation in patients with pseudohypoparathyroidism type I b. Mol. Cell Biol. 141:41-47, 1998

• 19) Jansen, M.:Uber atypische Chondrodystrophie (Achondroplasia) und uber eine noch nicht beschriebene angeborene Wachstumsstarung des Knochensystems:Metaphysare dysostosis. Z. Orthop. Chir. 61:253-286, 1934

• 20) Schipani, E., Klaus, K., Juppner, H.:A constitutive active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodisplasia. Science 268:98-100, 1995

• 21) Schipani, E., Langman, C. B., Parfitt, A. M. et al.:Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia. N. Engl. J. Med. 335:708, 1996

• 22) Schipani, E., Langman, C., Hunzelman, J. et al.:A novel parathyroid hormone (PTH) /PTHrelated peptide receptor mutation in Jansen's metaphyseal chondrodysplasia. J. Clin. Endocrinol. Metab. 84:3052-3057, 1999

• 23) Jobert, A. S., Zhang, P., Couvineau, A. et al.:Absence of functional receptors for parathyroid hormone and parathyroid hormone-related peptide in Blomstrand chondrodysplasia. J. Clin.Invest. 102:34, 1998
  pubmed

• 24) Blomstrand, S., Claesson, I., Save-Soderbergh, J.:A case of lethal congenital dwarfism with accelerated skeletal maturation. Pediatric Radiology 15:141, 1985

• 25) den Hollander, N. S., van der Harten, H. J., Vermeij-Keers, C. et al.:First-trimester diagnosis of Blomstrand lethal osteochondrodysplasia. Am. J. Med. Genet. 73:345, 1997
  pubmed

• 26) Karaplis A, He, M. B., Nguyen, A. et al.:Blomstrand chondrodisplasia caused by a missense mutation in the human parathyroid hormone receptor-1. Endocrinology 139:5255, 1999

• 27) Zhang, P., Jobert, A. S., Couvineau, A. et al:A homozygous inactivating mutation in the parathyroid hormone/parathyroid hormone-related peptide receptor causing Blomstrand chondrodysplasia. J. Clin. Endocrinol. Metab. 83:3365-3368, 1998
  pubmed

• 28) Schipani, E., Lanske, B., Hunzelman, J. et al:Targeted expression of constitutive active receptors for parathyroid hormone and parathyroid hormone-related peptide delays endochondral bone formation and rescures mice that lack parathyroid hormone-related peptide. Proc. Natl. Acad. Sci. USA 94:13689, 1997

• 29) Chung, U., Lanske, B., Lee, K. et al.:The parathyroid homone/parathyroid hormone-related peptide receptor coordinates endochondral bone development by directly controlling chondrocyte differentiation. Proc. Natl. Acad. Sci. USA 95:13030, 1998

• 30) Gardella, T. J., Luck, M. D., Jensen, G. S. et al.:Converting parathyroid hormone-related peptide (PTHrP) into potent PTH-2 receptor agonist. J. Biol. Chem. 271:19888-19893, 1996
  pubmed

• 31) Usdin, T. B., Bonner, T. I., Harta, G. et al.:distribution of parathyroid hormone-2 receptor messenger ribonucleic acid in rat. Endocrinology 137:4285-4297, 1996
  pubmed

• 32) Henderson, J. E., Amizuka, N., Warshawsky, H. et al.:Nucleolar targeting of PTHrP enhances survival of chondrocytes under conditions that promote cell death by apoptosis. Mol. Cell. Biol. 15:4064-4075, 1995
  pubmed

• 33) Lam, M. H., Olsen, S. L, Rankin, W. A. et al.:PTHrP and cell division:expression and localization of PTHrP in a kertinocyte cell line (HaCaT) during the cell cyle. J. Cell. Physiol. 173:433-446, 1997

• 34) Lam, M. H., House, C. M., Tiganis, T. et al.:Phosphorylation at the cyclin-dependent kinases site (Thr85) of parathyroid hormone-related protein negatively regulates its nuclear localization. J. Biol. Chem. 274:18559-18566, 1999
  pubmed

• 35) Lam, M. H., Briggs, L. J., Hu, W. et al.:Importin beta recognizes parathyroid hormone-related protein with high affinity and mediates its nuclear import in the absence of importin alpha. J. Biol. Chem. 274:7391-7398, 1999
  pubmed

• 36) Amizuka, N., Fukushi-Irie, M., Sasaki, T. et al.:In efficient Function of the Signal Sequence of PTHrP for Targeting into the Secretory Pathway. Biochem. Biophys. Res. Commun. 273:621-629, 2000

• 37) Aarts, M. M., Levy, D., He, B. et al:Parathyroid hormone related protein (PTHrP) interacts with RNA. J. Biol. Chem. 274:4832-4838, 1999
  pubmed

• 38) Aarts, M. M., Rix, A., Guo, J. et al.:The nucleolar targeting signal (NTS) of parathyroid hormone-related protein mediates endocytosis and nucleolar translocation. J. Bone Miner. Res. 14:1493-1503, 1999
  pubmed

• 39) Watson, P. H., Fraher, L. J., Hendy, G. N. et al:Nuclear localization of the type 1 PTH/PTHrP receptor in rat tissue. J. Bone Miner. Res. 15:1033-1044, 2000

P.238 掲載の参考文献

• 1) Brown, E. M., Gamba, G., Riccardi, d. et al.:Cloning and characterization of an extracellular Ca (2+)-sensing receptor from bovine parathyroid. Nature 366:575-580, 1993
  pubmed

• 2) Riccardi, D., Park, J., Lee, W. S. et al.:Cloning and functional expression of a rat kidney extracellular calcium/polyvalent cation-sensing receptor. Proc. Natl. Acad. Sci. USA 92:131-135, 1995

• 3) Ruat, M., Molliver, M. E., Snowman, A. M. et al:Calcium sensing receptor:molecular cloning in rat and localization to nerve terminals. Proc. Natl. Acad. Sci. USA 92:3161-3165, 1995
  pubmed

• 4) Garrett, J. E., Capuano, I. V., Hammerland, L. G. et al.:Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. J. Biol. Chem. 270:12919-12925, 1995
  pubmed

• 5) Oda, Y., Tu, C. L., Chang, W. et al:The calcium sensing receptor and its alternatively spliced form in murine epidermal differentiation. J. Biol. Chem. 275:1183-1190, 2000
  pubmed

• 6) Pi, M., Garner, S. C., Flannery, P. et al:Sensing of extracellular cations in CasR-deficient osteoblasts-Evidence for a novel cation-sensing mechanism. J. Biol. Chem. 275:3256-3263, 2000
  pubmed

• 7) Butters, R. Jr., Chattopadhyay, N., Nielsen, P. et al.:Cloning and characterization of a calcium-sensing receptor from the hypercalcemic New Zealand white rabbit reveals unaltered responsiveness to extracellular calcium. J. Bone. Miner. Res. 12:568-579, 1997
  pubmed

• 8) Diaz, R., Hurwitz, S., Chattopadhyay, N. et al.:Cloning, expression, and tissue localization of the calcium-sensing receptor in chicken (Gallus domesticus) . Am . J. Physiol. 273:R1008-R1016, 1997
  pubmed

• 9) Pace, A. J., Gama, L., Breitwieser, G. E.:Dimerization of the calcium-sensing receptor occurs within the extracellular domain and is eliminated by Cys-->Ser mutations at Cys 101 and Cys236. J. . Biol. Chem. 274:11629-11634, 1999
  pubmed

• 10) Conigrave, A. D., Quinn, S. J., Brown, E. M.:L-Amino acid sensing by the extracellular Ca2+-sensing receptor. Proc. Natl. Acad. Sci. USA 97:4814-4819, 2000
  pubmed

• 11) Bai, M., Trivedi, S., Lane, C. R. et al.:Protein kinase C phosphorylation of threonine at position 888 in Ca2+o-sensing receptor (CaR) inhibits coupling to Ca2+store release. J. Biol. Chem. 273:21267-21275, 1998
  pubmed

• 12) Garrett, J. E., Tamir, H., Kifor, O. et al.:Calcitonin-secreting cells of the thyroid express an extracellular calcium receptor gene. Endocrinology 136:5202-5211, 1995
  pubmed

• 13) Ray, J. M., Squires, P. E., Curtis, S. B. et al.:Expression of the calcium-sensing receptor on human antral gastrin cells in culture. J. Clin. Invest. 99:2328-2333, 1997
  pubmed

• 14) Chattopadhyay, N, Cheng, I., Rogers, K. et al.:Identification and localization of extracellular Ca (2+)-sensing receptor in rat intestine. Am. J. Physiol. 274:G122-G130, 1998
  pubmed

• 15) McNeil, S. E., Hobson, S. A., Nipper, V. et al.:Functional calcium-sensing receptors in rat fibroblasts are required for activation of SRC kinase and mitogen-activated protein kinase in response to extracellular calcium. J. Biol. Chem. 273:1114-1120, 1998
  pubmed

• 16) McNeil, L., Hobson, S., Nipper, V. et al.:Functional calcium-sensing receptor expression in ovarian surface epithelial cells. Am. J. Obstet. Gynecol. 178:305-313, 1998
  pubmed

• 17) Cheng, I., Klingensmith, M. E., Chattopadhyay, N. et al.:Identification and localization of the extracellular calcium-sensing receptor in human breast. J. Clin. Endocrinol. Metab. 83:703-707, 1998

• 18) Yamaguchi, T., Olozak, I., Chattopadhyay, N. et al.:Expression of extracellular calcium (Ca2+o)-sensing receptor in human peripheral blood monocytes. Biochem. Biophys. Res. Commun. 246:501-506, 1998
  pubmed

• 19) Chattopadhyay, N., Ye, C., Singh, D. P. et al.:Expression of extracellular calcium-sensing receptor by human lens epithelial cells. Biochem. Biophys. Res. Commun. 233:801-805, 1997
  pubmed

• 20) Tu, C. L., Oda, Y., Bikle, D. D.:Effects of a calcium receptor activator on the cellular response to calcium in human keratinocytes. J. Invest. Dermatol. 113:340-345, 1999
  pubmed

• 21) Chang, W., Tu, C., Chen, T. H. et al.:Expression and signal transduction of calcium-sensing receptors in cartilage and bone. Endocrinology 140:5883-5893, 1999

• 22) Rasschaert, J., Malaisse, W. J.:Expression of the calcium-sensing receptor in pancreatic islet B-cells. Biochem. Biophys. Res. Commun. 264:615-618, 1999
  pubmed

• 23) Romoli, R., Lania, A., Mantovani, G. et al:Expression of calcium-sensing receptor and characterization of intracellular signaling in human pituitary adenomas. J. Clin. Endocrinol. Metab. 84:2848-2853, 1999
  pubmed

• 24) Bradbury, R. A., Sunn, K. L, Crossley, M. et al.:Expression of the parathyroid Ca (2+)-sensing receptor in cytotrophoblasts from human term placenta. J. Endocrinol 156:425-430, 1998
  pubmed

• 25) Kameda, T., Mano, H., Yamada, Y. et al.:Calcium-sensing receptor in mature osteoclasts, which are bone resorbing cells. Biochem. Biophys. Res. Commun. 245:419-422, 1998
  pubmed

• 26) House, M. G., Kohlmeier, L, Chattopadhyay, N. et al.:Expression of an extracellular calcium-sensing receptor in human and mouse bone marrow cells. J. Bone Miner. Res. 12:1959-1970, 1997
  pubmed

• 27) Kanatani, M., Sugimoto, T., Kanzawa, M. et al.:High extracellular calcium inhibits osteoclast-like cell formation by directly acting on the calcium-sensing receptor existing in osteoclast precursor cells. Biochem. Biophys. Res. Commun. 261:144-148, 1999
  pubmed

• 28) Yamaguchi, T., Kifor, O., Chattopadhyay, N. et al.:Expression of extracellular calcium (Ca2+o)-sensing receptor in the clonal osteoblast-like cell lines, UMR-106 and SAOS-2. Biochem. Biophys. Res. Commun. 243:753-757, 1998
  pubmed

• 29) Yamaguchi, T., Chattopadhyay, N., Kifor, O. et al.:Mouse osteoblastic cell line (MC3T3-E1) expresses extracellular calcium (Ca2+o)-sensing receptor and its agonists stimulate chemotaxis and proliferation of MC3T3-E1 cells. J. Bone Miner. Res. 13:1530-1538, 1998

• 30) Quarles, L. D., Hartle, J. E., Siddhanti, S. R. et al.:Adistinct cation-sensing mechanism in MC3T3-E1 osteoblasts functionally related to the calcium receptor. J. Bone Miner. Res. 12:393-402, 1997

• 31) Lundgren, S., Carling, T., Hjalm, G. et al.:Tissue distribution of human gp330/megalin, a putative Ca (2+)-sensing protein. J. Histochem. Cytochem. 45:383-392, 1997

• 32) Zaidi, M., Shankar, V. S., Tunwell, R. et al.:Aryanodine receptor-like molecule expressed in the osteoclast plasma membrane functions in extracellular Ca2+sensing. J. Clin. Invest. 96:1582-1590, 1995

• 33) Brown, E. M., Pollak, M., Hebert, S. C.:The extracellular calcium-sensing receptor:its role in health and disease. Annu. Rev. Med. 49:15-29, 1998
  pubmed

• 34) Ye, C., Kanazirska, M., Quinn, S. et al.:Modulation by polycationic Ca (2+)-sensing receptor agonists of nonselective cation channels in rat hippocampal neurons. Biochem. Biophys. Res. Commun. 224:271-280, 1996
  pubmed

• 35) Brown, E. M.:Extracellular Ca2+sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers. Physiol. Rev. 71:371-411, 1991
  pubmed

• 36) Marx, S. J., Spiegel, A. M., Brown, E. M. et al.:Divalent cation metabolism. Familial hypocalciuric hypercalcemia versus typical primary hyperparathyroidism. . Am. J. Med. 65:235-242, 1978
  pubmed

• 37) Aida, K., Koishi, S., Inoue, M. et al:Familial hypocalciuric hypercalcemia associated with mutation in the human Ca (2+)-sensing receptor gene. J. Clin. Endocrinol. Metab. 80:2594-2598, 1995

• 38) Bai, M., Quinn, S., Trivedi, S. et al.:Expression and characterization of inactivating and activating mutations in the human Ca2+o-sensing receptor. J. Biol. Chem. 271:19537-19545, 1996
  pubmed

• 39) Bai, M., Janicic, N., Trivedi, S. et al.:Markedly reduced activity of mutant calcium-sensing receptor with an inserted Alu element from a kindred with familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. J. Clin. Invest. 99:1917-1925, 1997
  pubmed

• 40) Bai, M., Pearce, S. H., Kifor, O. et al.:In vivo and in vitro characterization of neonatal hyperparathyroidism resulting from a de novo, heterozygous mutation in the Ca2+-sensing receptor gene:normal maternal calcium homeostasis as a cause of secondary hyperparathyroidism in familia (benign hypercalcemia. J. Clin. Invest. 99:88-96, 1997

• 41) Chikatsu, N., Fukumoto, S., Suzawa, M. et al.:An adult patient with severe hypercalcemia and hypocalciuria due to a novel homozygous inactivating mutation of calcium-sensing receptor. Clin. Endocrinol. (Oxf. ) 50:537-543, 1999
  pubmed

• 42) Chou, Y. H., Pollak, M. R., Brandi, M. L. et al.:Mutations in the human Ca (2+)-sensing-receptor gene that cause familial hypocalciuric hypercalcemia. Am. J. Hum. Genet. 56:1075-1079, 1995
  pubmed

• 43) Heath, H. 3D., Odelberg, S., Jackson, C. E. et al.:Clustered inactivating mutations and benign polymorphisms of the calcium receptor gene in familial benign hypocalciuric hypercalcemia suggest receptor functional domains. J. Clin. Endocrinol. Metab. 81:1312-1317, 1996

• 44) Janicic, N., Pausova, Z., Cole, d. E. et al.:Insertion of an Alu sequence in the Ca (2+)-sensing receptor gene in familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Am. J. Hum. Genet. 56:880-886, 1995
  pubmed

• 45) Pearce, S. H., Trump, D., Wooding, C. et al.:Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J. Clin. Invest. 96:2683-2692, 1995
  pubmed

• 46) Pearce, S. H., Brown, E. M.:Calcium-sensing receptor mutations:insights into a structurally and functionally novel receptor. J. Clin. Endocrinol. Metab. 81:1309-1311, 1996
  pubmed

• 47) Pearce, S. H., Wooding, C., Davies, M. et al.:Calcium-sensing receptor mutations in familial hypocalciuric hypercalcaemia with recurrent pancreatitis. Clin. Endocrinol (Oxf) 45:675-680, 1996
  pubmed

• 48) Pollak, M. R., Brown, E. M., Chou, Y. II. et al.:Mutations in the human Ca (2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75:1297-1303, 1993

• 49) Lloyd, S. E., Pannett, A. A., Dixon, P. H. et al.:Localization of familial benign hypercalcemia, Oklahoma variant (FBHOk), to chromosome 19q13. Am. J. Hum. Genet. 64:189-195, 1999
  pubmed

• 50) Trump, D., Whyte, M. P., Wooding, C. et al.:Linkage studies in a kindred from Oklahoma, with familial benign (hypocalciuric) hypercalcaemia (FBH) and developmental elevations in serum parathyroid hormone levels, indicate a third locus for FBH. Hum. Genet. 96:183-187, 1995

• 51) Marx, S. J., Attie, M. F., Spiegel, A. M. et al:An association between neonatal severe primary hyperparathyroidism and familial hypocalciuric hypercalcemia in three kindreds. N. Engl. J. Med. 306:257-264, 1982
  pubmed

• 52) Kobayashi, M., Tanaka, H., Tsuzuki, K. et al.:Two novel missense mutations in calcium-sensing receptor gene associated with neonatal severe hyperparathyroidism. J. Clin. Endocrinol. Metab. 82:2716-2719, 1997
  pubmed

• 53) Ho, C., Conner, d. A., Pollak, M. R. et al.:A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat. Genet. 11:389-394, 1995
  pubmed

• 54) Bai, M., Trivedi, S., Kifor, O. et al.:Intermolecular interactions between dimeric calcium-sensing receptor monomers are important for its normal function. Proc. Natl. Acad. Sci. USA 96:2834-2839, 1999
  pubmed

• 55) Carling, T., Szabo, E., Ridefelt, P. et al.:Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J. Clin. Endocrinol. Metab. 85:2042-2047, 2000
  pubmed

• 56) Hosokawa, Y., Pollak, M. R., Brown, E. M. et al.:Mutational analysis of the extracellular Ca (2+-sensing receptor gene in human parathyroid tumors. J. Clin. Endocrinol. Metab. 80:3107-3110, 1995
  pubmed

• 57) Gogusev, J., Duchambon, P., Hory, B. et al.:Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 51:328-336, 1997
  pubmed

• 58) Kifor, O., Moore, F., Wang, P. et al.:Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 81:1598-1606, 1996
  pubmed

• 59) Chikatsu, N., Fukumoto, S., Takeuchi, Y. et al.:Cloning and characterization of two promoters for human calcium-sensing receptor (CaSR) and changes of CaSR expression in parathyroid adenomas. J. Biol. Chem. 275:7553-7557, 2000
  pubmed

• 60) Pollak, M. R., Brown, E. M., Estep, H. L. et al.:Autosomal dominant hypocalcaemia caused by a Ca (2+)-sensing receptor gene mutation. Nat. Genet. 8:303-307, 1994

• 61) Pearce, S. H., Williamson, C., Kifor, O. et al.:A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N. Engl. J. Med. 335:1115-1122, 1996
  pubmed

• 62) Lovlie, R., Eiken, H. G., Sorheim, J. I. et al:The Ca (2+)-sensing receptor gene (PCAR1) mutation T151M in isolated autosomal dominant hypoparathyroidism. Hum. Genet. 98:129-133, 1996
  pubmed

• 63) Okazaki, R., Chikatsu, N., Nakatsu, M. et al.:A novel activating mutation in calcium-sensing receptor gene associated with a family of autosomal dominant hypocalcemia. J. Clin. Endocrinol. Metab. 84:363-366, 1999
  pubmed

• 64) Watanabe, T., Bai, M., Lane, C. R. et al.:Familial hypoparathyroidism:identification of a novel gain of function mutation in transmembrane domain 5 of the calcium-sensing receptor. J. Clin. Endocrinol. Metab. 83:2497-2502, 1998
  pubmed

• 65) De Luca, F., Ray, K., Mancilla, E. E. et al.:Sporadic hypoparathyroidism caused by de novo gain-of-function mutations of the Ca (2+)-sensing receptor. J. Clin. Endocrinol. Metab. 82:2710-2715, 1997
  pubmed

• 66) Li, Y., Song, Y. H., Rais, N. et al.:Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism. J. Clin. Invest. 97:910-914, 1996

• 67) Klein, G. L, Nicolai, M., Langman, C. B. et al.:Dysregulation of calcium homeostasis after severe burn injury in children:possible role of magnesium depletion. J. Pediatr. 131:246-251, 1997
  pubmed

• 68) Nielsen, P. K., Rasmussen, A. K., Butters, R. et al.:Inhibition of PTH secretion by interleukin-l β in bovine parathyroid glands in vitro is associated with an up-regulation of the calcium-sensing receptor mRNA. Biochem. Biophys. Res. Commun. 238:880-885, 1997

• 69) Murphey, E. D., Chattopadhay, N., Traber, D. L. et al.:Increased parathyroid calcium-sensing receptor mRNA following burn injury in sheep. Bone 23:S458, 1998

P.252 掲載の参考文献

• 1) Massague, J.:TGF-β signal transduction. Annu. Rev. Biochem. 67:753-791, 1998

• 2) Rosenzweig, B. L., Imamura, T., Okadome, T. et al:Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc. Natl. Acad. Sci. USA 92:7632, 1995
  pubmed

• 3) Heldin, C. H., Miyazono, K., ten dijke, P.:TGF-β signalling from cell membrane to nucleus through SMAd proteins. Nature 390:465-471, 1997

• 4) ten dijke, P., Yamashita, H., Sampath, T. K. et al.:Identification of type I receptors for osteogenic protein-l and bone morphogenetic protein-4. J. Biol. Chem. 269:16985-16988, 1994

• 5) ten dijke, P., Yamashita, H., Ichijo, H. et al:Characterization of type I receptors for transforming growth factor-β and activin. Science 264:101-104, 1994

• 6) Ebisawa, T., Tada, K., Kitajima, L et al.:Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. J. Cell. Sci. 112:3519, 1999

• 7) Hahn, S. A., Schutte, M., Hoque, A. T. et al.:DPC4, a candidate tumor suppressor gene at human chromosome 18q21. 1. Science 271:350-353, 1996
  pubmed

• 8) Savage, C., Das, P., Finelli, A. L. et al.:Caenorhabditis elegans genes sma-2, sma-3, and sma-4 define a conserved family of transforming growth factor β pathway components. Proc. Natl. Acad. Sci. USA 93:790-794, 1996

• 9) Raftery, L. A., Twombly, V., Wharton, K. et al.:Genetic screens to identify elements of the decapentaplegic signaling pathway in Drosophila. Genetics 139:241-254, 1995
  pubmed

• 10) Sekelsky, J. J., Newfeld, S. J., Raftery, L. A. et al.:Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. Genetics 139:1347-1358, 1995
  pubmed

• 11) Zhou, S., Buckhaults, P., Zawel, L. et al.:Targeted deletion of Smad4 shows it is required for transforming growth factor β and activin in colorectal cancer cells. Proc. Natl. Acad. Sci. USA 95:2412-2416, 1998

• 12) Kawabata, M., Inoue, H., Hanyu, A. et al.:Smad proteins exist as monomers in vivo and undergo homo-and hetero-oligomerization upon activation by serine/threonine kinase receptors. EMBO J. 17:4056-4065, 1998
  pubmed

• 13) Imamura, T., Takase, M., Nishihara, A. et al.:Smad6 inhibits signalling by the TGF-β superfamily. Nature 389:622-626, 1997

• 14) Nakao, A., Afrakhte, M., Moren, A. et al.:Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling. Nature 389:631-635, 1997

• 15) Takase, M., Imamura, T., Sampath, T. K. et al.:Induction of Smad6 mRNA by bone morphogenetic proteins. Biochem. Biophys. Res. Commun. 244:26-29, 1998
  pubmed

• 16) Ulloa, L, Doody, J., Massague, J.:Inhibition of transforming growth factor-β/SMAd signalling by the interferon-γ/STAT pathway. Nature 397:710-713, 1999

• 17) Afrakhte, M., Moren, A., Jossan, S. et al:Induction of inhibitory Smad6 and Smad7 mRNA by TGF-β family members. Biochem. Biophys. .Res. Commun. 249:505-511, 1998

• 18) Bitzer, M., von Gersdorff, G., Liang, d. et al:A mechanism of suppression of TGF-β/SMAd signaling by NF-κB/RelA. Genes. Dev. 14:187-197, 2000

• 19) Shi, Y., Hata, A., Lo, R. S. et al.:A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 388:87-93, 1997
  pubmed

• 20) Lo, R. S., Chen, Y. G., Shi, Y. et al.:The L3 loop:a structual motif determining specific interactions between SMAd proteins and TGF-β receptors. EMBO J. 17:996-1005, 1998

• 21) Chen, Y. G., Massague, J.:Smad1 recognition and activation by the ALKI group of transforming growth factor-β family receptors. J. Biol. Chem. 274:3672-3677, 1999

• 22) Lagna, G., Hemmati-Brivanlou, A.:A molecular basis for Smad specificity. Dev. Dyn. 214:269-277, 1999

• 23) Shi, Y., Wang, Y. F., Jayaraman, L. et al.:Crystal structure of a Smad MH1 domain bound to DNA binding in TGF-β signaling. Cell 94:585-594, 1998

• 24) Yagi, K., Goto, D., Hamamoto, T. et al.:Alternatively spliced variant of Smad2 lacking exon3. Comparison with wild-type Smad2 and Smad3. J. Biol. Chem. 274:703-709, 1999

• 25) Kretzschmar, M., Doody, J., Massague, J.:Opposing BMP and EGF signalling pathways converge on the TGF-β family mediator Smad1. Nature 389:618-622, 1997

• 26) Kretzschmar, M., Doody, J., Timokhina, I. et al.:A mechanism of repression of TGFβ/Smad signaling by oncogenic Ras. Genes. Dev. 13:804-816, 1999

• 27) de Caestecker, M. P., Parks, W. T., Frank, C. J. et al.:Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. Genes. Dev. 12:1587-1592, 1998
  pubmed

• 28) Brown, J. D., DiChiara, M. R., Anderson, K. R. et al.:MEKK-1, a component of the stress (stress-activated protein kinase/c-Jun N-terminal kinase) pathway, can selectively activate Smad2-mediated transcriptional activation in endothelial cells. J. Biol. Chem. 274:8797-8805, 1999
  pubmed

• 29) Zhang, Y., Feng, X. H., derynck, R.:Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-β-induced transcription. Nature 394:909-913, 1998

• 30) Liberati, N. T., Datto, M. B., Frederick, J. P. et al.:Smads bind directly to the Jun family of AP-1 transcription factors. Proc. Natl. Acad. Sci. USA 96:4844-4849, 1999

• 31) Sano, Y., Harada, J., Tashiro, S. et al.:ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-β signaling. J. Biol. Chem. 274:8949-8957, 1999

• 32) Chen, X., Weisberg, E., Fridmacher, V. et al.:Smad4 and FAST-1 in the assembly of activin-responsive factor. Nature 389:85-89, 1997
  pubmed

• 33) Komori, T., Yagi, H., Nomura, S. et al.:Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755-764, 1997

• 34) Hanai, J., Chen, L. F., Kanno, T. et al.:Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline C α promoter. J. Biol. Chem. 274:31577-31582, 1999

• 35) Zawel, L., Le dai, J., Buckhaults, P. et al.:Human Smad3 and Smad4 are sequence-specific transcription activators. Mol. Cell. 1:611-617, 1998

• 36) Dennler, S., Itoh, S., Vivien, d. et al.:Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-typel gene. EMBO J. 17:3091-3100, 1998

• 37) Jonk, L. J., Itoh, S., Heldin, C. H. et al.:Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-β, activin, and bone morphogenetic protein-inducible enhancer. J. Biol. Chem. 273:21145-21152, 1998

• 38) Pardali, E., Xie, X. Q., Tsapogas, P. et al.:Smad and AML proteins synergistically confer transforming growth factor β1 responsiveness to human germ-line IgA genes. J. Biol. Chem. 275:3552-3560, 2000

• 39) Kim, J., Johnson, K., Chen, H. J. et al.:Drosophila Mad binds to DNA and directly mediates activation of vestigial by Decapentaplegic. Nature 388:304, 1997
  pubmed

• 40) Kusanagi, K., Inoue, H., Ishidou, Y. et al.:Characterization of a bone morphogenetic protein-responsive Smad-binding element. Mol. Biol. Cell. 11:555-565, 2000
  pubmed

• 41) Ishida, W., Hamamoto, T., Kusanagi, K. et al:Smad6 is a Smad1/5-induced smad inhibitor Characterization of bone morphogenetic protein-responsive element in the mouse Smad6 promoter. J. Biol. Chem. 275:6075-6079, 2000
  pubmed

• 42) Parfitt, A. M.:Osteonal and hemi-osteonal remodeling:the spatial and temporal framework for signal traffic in adult human bone. J. Cell. Biochem. 55:273-286, 1994

• 43) Pelton, R. W., Saxena, B., Jones, M. et al.:Immunohistochemical localization of TGFβ1, TGFβ2, and TGFβ3 in the mouse embryo:expression patterns suggest multiple roles during embryonic development. J. Cell. Biol. 115:1091-1105, 1991

• 44) Oursler, M. J.:Osteoclast synthesis and secretion and activation of latent transforming growth factor β. J. Bone Miner. Res. 9:443-452, 1994

• 45) Erlebacher, A., Derynck, R.:Increased expression of TGF-β2 in osteoblasts results in an osteoporosis-like phenotype. J. Cell. Biol. 132:195-210, 1996

• 46) Erlebacher, A., Filvaroff, E. H., Ye, J. Q. et al.:Osteoblastic responses to TGF-β during bone remodeling. Mol. Biol. Cell. 9:1903-1918, 1998

• 47) Filvaroff, E., Erlebacher, A., Ye, J. et al.:Inhibition of TGF-β receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass. Development 126:4267-4279, 1999

• 48) Katagiri, T., Yamaguchi, A., Komaki, M. et al.:Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J. Cell. Biol. 127:1755-1766, 1994
  pubmed

• 49) Wieser, R., Wrana, J. L., Massague, J.:GS domain mutations that constitutively activate T β R-I, the downstream signaling component in the TGF-β receptor complex. EMBO J. 14:2199-2208, 1995

• 50) Fujii, M., Takeda, K., Imamura, T. et al:Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol. Biol Cell. 10:3801-3813, 1999
  pubmed

• 51) Atfi, A., Djelloul, S., Chastre, E. et al.:Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor β-mediated signaling. J. Biol. Chem. 272:1429-1432, 1997

• 52) Liberati, N. T., Datto, M. B., Frederick, J. P. et al:Smads bind directly to the Jun family of AP-1 transcription factors. Proc. Natl. Acad. Sci. USA 96:4844-4849, 1999

• 53) Hocevar, B. A., Brown, T. L, Howe, P. H. et al.:TGF-β induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J. 18:1345-1356, 1999

• 54) Nakamura, K., Shirai, T., Morishita, S. et al:p38 mitogen-activated protein kinase functionally contributes to chondrogenesis induced by growth/differentiation factor-5 in ATDC5 cells. Exp. Cell. Res. 250:351-363, 1999
  pubmed

P.260 掲載の参考文献

• 1) Thomas, D. M., Hards, D. K., Rogers, S. D. et al.:Insulin and bone, Clinical and scientific view. Endocrinol. Metab. Clin. North Am. 4:5-17, 1997

• 2) Thomas, D. M., Hards, D. K., Rogers, S. D. et al.:Insulin receptor expression in bone. J. Bone Miner. Res. 11:1312-1320, 1996

• 3) Canalis, E.:Insulin like growth factors and the local regulation of bone formation. Bone 14:273-276, 1993
  pubmed

• 4) Rosen, C. J., Donahue, L. R.:Insulin-like growth factors and bone, the osteoporosis connection revisited. Proc. Soc.Exp. Biol. Med. 219:1-7, 1998
  pubmed

• 5) Hough, S., Avioli, L. V., Teitelbaum, S. L. et al.:Correction of abnormal bone and mineral metabolism in chronic streptozotocin-induced diabetes mellitus in the rat by insulin therapy. Endocrinology 108:2228-2234, 1981
  pubmed

• 6) Buysschaert, M., Cauwe, F., Jamart, J. et al.:Proximal femur density in type I and type II diabetic patients. DiabetMetab. Rev. 18:32-37, 1992

• 7) Piepkorn, B., Kann, P., Forst, T. et al.:Bone mineral density and bone metabolism in diabetes mellitus. Horm. Metab. Res. 29:584-591, 1997
  pubmed

• 8) Krakauer, J. C., McKenna, M. J., Rao. d, S. et al.:Bone mineral density in diabetes. Diabetes Care 20:1339-1340, 1997
  pubmed

• 9) Haffner, S. M., Bauer, R. L.:The association of obesity and glucose and insulin concentrations with bone density in premenopausal and postmenopausal women. Metabolism 42:735-738, 1993
  pubmed

• 10) Kao, C. H., Tsou, C. T., Chen, C. C. et al:Bone mineral density in patients with noninsulin-dependent diabetes mellitus by dual photon absorptiometry. Nucl. Med. Commun. 14:373-377, 1993
  pubmed

• 11) Van Daele, P. L, Stolk, R. P., Burger. H. et al:Bone density in non-insulin-dependent diabetes mellitus. Ann. Intern. Med. 122:409-414, 1995
  pubmed

• 12) Rosen, C. J., Dimai, H. P., Vereault, d. et al.:Circulating and skeletal insulin-like growth factor-I (IGF-d concentrations in two inbred strains of mice with different bone mineral densities. Bone 21:217-223, 1997

• 13) Canalis, E.:Insulin-like growth factors and osteoporosis. Bone 21:215-216, 1997
  pubmed

• 14) Reed, B. Y., Zerwekh, J. E., Sakhaee, K. et al.:Serum IGF-I is low and correlated with osteoblastic surface in idiopathic osteoporosis. J. Bone Miner. Res. 10:1218-1224, 1995

• 15) Laron, Z., Klinger, B., Silbergeld, A.:Patients with Laron syndrome have osteopenia/osteoporosis. J. Bone Miner. Res. 14:156-161, 1999

• 16) Mamada, T., Nakamura, K., Hoshino, Y. et al.:Bone mineral density in patients with ossification of the posterior longitudinal ligament. Minimal decrease of bone mineral density with aging. Spine 22:2388-2392, 1997
  pubmed

• 17) Kawaguchi, H., Kurokawa, T., Kodama, Y. et al.:Metabolic background of ossification of the posterior longitudinal ligament. In OPLL:Ossification of the Posterior Longitudinal Ligament. (Yonenobu, K., Sakou, T., Ono, K. eds. ) Springer-Verlag, Tokyo, 1997, p. 73-77

• 18) Shingyouchi, Y., Nagahama, A., Niida, M.:Ligamentous ossification of the cervical spine in the late middle-aged Japanese men. Its relation to body mass index and glucose metabolism. Spine 21:2474-2478, 1996
  pubmed

• 19) Takeuchi, Y., Matsumoto, T., Takuwa, Y. et al.:High incidence of obesity and elevated serum immunoreactive insulin level in patients with paravertebral ligamentous ossification;a relationship to the development of ectopic ossification. J. Bone Miner. Metab. 7:17-21, 1989

• 20) Tamemoto, H., Kadowaki, T., Tobe, K. et al.:Insulin resistance and growth retardation in mice lacking insulin receptor substrate-l. Nature 372:182-186, 1994

• 21) Ogata, N., Chikazu, D., Kubota, N. et al.:Insulin receptor substratein osteoblast is indispensable for maintaining bone turnover. J. Clin. Invest. 105:935-943, 2000

P.272 掲載の参考文献

• 1) 上野直人, 野地澄晴:ダイナミックな器官形成, ニワトリの翼. 新形づくりの分子メカニズム. 東京, 羊土社, 1999, p.96-134

• 2) 竹内 純, 小柴和子, 小椋利彦:前後肢の違いを決めるTbx遺伝子とidentityの獲得. 実験医学18(9):1183-1193, 2000

• 3) Rodriguez, E. C., Tsukui, T., Yonei, S. et al.:The T-box genes Tbx4 and Tbx5 regulate limb outgrowth and identity [see comments]. Nature 398:814-818, 1999

• 4) Takeuchi, J. K., Koshiba, T. K., Matsumoto, K. et al.:Tbx5 and Tbx4 genes determine the wing /leg identity of limb buds[see comments]. Nature 398:810-814, 1999

• 5) Ohuchi, II., Nakagawa, T., Yamamoto, A. et al.:The mesenchymal factor, FGF10, initiates and maintains the outgrowth of the chick limb bud through interaction with FGF8, an apical ectodermal factor. Development 124:2235-2244, 1997

• 6) Xu, X., Weinstein, M., Li, C. et al.:Fibroblast growth factor receptor 2(FGFR2)-mediated reciprocal regulation loop between FGF8 and FGFIO is essential for limb induction. Development 125:753-765, 1998
  pubmed

• 7) Laufer, E., Nelson, C. E., Johnson, R. L. et al.:Sonic hedgehog and Fgf-4 act through a signaling cascade and feedback loop to integrate growth and patterning of the developing limb bud. Cell 79:993-1003, 1994
  pubmed

• 8) Niswander, L, Jeffrey, S., Martin, G. R. et al:A positive feedback loop coordinates growth and patterning in the vertebrate limb. Nature 371:609-612, 1994

• 9) Tabin, C.:The initiation of the limb bud:growth factors, Hox genes and retinoids. Cell 80:671-674, 1995
  pubmed

• 10) Riddle, R., Johnson, R. L., Laufer, E. et al:Sonic hedgehog mediates the polarizing activity of the ZPA. Cell 75:1401-1416, 1993
  pubmed

• 11) Echelard, Y., Epstein, D. J., St, J. B. et al.:Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity. Cell 75:1417-1430, 1993

• 12) Johnson, R. L, Laufer, E., Riddle, R. d. et al.:Ectopic expression of Sonic hedgehog alters dorsalventral patterning of somites. Cell 79:1165-1173, 1994
  pubmed

• 13) Francis, P. H., Richardson, M. K., Brickell, P. M. et al.:Bone morphogenetic proteins and a signalling pathway that controls patterning in the developing chick limb. Development 120:209-218, 1994

• 14) Bitgood, M. J., McMahon, A. P.:Hedgehog and Bmp genes are coexpressed at many diverse sites of cell-cell interaction in the mouse embryo. Dev. Biol. 172:126-238, 1995
  pubmed

• 15) Kawakami, Y., Ishikawa, T., Shimabara, M. et al.:BMP signaling during bone pattern determination in the developing limb. Development 122:3557-3566, 1996
  pubmed

• 16) Parr, B. A., McMahon, A. P.:Dorsalizing signal Wnt-7a required for normal polarity of D-V and A-P axes of mouse limb. Nature 374:350-353, 1995

• 17) Riddle, R. D., Ensini, M., Nelson, C. et al.:Induction of the LIM homeobox gene Lmx1 by WNT7a establishes dorsoventral pattern in the vertebrate limb. Cell 83:631-640, 1995
  pubmed

• 18) Rodriguez, E. C., Schwabe, J. W., De, L. P. J. et al.:Radical fringe positions the apical ectodermal ridge at the dorsoventral boundary of the vertebrate limb[see comments][published erratum appears in Nature 1997 Aug 28;388 (6645):906]. . Nature 386:360-366, 1997

• 19) Logan, C., Hornbruch, A.,:Campbell, I. et al.:The role of Engrailed in establishing the dorsoventral axis of the chick limb. Development 124:2317-2324, 1997
  pubmed

• 20) Nusse, R., Varrdus, H. E.:Wnt genes. Cell 69:1073-1087, 1992

• 21) Cadigan, K. M., Nusse, R.:Wnt signaling:a common theme in animal development. Genes. Dev. 11:3286-3305, 1997
  pubmed

• 22) Niswander, L., Martin, G. R.:FGF-4 and BMP-2 have opposite effects on limb growth. Nature 361:68-71, 1993
  pubmed

• 23) Niswander, L., Tickle, C., Vogel, A. et al.:Function of FGF-4 in limb development. Mol. Reprod. Dev. 39:83-88, 1994
  pubmed

• 24) Marigo, V., Roberts, D. J., Lee, S. M. et al.:Cloning, expression, and chromosomal location of SHH and IHH:two human homologues of the Drosophila segment polarity gene hedgehog. Genomics 28:44-51, 1995
  pubmed

• 25) Ciang, C., Litingtung, Y., Lee, E. et al.:Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. Nature 383:407-413, 1996

• 26) St-Jacques, B., Hammerschmidt, M., McMahon, A. P.:Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes. Dev. 13:2072-2086, 1999
  pubmed

• 27) Murtaugh, C. L., Chyung, J. H., Lassar, A. B.:Sonic hedgehog promotes somitic chondrogenesis by altering the cellular response to BMP signaling. Genes. Dev. 13:225-237, 1999

• 28) lwasaki, M., Le, A. X., Helms, J. A.:Expression of indian hedgehog, bone morphogenetic protein 6 and gli during skeletal morphogenesis. Mech. Dev. 69:197-202, 1997

• 29) Kinto, N., Iwamoto, M., Enomoto-Iwamoto, M. et al.:Fibroblasts expressing sonic hedgehog induce osteoblast differentiation and ectopic bone formation. FEBS Lett. 404:319-323, 1997

• 30) lwamoto, M., Enomoto-Iwamoto, M., Kurisu, K.:Actions of hedgehog proteins on skeletal cells. Crit. Rev. Oral. Biol.Med. 10:477-486, 1999

• 31) Enomoto-Iwamoto, M., Nakamura, T., Aikawa, T. et al.:Hedgehog proteins stimulate chondrogenic cell differentiation and cartilage formation. J. Bone Miner. Res. 2000 (in press)

• 32) Vortkamp, A., Lee, K., Lanske, B. et al.:Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science 273:613-622, 1996
  pubmed

• 33) Scott, N. S., Choung, C.-M.:dual action of sonic hedgehog on chondrocyte hypertrophy:retrovirus mediated ectopic sonic hedgehog expression in limb bud micromass culture induces novel cartilage nodules that are positive for alkaline phosphatase and type X collagen. J. Cell Sci. 110:2691-2701, 1997

• 34) Watanabe, A., Ide, H.:Basic FGF maintains some characteristics of the progress zone of chick limb bud in cell culture. Dev. Biol. 159:223-231, 1993
  pubmed

• 35) Rousseau, F., Bonaventure, J., Legeai, M. L. et al.:Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371:252-254, 1994

• 36) Wang, Y., Spatz, M. K., Kannan, K. et al.:A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3. Proc. Natl. Acad. Sci. USA 96:4455-4460, 1999

• 37) Deng, C., Wynshaw, B. A., Zhou, F. et al.:Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84:911-921, 1996

• 38) Minowada, G., Jarvis, L. A., Chi, C. L. et al.:Vertebrate Sprouty genes are induced by FGF signaling and can cause chondrodysplasia when overexpressed. Development 126:4465-4475, 1999
  pubmed

• 39) Kato, Y., Iwamoto, M., Koike, T.:Fibroblast growth factor stimulates colony formation of differentiated chondrocytes in soft agar. J. Cell Physiol. 133:491-498, 1987

• 40) Sahni, M., Ambrosetti, D. C., Mansukhani, A. et al.:FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-l pathway. Genes. Dev. 13:1361-1366, 1999

• 41) Enomoto-Iwamoto, M., Iwamoto, M., Kazuhisa, N. et al.:Involvement of α5β1 integrin in matrix interactions and proliferation of chondrocytes. J. Bone Miner. Res. 12:1124-1132, 1997

• 42) Zou, H., Niswander, L.:Requirement for BMP signaling in interdigital apoptosis and scale formation. Science 272:738-741, 1996
  pubmed

• 43) Yokouchi, Y., Sakiyama, J., Kameda, T. et al.:BMP-2/-4 mediate programmed cell death in chicken limb buds. Development 122:3725-3734, 1996
  pubmed

• 44) Yi, S. E., daluiski, A., Pederson, R. et al.:The type I BMP receptor BMPRIB is required for chondrogenesis in the mouse limb. Development 127:621-630, 2000
  pubmed

• 45) Enomoto-Iwamoto, M., Iwamoto, M., Mukudai, Y. et al.:Bone morphogenetic protein signaling is required for maintenance of differentiated phenotype, control of proliferation, and hypertrophy in chondrocytes. J. Cell Biol. 140:409-418, 1998
  pubmed

• 46) Zou, H., Wieser, R., Massague, J. et al:Distinct roles of type I bone morphogenetic protein receptors in the formation and differentiation of cartilage. Genes. Dev. 11:2191-2203, 1997
  pubmed

• 47) Thomas, J. T., Kilpatrick, M. W., Lin, K. et al.:Disruption of human limb morphogenesis by a dominant negative mutation in CDMP1. Nat. Genet. 17:58-64, 1997
  pubmed

• 48) Tsumaki, N., Tanaka, K., Arikawa-Hirasawa, E. et al.:Role of CDMP-1 in skeletal morphogenesis:promotion of mesenchymal cell recruitment and chondrocyte differentiation. J. Cell Biol. 144:161-173, 1999
  pubmed

• 49) Parr, B. A., McMahon, A. P.:Dorsalizing signal Wnt-7a required for normal polarity of D-V and A-P axes of mouse limb. Nature 374:350-353, 1995

• 50) Kawakami, Y., Wada, N., Nishimatsu, S. I. et al.:Involvement of Wnt-5a in chondrogenic pattern formation in the chick Iimb bud. Dev. Growth Differ. 41:29-40, 1999

• 51) Rudnicki, J. A., Brown, A. M.:Inhibition of chondrogenesis by Wnt gene expression in vivo and in vitro. Dev. Biol. 185:104-118, 1997
  pubmed

• 52) Wang, S., Krinks, M., Lin, K. et al:Frzb, a secreted protein expressed in the Spemann organizer, binds and inhibits Wnt-8. Cell 88:757-766, 1997
  pubmed

• 53) Leyns, L, Bouwmeester, T., Kim, S. H. et al.:Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer. Cell 88:747-756, 1997
  pubmed

• 54) Hoang, B. H., Thomas, J. T., Abdul, K. F. et al.:Expression pattern of two Frizzled-related genes, Frzb-1 and Sfrp-1, during mouse embryogenesis suggests a role for modulating action of Wnt family members. Dev. Dyn. 212:364-372, 1998

• 55) Ladher, R. K., Church, V. L, Allen, S. et al:Cloning and expression of the Wnt antagonists Sfrp-2 and Frzb during chick development. Dev. Biol. 218:183-198, 2000
  pubmed

• 56) Duprez, D., Leyns, L, Bonnin, M. A. et al:Expression of Frzb-1 during chick development. Mech. Dev. 89:179-183, 1999
  pubmed

• 57) Wada, N., Kawakami, Y., Ladher, R. et al.:Involvement of Frzb-1 in mesenchymal condensation and cartilage differentiation in the chick limb bud. Int. J. Dev. Biol. 43:495-500, 1999
  pubmed

• 58) Wang, S., Krinks, M., Moos, M. J.:Frzb-1, an antagonist of Wnt-1 and Wnt-8, does not block signaling by Wnts-3A,-5A, or-ll. Biochem. Biophys. Res. Commun. 236:502-504, 1997

• 59) Eastman, Q., Grosschedl, R.:Regulation of LEF-1/TCF transcription factors by Wnt and other signals. Curr. Opin. Cell. Biol. 11:233-240, 1999
  pubmed

• 60) Ishitani, T., Ninomiya, T. J., Nagai, S. et al.:The TAKl-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. Nature 399:798-802, 1999

• 61) Nishita, M., Hashimoto, M. K., Ogata, S. et al.:Interaction between Wnt and TGF-β signallihg pathways during formation of Spemann's organizer. Nature 403:781-785, 2000

P.286 掲載の参考文献

• 1) Suda, T., Takahashi, N., Udagawa, N. et al.:Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20:345-357, 1999
  pubmed

• 2) Kong, Y. Y., Yoshida, H., Sarosi, I. et al:OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323, 1999
  pubmed

• 3) Simonet, W. S., Lacey, d. L., Dunstan, C. R. et al:Osteoprotegerin:a novel secreted protein involved in the regulation of bone density. Cell 89:309-319, 1997
  pubmed

• 4) Tsuda, E., Goto, M., Mochizuki, S. et al:Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 234:137-142, 1997
  pubmed

• 5) Jimi, E., Nakamura, I., Ikebe, T. et al.:Activation of NF-κB is involved in the survival of osteoclasts promoted by interleukin-1. J. Biol. Chem. 273:8799-8805, 1998

• 6) 稲田全規 ・宮浦千里:炎症性骨吸収とマトリックスメタロプロテアーゼ. CLINICAL CALCIUM 8:300-305, 1998

• 7) Kusano, K., Miyaura, C., Inada, M. et al:Regulation of matrix metalloproteinases (MMP-2, 3, 9, and 13) by interleukin-1 and interleukin-6 in mouse calvaria:Association of MMP induction with bone resorption. Endocrinology 139:1338-1345, 1998
  pubmed

• 8) Chen, Q.-R., Miyaura, C., Higashi, S. et al:Activation of cytosolic phospholipase A2 by platelet-derived growth factor is essential for cyclooxygenase-2-dependent prostaglandin E2 synthesis in mouse osteoblasts cultured with interleukin-1. J. Biol. Chem. 272:5952-5958, 1997
  pubmed

• 9) Tai, H., Miyaura, C., Pilbeam, C. C. et al:Transcriptional induction of cyclooxygenase-2 in osteoblasts is involved in interleukin-6-induced osteoclast formation. Endocrinology 138:2372-2379, 1997
  pubmed

• 10) Onoe, Y., Miyaura, C., Kaminakayashiki, T. et al.:IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J. Immunol. 156:758-764, 1996
  pubmed

• 11) 宮浦千里:ホルモンおよびサイトカインによる骨吸収の調節. 生化学70:516-530, 1998

• 12) Akatsu, T., Takahashi, N., Udagawa, N. et al:Role of prostaglandins in interleukin-1-induced bone resorption in mice in vitro. J. Bone Miner. Res. 6:183-190, 1991
  pubmed

• 13) 小林拓也, 牛首文隆, 成宮 周:受容体ノックアウトマウスを用いた新しい生理機能の解析. 現代医療31:171-184, 1999

• 14) Miyaura, C., Inada, M., Suzawa, T. et al.:Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice. J. Biol Chem. 275:19819-19823, 2000
  pubmed

• 15) Sakuma, Y., Tanaka, K., Suda, M. et al:Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J. Bone Miner. Res. 15:218-227, 2000
  pubmed

• 16) Suzawa, T., Miyaura, C., Inada, M. et al.:The role of prostaglandin E receptor subtypes (EPl EP2, EP3 and EP4) in bone resorption:An analysis using specific agonists for the respective EPs. Endocrinology 141:1554-1559, 2000

• 17) Li, X., Okada, Y., Pilbeam, C. C. et al.:Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology 141:2054-2061, 2000
  pubmed

• 18) Masuzawa, T., Miyaura, C., Onoe, Y. et al.:Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow. J. Clin. Invest. 94:1090-1097, 1994
  pubmed

• 19) Miyaura, C., Onoe, Y., Inada, M. et al.:Increased B-lymphopoiesis by interleukin-7 induces bone loss in mice with intact ovarian function:Similarity to estrogen deficiency. Proc. Natl. Acad. Sci. USA 94:9360-9365, 1997
  pubmed

• 20) Onoe, Y., Miyaura, C., Ohta, H. et al.:Expression of estrogen receptor β in rat bone. Endocrinology 138:4509-4512, 1997

• 22) Kanematsu, M., Sato, T., Takai, H. et al.:Prostaglandin E2 induces expression of receptor activator of nuclear factor-πB ligand/osteoprotegrin ligand on pre-B cells:Implications for accelerated osteoclastogenesis in estrgoen deficiency. J. Bone Miner. Res. 15:1321-1329, 2000

• 23) Kawaguchi, H., Pilbeam, C. C., Vargas, S. J. et al.:Ovariectomy enhances and estrogen replacement inhibits the activity of bone marrow factors that stimulate prostaglandin production in cultured mouse calvariae. J. Clin. Invest. 96:539-548, 1995
  pubmed

• 21 Asami, T., Inada, M., Mizunuma, H. et al.:Expression of osteoclast differentiation factor (ODF/RANKL/OPG1) in trab β cular bone and bone marrow B-lymphocytes in OVX mice. J. Bone Miner. Res. 14:S152, 1999

第3章 骨粗鬆症の病態と診断の分子医学

P.296 掲載の参考文献

• 1) Eastell, R.:Treatment of postmenopausal osteoporosis. N. Engl. J. Med. 338:736-746, 1998
  pubmed

• 2) Gallagher, J. C.:Estrogen:prevention and treatment of osteoporosis, in Osteoporosis. (Marcus, R., Feldman, D., Kelsery, J. eds. ) Academic Press, San diego, 1996, p.1191-1208

• 3) Eisman, J. A.:Genetics of osteoporosis. Endocr. Rev. 20:788-804, 1999
  pubmed

• 4) Cummings, S. R., Browner, W. S., Bauer, D. et al.:Endogehous hormones and the risk of hip and vertebral fractures among older women. N. Engl. Med. 339:733-738, 1998
  pubmed

• 5) Bilezikian, J. P., Morishima, A., Bell, J. et al.:Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl. J. Med. 339:599-603, 1998

• 6) Carani, C., Qin, K, Simoni, M. et al.:Effect of testosterone and estradiol in a man with aromatase deficiency. N. Engl. J. Med. 337:91-95, 1998

• 7) Fisher, C. R., Graves, K. H., Parlow, A. F. et al.:Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc. Natl. Acad. Sci. USA 495:6965-6970, 1998

• 8) Komm, B. S., Terpening, C. M., Benz, d. J. et al.:Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 241:81-84, 1988
  pubmed

• 9) Eriksen, E. F., Colvard, d. S., Berg, N. J. et al.:Evidence of estrogen receptors in normal human osteoblast-like cells. Science 241:84-86, 1988
  pubmed

• 10) Oursler, M. J., Osdoby, P., Pyfferoen, J. et al.:Avian osteoclasts as estrogen target cells. Proc. Natl. Acad. Sci. USA 88:6613-6617, 1991
  pubmed

• 11) Onoe, Y., Miyaura, C., Ohta, H. et al.:Expression of estrogen receptor beta in rat bone. Endocrinology 138:4509-4512, 1997
  pubmed

• 12) Smith, E. P., Bpyd, J., Frank, G. R. et al.:Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. N. Engl. J. Med. 331:1056-1061, 1994

• 13) Couse, J. F., Korach, KS.:Estrogen receptor null mice:what have we learned and where will they lead us? Endocr. Rev. 20:358-417, 1999
  pubmed

• 14) Windahl, S. H., Vidal, O., Andersson, G. et al.:Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERβ-/-mice. J. Clin. Invest. 104:895-901, 1999

• 15) Uebelhart, D., Schlemmer, A., Johansen, J. S. et al.:Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J. Clin. Endocrinol. Metab. 72:367-373, 1991

• 16) Calvo, M. S., Eyre, d. R., Gundberg, C. M.:Molecular basis and Clinical application of biological markers of bone turnover. Endocr. Rev. 17:333-368, 1996
  pubmed

• 17) Spelsberg, T. C., Subramaniam, M., Riggs, B. L. et al.:The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol. Endocrinol. 13:819-828, 1999
  pubmed

• 18) Pacifici, R.:Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J. Bone Miner. Res. 11:1043-1051, 1996
  pubmed

• 19) Manolagas, S. C., Jilka, R. L:Bone marrow, cytokines, and bone remodeling:emerging insights into the pathophysiology of osteoporosis. N. Engl. J. Med. 332:305-310, 1995
  pubmed

• 20) Pacifici, R., Rifas, L, Teitelbaum, S. et al.:Spontaneous release of interleukin l from human blood monocytes reflects bone formation in idiopathic osteoporosis. Proc. Natl. Acad. Sci. USA 84:4616-4620, 1987

• 21) Pacifici, R., Rifas, L., McCracken, R. et al.:Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin l release. Proc. Natl. Acad. Sci. USA 86:2398-2402, 1989

• 22) Pacifici, R., Brown, C., Puscheck, E. et al.:Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononeclear cells. Proc. Natl. Acad. Sci. USA 88:5134-5138, 1991
  pubmed

• 23) Kitazawa, R., Kimble, R. B., Vannice, J. L. et al.:Interleukin-l receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J. Clin. Invest. 94:2397-2406, 1994

• 24) Lorenzo, J. A., Naprta, A., Rao, Y. et al.:Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinology 139:3022-3025, 1998

• 25) Ammann, P., Rizzoli, R., Bonjour, J. P. et al.:Transgenic mice expressing soluble tumor necrosis factor receptor are protected against bone loss caused by estrogen deficiency. J. Clin. Invest. 99:1699-1703, 1997
  pubmed

• 26) Kimble, R. B., Srivastava, S., Ross, F. P. et al.:Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1-and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J. Biol. Chem. 271:28890-28897, 1996
  pubmed

• 27) Srivastava, S., Weitzmann, M. N., Kimble, R. B. et al.:Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation of Egr-1 and its interaction with Sp-1. J. Clin. Invest. 102:1850-1859, 1998

• 28) Girasole, G., Jilka, R. L., Passeri, G. et al.:17β-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro:apotential mechanism for the antiosteoporotic effect of estrogens. J. Clin. Invest. 89:883-891, 1992

• 29) Jilka, R. L., Hangoc, G., . Girasole, G. et al.:Increased osteoclast development after estrogen loss:mediation by interleukin-6. Science 257:88-91, 1992
  pubmed

• 30) Poli, V., Balena, R., Fattori, E. et al.:Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13:1189-1196, 1994
  pubmed

• 31) Kawasaki, K., Gao, Y. H., Yokose, S. et al.:Osteoclasts are present in gp130-deficient mice. Endocrinology 138:4959-4965, 1997
  pubmed

• 32) Kawaguchi, H., Pilbeam, C. C., Vargas, S. J. et al.:Ovariectomy enhances and estrogen replacement inhibits the activity of bone marrow factors that stimulate prostaglandin production in culturedmouse calvariae. J. Clin. Invest. 96:539-548, 1995

• 33) Miyaura, C., Kusano, K., Masuzawa, T. et al.:Endogenous bone-resorbing factors in estro gendeficiency:cooperative effects of IL-1 and IL-6. J. Bone Miner. Res. 10:1365-1373, 1995

• 34) Jilka, R. L, Takahashi, K., Munshi, M. et al.:Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow:evidence for autonomy from factors released during bone resorption. J. Clin. Invest. 101:1942-1950, 1998
  pubmed

• 35) Suda, T., Takahashi, N., Udagawa, N. et al.:Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev . 20:345-357, 1999
  pubmed

• 36) Filvaroff, E., derynck, R.:A signaling system for osteoclast regulation. Curr. Biol. 8:R679-R682, 1998
  pubmed

• 37) Roodman, G. D.:Advances in bone biology:the osteoclast. Endocr. Rev. 17:308-332, 1996
  pubmed

• 38) Lacey, D. L., Timms, E., Tan, H. L. et al:Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176, 1998
  pubmed

• 39) Yasuda, H., Shima, N., Nakagawa, N. et al.:Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95:3597-3602, 1998
  pubmed

• 40) Fuller, K., Wong, B., Fox, S. et al.:TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J. Exp. Med. 188:997-1001, 1998
  pubmed

• 41) Kong, Y. Y., Yoshida, H., Sarosi, I. et al.:OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323, 1999
  pubmed

• 42) Hsu, H., Lacey, D. L., Dunstan, C. R. et al.:Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96:3540-3545, 1999
  pubmed

• 43) Dougall, W. C., Glaccum, M., Charrier, K. et al.:RANK is essential for osteoclast and lymph node development. Genes Dev. 13:2412-2424, 1999
  pubmed

• 44) Lomaga, M. A., Yeh, W. C., Sarosi, I. et al.:TRAF6 deficiency results in osteopetrosis and defective interleukin-1, Cd-40, and LPS signaling. Genes Dev. 13:1015-1024, 1999

• 45) Simonet, W. S., Lacey, D. L., Dunstan, C. R. et al.:Osteoprotegerin:a novel secreted protein involved in the regulation of bone density. Cell 89:309-319, 1997
  pubmed

• 46) Bucay, N., Sarosi, I., Dunstan, C. R. et al.:Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12:1260-1268, 1998
  pubmed

• 47) Kobayashi, K., Takahashi, N., Jimi, E. et al.:Tumor necrosis factor a stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 17:275-286, 2000

• 48) Hofbauer, LC., Khosla, S., Dunstan, C. R. et al.:The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. 15:2-12, 2000
  pubmed

• 49) Yano, K., Tsuda, E., Washida, N. et al:Immunological characterization of circulating osteo-protegerin/osteoclastogenesis inhibitory factor:increased serum concentrations in postmenopausal women with osteoporosis. J. Bone Miner. Res. 14:518-527, 1999

• 50) Sato, T., Ikeda, K., Watanabe, K.:Generation of bone-resorbing osteoclasts from B220-positive cells:its role in accelerated osteoclastogenesis in estrogen deficiency. J. Bone Miner. Res. (in press)

• 51) Manolagas, S. C.:Birth and death of bone cells:basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21:115-137, 2000
  pubmed

• 52) Hughes, D. E., Dai, A., Tiffee, J. C. et al.:Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nat. Med. 2:1132-1136, 1996

• 53) Kameda, T., Mano, H . ., Yuasa, T. et al:Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J. Exp. Med. 186:489-495, 1997
  pubmed

• 54) Kincade, P. W., Medina, K. L, Smithson, G. et al.:Pregnancy:a clue to normal regulation of B lymphopoiesis. Immunol. Today 15:539-544, 1994
  pubmed

• 55) Masuzawa, T., Miyaura, C., Onoe, Y. et al.:Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow. J. Clin. Invest, 94:1090-1097, 1994
  pubmed

• 56) Miyaura, C., Onoe, Y., Inada, M. et al.:Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function:similarity to estrogen deficiency. Proc. Natl. Acad. Sci. USA 94:9360-9365, 1997
  pubmed

• 57) 浅見哲司ほか:エストロゲン欠乏による骨髄リンパ球造血の亢進と破骨細胞分化誘導因子(ODF)の発現増大の相関. 日本骨代謝学会雑誌17:58, 1999

• 58) Kanematsu, M., Sato, T., Takai, H. et al:Prostaglandin E2 induces expression of RANKL/OPGL on pre-B cells:implications for accelerated osteoclastogenesis in estrogen deficiency. J. Bone Miner. Res. 15:1321-1329, 2000

• 59) Riggs, B. L., Khosla, S., Melton, L. J. III.:Aunitary model for involutional osteoporosis:estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J. Bone Miner. Res. 13:763-773, 1998

• 60) Prince, R. L.:Estrogen effects on calcitropic hormones and calcium homeostasis. Endocr. Rev. 15:301-309, 1994
  pubmed

• 61) Colin, E. M., Van Den Bemd, G. J., Van Aken, M. et al.:Evidence for invovlement of 17b-estradiol in intestinal calcium absorption independent of 1,25-dihydrozyvitamin D3 level in the rat. J. Bone Miner. Res. 14:57-64, 1999

• 62) Bolscher, M. T., Netelenbos, J. C., Barto, R. et al.:Estrogen regulation of intestinal calcium absorption in the intact and ovariectomized adult rat. J. Bone Miner. Res. 14:1197-1202, 1999

• 63) Slemenda, C. W., Longcope, C., Zhou, L. et al.:Sex steroids and bone mass in older man:positive associations with serum estrogens and negative associations with androgens. J. Clin. Invest. 100:1755-1759, 1997
  pubmed

• 64) Khosla, S., Melton, L. J. III., Atkinson, E. J. et al.:Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women:akey role for bioavailable estrogen. J. Clin. Endocrinol. Metab. 83:2266-2274, 1998

• 65) Rodan, G. A.:Mechanical loading, estrogen deficiency, and the coupling of bone formation to bone resorption. J. Bone Miner. Res. 6:527-530, 1991
  pubmed

• 66) Westerlind, K. C., Wronski, T. J., Ritman, E. L. et al.:Estrogen regulates the rate of bone turnover but bone balance in ovariectomized rats is modulated by prevailing mechanical strain. Proc. Natl. Acad. Sci. USA 94:4199-4204, 1997
  pubmed

P.310 掲載の参考文献

• 1) Riggs, B. L, Khosla, S., Melton, I. J. L.:A unitary model for involutional osteoporosis:Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J. Bone Miner. Res. 13:763-773, 1998

• 2) Riggs, B. L, Melton, IIL L. J.:Involutional osteoporosis. N. Engl. J. Med. 314:1676-1686, 1986

• 3) Takahashi, M., Kushida, K., Hoshino, H. et al.:Biochemical markers of bone turnover do not decline after menopause in healthy women. Br. J. Obstet. Gynaecol 106:427-431, 1999

• 4) Theiler, R., Stahelin, H. B., Kranzlin, M. et al.:High bone turnover in the elderly. Arch. Phys. Med. Rehabil. 80:485-489, 1999
  pubmed

• 5) Bollen, A. M., Kiyak, H. A., Eyre, D. R.:Longitudinal evaluation of a bone resorption marker in elderly subjects. Osteoporos. Int. 7:544-549, 1997
  pubmed

• 6) Yoshimura, N., Hashimoto, T., Sakata, K. et al.:Biochemical markers of bone turnover and bone loss at the lumbar spine and femoral neck:the Taiji study. Calcif. Tissue Int. 65:198-202, 1999
  pubmed

• 7) Dawson-Hughes, B., Harris, S. S., Krall, E. A. et al:Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N. Engl. Med. 337:670-676, 1997
  pubmed

• 8) D'Ippolito, G., Schiller, P. C., Ricordi, C. et al.:Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow. J. Bone Miner. Res. 14:1115-1122, 1999

• 9) Bergman, R. J., Gazit, D., Kahn, A. J. et al.:Age-related changes in osteogenic stem cells in mice. J. Bone miner. Res. 11:568-577, 1996
  pubmed

• 10) Jilka, R. L, Weinstein, R. S., Takahashi, K. et al.:Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J. Clin. Invest. 97:1732-1740, 1996

• 11) Kodama, Y., Takeuchi, Y., Suzawa, M. et al.:Reduced expression of interleukin-11 in bone marrow stromal cells of senescence-accelerated mice (SAMP6):relationship to osteopenia with enhanced adipogenesis. J. Bone Miner. Res. 13:1370-1377, 1998
  pubmed

• 12) Kawaguchi, H., Manabe, N., Miyaura, C. et al.:Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia. J. Clin. Invest. 104:229-237, 1999
  pubmed

• 13) Rosen, C. J.:Growth hormone, insulin-like growth factors, and the senescent skeleton:Ponce de Leon:s Fountain revisited? J. Cell Biochem. 56:348-356, 1994

• 14) Pfeilschifter, J., Diel, I., Pilz, U. et al.:Mitogenic responsiveness of human bone cells in vitro to hormones and growth factors decreases with age. J. Bone Miner. Res. 8:707-717, 1993

• 15) Fleet, J. C., Cashman, K., Cox, K. et al.:The effects of aging on the bone inductive activity of recombinant human bone morphogenetic protein-2. Endocrinology 137:4605-4610, 1996
  pubmed

• 16) Donahue, H. J., Zhou, Z., Li, Z. et al.:Age-related decreases in stimulatory G protein-coupled adenylate cyclase activity in osteoblastic cells. Am. J. Physiol. 273:E776-E781, 1997

• 17) Poli, V., Balena, R., Fattori, E. et al.:Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13:1189-1196, 1994
  pubmed

• 18) Lorenzo, J. A., Naprta, A., Rao, Y. et al:Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy[see comments]. Endocrinology 139:3022-3025, 1998
  pubmed

• 19) Ammann, P., Rizzoli, R., Bonjour, J. P. et al:Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J. Clin. Invest. 99:1699-1703, 1997
  pubmed

• 20) Anderson, D. M., Maraskovsky, E., Billingsley, W. L. et al:A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature (Lond) 390:175-179, 1997
  pubmed

• 21) Lacey, d. L., Timms, E., Tan, H. L. et al.:Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176, 1998
  pubmed

• 22) Wong, B. R., Rho, J., Arron, J. et al.:TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272:25190-25194, 1997

• 23) O'Brien, C. A., Gubrij, I., Lin, S. C. et al.:STAT3 Activation in Stromal/Osteoblastic Cells Is Required for Induction of the Receptor Activator of NF-κB Ligand and Stimulation of Osteoclastogenesis by gp130-utilizing Cytokines or Interleukin-l but Not 1,25-dihydroxyvitamin D3 or Parathyroid Hormone. J. Biol. Chem. 274:19301-19308, 1999

• 24) Azuma, Y., Kaji, K., Katogi, R. et al.:Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem. 275:4858-4864, 2000

• 25) Kobayashi, K., Takahashi, N., Jimi, E. et al.:Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191:275-286, 2000

• 26) Jimi, E., Nakamura, I., Duong, L. T. et al:Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp. Cell Res. 247:84-93, 1999
  pubmed

• 27) Aerssens, J., Boonen, S., Joly, J. et al.:Variations in trabecular bone composition with anatomical site and age:potential implications for bone quality assessment. J. Endocrinol. 155:411-421, 1997
  pubmed

• 28) Nicolas, V., Prewett, A., Bettica, P. et al.:Age-related decreases in insulin-like growth factor-I and transforming growth factor-β in femoral cortical bone from both men and women:implications for bone loss with aging. J. Clin. Endocrinol. Metab. 78:1011-1016, 1994

• 29) Horst, R. L, Goff, J. P., Reinhardt, T. A.:Advancing age results in reduction of intestinal and bone 1,25-dihydroxyvitamin D receptor. Endocrinology 126:1053-1057, 1990
  pubmed

• 30) Mulroney, S. E., Woda, C., Haramati, A.:Changes in renal phosphate reabsorption in the aged rat. Proc. Soc. Exp. .Biol. Med. 218:62-67, 1998
  pubmed

• 31) Ledger, G. A., Burritt, M. F., Kao, P. C. et al.:Abnormalities of parathyroid hormone secretion in elderly women that are reversible by short term therapy with 1,25-dihydroxyvitamin D3. J. Clin. Endocrinol. Metab. 79:211-216, 1994
  pubmed

• 32) Haden, S. T., Brown, E. M., Hurwitz, S. et al.:The effects of age and gender on parathyroid hormone dynamics. Clin. Endocrinol. 52:329-338, 2000
  pubmed

• 33) Boonen, S., Aerssens, J., dequeker, J.:Age-related endocrine deficiencies and fractures of the proximal femur. I implications of growth hormone deficiency in the elderly. J. Endocrinol. 149:7-12, 1996
  pubmed

• 34) Sugimoto, T., Nishiyama, K., Kuribayashi, F. et al.:Serum levels of insulin-like growth factor (IGF)1, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J. Bone Miner. Res. 12:1272-1279, 1997
  pubmed

• 35) Marcus, R., Hoffman, A. R.:Growth hormone as therapy for older men and women. Annu. Rev. Pharmacol. Toxicol. 38:45-61, 1998
  pubmed

• 36) Marie, P.:Growth factors and bone formation in osteoporosis:roles for IGF-Iand TGF-β. Rev. Rhum. Engl. Ed. 64:44-53, 1997

• 37) Lamberts, S. W., van den Beld, A. W., van der Lely, A. J.:The endocrinology of aging. Science (Wash. DC) 278:419-424, 1997

• 38) Baulieu, E. E., Thomas, G., Legrain, S. et al.:dehydroepiandrosterone (DHEA), DHEA sulfate, and aging:contribution of the DHEAge Study to a sociobiomedical issue. Proc. Natl. Acad. Sci. USA 97:4279-4284, 2000
  pubmed

• 39) Stephan, J. J., Lachman, M., Zverina, J. et al:Castrated men exhibit bone loss:Effect of calcitonin treatment on biochemical indices of bone remodeling. J. Clin. Endocrinol. Metab. 69:523-527, 1989

• 40) Smith, E. P., Boyd, J., Frank, G. R. et al.:Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 331:1056-1061, 1994

• 41) MacGimvray, M. H., Morishima, A., Conte, F. et al.:Pediatric endocrinology update:an overview. The essential roles of estrogens in pubertal growth, epiphyseal fusion andbone turnover:lessons from mutations in the genes for aromatase and the estrogen receptor. Horm. Res. 1:2-8, 1998

• 42) Bilezikian, J. B., Morishima, A., Bell, J. et al.:Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N. Engl. J. Med. 339:599-603, 1998

• 43) Slemenda, C. W., Longcope, C., Zhou, L. et al.:Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J. Clin. Invest. 100:1755-1759, 1997
  pubmed

• 44) Vanderschueren, D., Van-Herck, E., de-Coster, R. et al.:Aromatization of androgens is important for skeletal maintenance of aged male rats. Calcif. Tissue Int. 59:179-183, 1996
  pubmed

• 45) Cummings, S. R., Browner, W. S., Bauer, d. et al:Endogenous hormones and the risk of the hip and vertebral fractures among older women. N. Engl. J. Med. 339:733-738, 1998

• 46) Takeda, T., Hosokawa, M., Takeshita, S. et al.:Anew murine model of accelerated senescence. Mech. Ageing Dev. 17:183-194, 1981

• 47) Takeda, T., Hosokawa, M., Higuchi, K.:Senescence-accelerated mouse (SAM):anovel murine model of accelerated senescence. J. Am. Geriatr. Soc. 39:911-919, 1991

• 48) Matsushita, M., Tsuboyama, T., Kasai, R. et al:Age-related changes in bone mass in the senescence-accelerated mouse (SAM) . SAM-R/3 and SAM-P/6 as new murine models for senile osteoporosis. Am. J. Pathol. 125:276-283, 1986

• 49) Kajkenova, O., Lecka-Czernik, B., Gubrij, I. et al.:Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis andlow turnover osteopenia. J. Bone Miner. Res. 12:1772-1779, 1997

• 50) Ohsumi, J., Miyadai, K., Kawashima, I. et al.:Adipogenesis inhibitory factor. A novel inhibitory regulator of adipose conversion in bone marrow. FASEB J. 288:13-16, 1991

• 51) Kawashima, I., Ohsumi, J., Mita-Honjo, K. et al.:Molecular cloning of cdNA encoding adipogenesis inhibitory factor and identity with interleukin-11. FASEB J. 283:199-202, 1991

• 52) Tohjima, E., Inoue, D., Yamamoto, N. et al.:Analysis of regulatory elements of mouse interleukin-11 gene transcription:insight into the mechanism of impairment of bone formation in senescence-acceleratd mice (SAM) . J. Bone Miner. Res. 14 (suppl.1):S152, 1999

• 53) Kuliwaba, J. S., Findlay, d. M., Atkins, G. J. et al.:Enhanced expression of osteocalcin mRNA in human osteoarthritic trabecular bone of the proximal femur is associated with decreased expression of interleukin-6 and interleukin-11 mRNA. J. Bone Miner. Res. 15:332-341, 2000
  pubmed

• 54) Kuro-o, M., Matsumura, Y., Aizawa, H. et al:Mutation of the mouse klotho gene leads to a syndrome resembling ageing[see comments]. Science (Wash. DC) 278:45-51, 1997

• 55) Yasuda, H., Shima, N., Nakagawa, N. et al.:Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG):amechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329-1337, 1998

• 56) Simonet, W. S., Lacey, D. L, Dunstan, C. R. et al:Osteoprotegerin:anovel secreted protein involved in the regulation of bone density. Cell 89:309-319, 1997

• 57) Yano, K., Tsuda, E., Washida, N. et al.:Immunological characterization of circulating osteoprotegerin/ osteoclastogenesis inhibitory factor:increased serum concentrations in postmenopausal women with osteoporosis. J. Bone Miner. Res. 14:518-527, 1999

• 58) Ducy, P., Amling, M., Takeda, S. et al:Leptin inhibits bone formation through a hypothalamic relay:acentral control of bone mass. Cell 100:197-207, 2000

P.323 掲載の参考文献

• 1) 名和田 新, 高柳淳一, 柳瀬敏彦ほか:グルココルチコイド療法の適応症と治療計画. Mol. Med. 30:592-600, 1993

• 2) 名和田 新:ステロイド性骨粗鬆症. 日本内科学会雑誌89:2116-2121, 2000

• 3) 名和田 新, 高柳涼一, 柳瀬敏彦ほか:副腎皮質ステロイドホルモン過剰による骨変化の分子機構. 分子骨代謝学と骨粗鬆症. (松本俊夫 編)メディカルレビュー社, 東京, 1996, p. 261-269

• 4) 名和田 新, 生山祥一郎, 後藤公宣ほか:内科医からみた慢性関節リウマチにおけるステロイドの功罪. 整形外科, 慢性関節リウマチ34:30-34, 1998

• 5) Hofbauer, L. C., Gori, F., Riggs, B. L. et al.:Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells:Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis. Endocrinology 140:4382-4389, 1999
  pubmed

• 6) Manelli, F.:Glucocorticoid-induced osteoporosis. TEM 11:79-85, 2000
  pubmed

• 7) American College of Rheumatology Task Force on Osteoporosis Guideline:Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 39:1791-1801, 1996
  pubmed

• 8) Eastell, R., Reid, d. M., Compston, J. et al.:AUK consensus group on management of glucocorticoid osteoporosis:an update. J. Int. Med. 244:271-292, 1998

• 9) 名和田 新, 田中誠一:副腎アンドロゲンの骨粗鬆症における役割. 医学のあゆみ165:538-541, 1993

• 10) Nawata, H., Tanaka, S., Tanaka, S. et al:Aromatase in bone cell:association with osteoporosis in postmenopausal women. J. Steroid Biochem. Molec. Biol. 53:165-174, 1995
  pubmed

• 11) Smith, E. P., Boyd, J., Frank, G. R. et al.:Estrogen resistance caused by a mutation in the estrogen-receptor gene in man. N. Engl. J. Med. 331:1056-1061, 1994

• 12) Morishima, A., Grumbach, M. M., Simpson, E. R. et al:Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogen. J. Clin. Endocrinol. Metab. 80:3689-3698, 1995
  pubmed

P.334 掲載の参考文献

• 1) Wekerle, H., Ketelsen, U. P.:Thymic nurse cells:Ia-bearing epithelium involved in T-lymphocyte differentiation? Nature 283:402-404, 1980

• 2) Wekerle, H., Ketelsen, U. P, Ernst, M.:Thymic nurse cells. Lymphoepitherial cell complexes in murine thymus:Morphological and serological characterization. J. Exp. Med. 151:925-944, 1980
  pubmed

• 3) Iwabuchi, K., Nakayama, K., McCoy, R. L. et al.:Cellular and peptide requirements for in vivo clonal deletion of immature thymocytes. Proc. Natl. Acad. Sci. USA 89:9000-9004, 1992
  pubmed

• 4) Pezzano, M., Li, Y., Phlip, d. et al.:Thymic nurse cells of early Cd4+Cd8+thymocytes from apoptosis. Cell. Mol. Biol. 41:1099-1111, 1995

• 5) Pezzano, M., Phlip, D., Stephenson, S. et al.:Positive selection by thymic nurse cells requires IL-1β and is associated with an increased Bcl-2 expression. Cell. Immunol. 169:174-184, 1996

• 6) Oliveira-dos-Santos, A. J., Penninger, J. M., Rieker-Geley, T. et al.:Thymic heterotypic cellular complexes in gene-targeted mice with defined blocks in T cell development and adhesion molecule expression. Eur. J. Immunol. 28:2882-2892, 1998

• 7) Pezzano, M., King, K. D., Phlip, D. D. et al.:Athymic nurse cell-specific monoclonal antibody. Cell. Immunol. 185:123-133, 1998

• 8) Nakagawa, S., Hata, M., Seki, M. et al.:Interaction of cutaneous stromal cells and γ/δ T cell receptor (TcR)-positive cells. I. Vγ-γ/δTcR T cells migrating from organ-cultured murine skin proliferate by co-culture with cutaneous stromal cells in the presence of interleukin-2. Eur. J. Immunol 23:1705-1710, 1993

• 9) Iwagami, S., Furue, S., Toyosaki, T. et al:Establishment and characterization of nurse cell-like clones from human skin. Nurse cell-like clones can stimulate autologous mixed lymphocyte reaction. J. Immunol. 153:2927-2938, 1994
  pubmed

• 10) Tomita, T., Takeuchi, E., Toyosak-Maeda, T. et al.:Establishment of nurse-like stromal cells from bone marrow of patients with rheumatoid arthritis:indication of characteristic bone marrow microenvironment in patients with rheumatoid arthritis. Rheumatology (Oxford) 38:854-863, 1999

• 11) Takeuchi, E., Tomita, T., Toyosaki-Maeda, T. et al.:Establishment and characterization of nurse-like stromal cell lines from synovial tissues of patients with rheumatoid arthritis. Arthritis Rheum. 42:221-228, 1999
  pubmed

• 12) Shimaoka, Y., Attrep, J. F, Ilirano, T. et al.:Nurse-like cells from bone marrow and synovium of patients with rheumatoid arthritis promotes survival and enhance function of human B cells. J. Clin. Invest. 102:606-618, 1998

• 13) Tanabe, M, Ochi, T., Tomita, T. et al.:Remarkable elevation of interleukin 6 and interleukin 8 levels in the bone marrow serum of patients with rheumatoid arthritis. J. Rheumatol. 21:830-835, 1994
  pubmed

• 14) 越智隆弘, 鈴木隆二, 前田(豊崎)朋子:慢性関節リウマチと骨髄病変. 治療学33:822-824, 1999

• 15) Edwards, J. C. W.:The synovium, in Rheumatology. (Klippel, J. H., dieppe, P. A. eds. ) Mosby, London, Philadelphia, St. Louis, Sydney, Tokyo, 1998, section 5, 6-l

• 16) Toyosaki, T., Tsuruta, Y., Yoshioka, T. et al.:Recognition of rheumatoid arthritis synovial antigen by Cd4+, Cd8-Tcell clones established from rheumatoid arthritis joints. Arthritis Rheum. 41:92-100, 1998

• 17) 鈴木隆二, 冨田哲也, 越智隆弘ほか:リウマチ病変とナース細胞. リウマチ病セミナーVIII. (七川歡次 監)永井書店, 大阪, 1997, p.155-163

• 18) 高野裕史, 冨田哲也, 前田(豊崎)朋子ほか:RA間質(ナース)細胞による末梢血単球の前破骨細胞への変化. リウマチ40:360, 2000

• 19) Higuchi, S., Tabata, N., Tajima, M. et al:Induction of human osteoclast-like cells by treatment of blood monocytes with anti-fusion reguratory protein-1/Cd98 monoclonal antibodies. J. Bone Miner. Res. 13:44-49, 1998

• 20) Tomita, T., Kaneko, M., Nakase, T. et al:Contribution of RA nurse cells to articular cartilage degradation. Arthritis Rheum. 42:S89, 1999

• 21) 冨田哲也, 金子元春, 高野裕史ほか:慢性関節リウマチ間質(ナース)細胞による軟骨破壊. リウマチ40:364, 2000

P.347 掲載の参考文献

• 1) Krolner, B., Toft, B., PorsNielsen, S. et al.:Physical exercise as prophylaxis against involutional vertebral bone loss:acontrolled trial. Clin. Sci. 64:541-546, 1983

• 2) Kodama, Y., Nakayama, K., Fuse, H. et al.:Inhibition of bone resorption by pamidronate cannot restore normal gain in cortical bone mass and strength in tail-suspended rapidly growing rats. J. Bone Miner. Res. 12:1058-1067, 1997
  pubmed

• 3) Sakata, T., Sakai, A., Tsurukami, H. et al.:Trabecular bone turnover and bone marrow cell development in tail-suspended mice. J. Bone Miner. Res. 14:1596-1604, 1999
  pubmed

• 4) Morey, E. R., Baylink, D. J.:Inhibition of bone formation during space flight. Science 201:1138-1141, 1978
  pubmed

• 5) Vico, L, Chappard, D., Alexandre, C. et al:Effects of weightlessness on bone mass and osteoclast number in pregnant rats after a five day space flight (Cosmos 1514) . Bone 8:95-103, 1987

• 6) Bassett, C. A. L., Becker, R. O.:Generation of electric potentials in bone ip response to mechanical stress. Science 137:1063-1064, 1962

• 7) Somjen, D., Binderman, I., Berger, E. et al.:Bone remodelling induced by physical stress is prostaglandin E2 mediated. Biochim. Biophys. Acta 627:91-100, 1980
  pubmed

• 8) Binderman, I., Shimshoni, Z., Somjen, d.:Biochemical pathways involved in the translation of physical stimulus into biological message. Calcif. Tissue Int. 36 (Suppl.):S82-S85, 1984

• 9) Sandy, J. R., Meghji, S., Farndale, R. W. et al.:dual elevation of cyclic AMP and inositol phosphates in response to mechanical deformation of murine osteoblasts. Biochim. Biophys. Acta 1010:265-269, 1989
  pubmed

• 10) Burr, D. B., Milgrom, C., Fyhrie, D. et al.:In vivo measurement of human tibial strains during vigorous activity. Bone 18:405-410, 1996
  pubmed

• 11) Owan, I., Ibaraki, K., Duncan, R. L. et al.:Which activates mechanotransduction in bone-extracellular fluid flow or mechanical strain? Mechanical Loading of Bones and Joints. (Takahashi, H. E. ed. ) Springer-Verlag, Tokyo, Berlin, Heidelberg, New York, 1999, p.303-309

• 12) Hillsley, M. V., Frangos, J. A.:Alkaline phosphatase in osteoblasts is down-regulated by pulsatile fluid flow. Calcif. Tissue Int. 60:48-53, 1997
  pubmed

• 13) Otter, M. W., Palmieri, V. R., Wu, D. D. et al.:A comparative analysis of streaming potentials in vivo and in vitro. J. Orthop. Res. 10:710-719, 1992

• 14) Joldersma, M., Burger, E. H., Semeins, C. M.:Mechanical stress induces COX-2 mRNA expression in bone cells from elderly women. J. Biomech. 33:53-61, 2000
  pubmed

• 15) Reich, K. M., Gay, C. V., Frangos, J. A.:Fluid shear stress as a mediator of osteoblast cyclic adenosine monophosphate production. J. Cell. Physiol. 143:100-104, 1990
  pubmed

• 16) Reich, K. M., Frangos, J. A.:Protein kinase C mediates flow-induced prostaglandin E2 production in osteoblasts. Calcif. Tissue Int. 52:62-66, 1993
  pubmed

• 17) Johnson, d. L., McAllister, T. N., Frangos, J. A.:Fluid flow stimulates rapid and continuous release of nitric oxide in osteoblasts. Am. J. Physiol. 271:E205-E208, 1996
  pubmed

• 18) Donahue, H. J., McLeod, K. J., Rubin, C. T. et al.:Cell-to-cell communication in osteoblastic networks:cell line-dependent hormonal regulation of gap junction function. J. Bone Miner. Res. 10:881-889, 1995
  pubmed

• 19) Doty, S. B.:Morphological evidence of gap junctions between bone cells. Calcif. Tissue Int. 33:509-512, 1981
  pubmed

• 20) Mason, D. J., Suva, L. J., Genever, P. G. et al.:Mechanically regulated expression of a neural glutamate transporter in bone:a role for excitatory amino acids as osteotropic agents? Bone 20:199-205, 1997

• 21) Skerry, T. M.:Identification of novel signaling pathways during functional adaptation of the skeleton to mechanical loading:the role of glutamate as a paracrine signaling agent in the skeleton. J. Bone Miner. Metab. 17:66-70, 1999
  pubmed

• 22) Klein-Nulend, J., van der Plas, A., Semeins, C. M. et al.:Sensitivity of osteocytes to biomechanical stress in vitro. FASEB J. 9:441-445, 1995
  pubmed

• 23) Chambers, T. J., Fox, S., Jagger, C. J. et al.:The role of prostaglandins and nitric oxide in the response of bone to mechanical forces. Osteoarthritis Cartilage 7:422-423, 1999
  pubmed

• 24) Kawata, A., Mikuni-Takagaki, Y.:Mechanotransduction in stretched osteocytes-temporal expression of immediate early and other genes. Biochem. Biophys. Res. Commun. 246:404-408, 1998
  pubmed

• 25) Mikuni-Takagakl, Y.:Mechanical responses and signal transduction pathways in stretched osteocytes. J. Bone Miner. Metab. 17:57-60, 1999

• 26) Matsumoto, T., Nakayama, K., Kodama, Y. et al.:Effect of mechanical unloading and reloading on periosteal bone formation and gene expression in tail-suspended rapidly growing rats. Bone 22:89S-93S, 1998
  pubmed

• 27) Turner, C. H., Akhter, M. P.:The mechanics of bone adaptation, in Mechanical Loading of Bone and Joints. (Takahashi, H. E. ed. ) Springer-Verlag, Tokyo, Berlin, Heidelberg, New York, 1999, p. 79-91

• 28) Forwood, M. R.:Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo. J. Bone Miner. Res. 11:1688-1693, 1996
  pubmed

• 29) Chow, J. W., Chambers, T. J.:Indomethacin has distinct early and late actions on bone formation induced by mechanical stimulation. Am. J. Physiol. 270:E287-E292, 1994

• 30) Fox, S. W., Chambers, T. J., Chow, J. W.:Nitric oxide is an early mediator of the increase in bone formation by mechanical stimulation. Am. J. Physiol. 270:E955-E960, 1996
  pubmed

• 31) Turner, C. H., Takano, Y., Owan, I. et al:Nitric oxide inhibitor L-NAME suppresses mechanically-induced bone formation in rats. Am. J. Physiol. 270:E634-E639, 1996
  pubmed

• 32) Zhang, R., Supowit, S. C., Klein, G. L. et al.:Rat tail suspension reduces messenger RNA level for growth factors and osteopontin and decreases the osteoblastic differentiation of bone marrow stromal cells. J. Bone Miner. Res. 10:415-423, 1995
  pubmed

• 33) Machwate, M., Zerath, E., Holy, X. et al.:Insulin-like growth factor-I increases trabecular bone formation and osteoblastic cell proliferation in unloaded rats. Endocrinology 134:1031-1038, 1994
  pubmed

• 34) Rubin, J., Biskobing, D., Fan, X. et al:Pressure regulates osteoclast formation and MCSF expression in marrow culture. J. Cell. Physiol. 170:81-87, 1997
  pubmed

• 35) Armstrong, J. W., Balch, S., Chapes, S. K. et al:Interleukin-2 therapy reverses some immunosuppressive effects of skeletal unloading. J. Appl. Physiol. 77:584-589, 1994
  pubmed

• 36) Grewal, T. S., Genever, P. G., Brabbs, A. C. et al:Best5:a novel interferon-inducible gene expressed during bone formation. FASEB J. 14:523-531, 2000
  pubmed

• 37) Burkhart, J. M., Jowsey, J.:Parathyroid and thyroid hormones in the development of immobilization osteoporosis. Endocrinology 81:1053-1062, 1967 38) Lindgren, U.:The effect of thyroparathyroidectomy:development of disuse in adult rats. Clin. Orthop. 118:251-256, 1976

• 39) Sakai, A., Nakamura, T., Tsurukami, H. et al.:Bone marrow capacity for bone cells and trabecular bone turnover in immobilized tibia after sciatic neurectomy in mice. Bone 18:479-486, 1996
  pubmed

• 40) Shaker, J. L, Fallon, M. D., Goldfarb, S. et al.:WR-2721 reduces bone loss after hindlimb tenotomy in rats. J. Bone Miner. Res. 4:885-890, 1989
  pubmed

• 41) Chow, J. W., Fox, S., Jagger, C. J. et al:Role for parathyroid hormone in mechanical responsiveness of rat bone. Am. J. Physiol. 274:E146-E154, 1998
  pubmed

• 42) Sakai, A., Sakata, T., Ikeda, S. et al.:Intermittent administration of human parathyroid hormone (1-34) prevents immobilization-related bone loss by regulating bone marrow capacity for bone cells in ddY mice. J. Bone Miner. Res. 14:1691-1699, 1999
  pubmed

• 43) Bikle, D. D., Harris, J., Halloran, B. P. et al.:Skeletal unloading induces resistance to insuline-like growth factor I. J. Bone Miner. Res. 9:1789-1796, 1994

• 44) Thompson, D. D., Rodan, G. A.:Indomethacin inhibition of tenotomy-induced bone resorption in rats. J. Bone Miner. Res. 4:409-414, 1988
  pubmed

• 45) Fiorentino, S., Melillo, G., Fedele, G. et al.:Ketoprofen lysine salt inhibits disuse-induced osteopenia in a new non-traumatic immobilization model in rat. Pharmacol. Res. 33:277-281, 1996

• 46) Halloran, B. P., Bikle, d. D., Harris, J. et al:Skeletal unloading induces selective resistance to the anabolic actions of growth hormone on bone. J. Bone Miner. Res. 10:1168-1176, 1995

P.364 掲載の参考文献

• 1) Feldkamp, L. A., Goldstein, S. A., Parfitt, A. M. et al.:The direct examination of three-dimensional bone architecture in vitro by computed tomography. J. Bone Miner. Res. 4:3-ll, 1989
  pubmed

• 2) Bonse, U., Busch, F., Gunnewig, O. et al:3D computed X-ray tomography of human cancellous bone at 8mm spatial and 10-4 energy resolution. Bone Miner. 25:25-38, 1994

• 3) Kinney, J. H., Lane, N. E., Haupt, D. L.:In vivo, three-dimensional microscopy of trabecular bone. J. Bone Miner. Res. 10:264-270, 1995
  pubmed

• 4) Ruegesegger, P., Koller, B., Muller, R. et al:A microtomographic system for the nondestructive evaluation of bone architecture. Calcif Tissue Int. 58:24-29, 1996

• 5) Parfitt, A. M., Mathews, C. H., Villanueva, A. R. et al.:Relationships between surface, volume and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J. Clin. Invest. 72:1396-1409, 1983
  pubmed

• 6) Hildebrand, T., Ruegsegger, P.:A new method for the model independent assessment of thickness in three-dimensional images. J. Microsc. 185:67-75, 1997

• 7) Hildebrand, T., Ruegsegger, P.:Quantificatin of bone microarchitecture with the structurc model index. CMBBE 1:15-23, 1997
  pubmed

• 8) Hahn, M., Vogel, M., Pompesius-Kempa, M. et al:Trabecular bone pattern factor:a new parameter for simple quantification of bone microarchitecture. Bone 13:327-330, 1992
  pubmed

• 9) DeHoff, R. T., Aigeltinger, E. H., Craig, K. R. et al:Experimental determination of the topological properties of three-dimensional microstructure. J. Microsc. 95:69, 1972

• 10) Odgaard, A., Gundersen, H. J. G.:Quantification of connectivity in cancellous bone, with special emphasis on 3-D reconstructions. Bone 14:173-182, 1993

• 11) Garrahan, N. J., Mellish, R. W., Compston, J. E.:A new method for the two-dimensional analysis of bone structure in human iliac crest biopsies. J. Microsc. 142:341-349, 1986
  pubmed

• 12) Vesterby, A.:Star volume of marrow space and trabeculae in iliac crest:sampling procedure and correlation to star volume of first lumbar vertebra. Bone 11:149-155, 1990
  pubmed

• 13) Muller, R., Hildebrand, T., Ruegesegger, P. et al.:Structural bone properties from different sites of the human skeleton assessed by micro-computed tomography. Osteoporosis Int, 7:271, 1997

• 14) Hildebrand, T., Laib, A., Mueller, R. et al.:Direct three-dimensionalmorphometric analysis of human cancellous bone:Microstructural data from spine, femur iliac crest, and calcaneus. J. Bone Miner. Res. 14:1167-1174, 1999

• 15) 伊東昌子ほか:ヒト腸骨三次元骨梁構造の加齢変化. 1999年 代謝性骨疾患研究会にて報告.

• 16) Ito, M., Nakamura, T., Matsumoto, T. et al.:Analysis of trabecular microarchitecture of human iliac bone using microcomputed tomography in patients with hip arthrosis with or without vertebral fracture. Bone 23:163-169, 1998

• 17) Kinney, J. H., Ladd, A. J. C.:The relationship between three-dimensional connectivity and the elastic properties of trabecular bone. JJBMR 13:839-845, 1998

• 18) Uchiyama, T., Tanizawa, T., Muramatsu, H. et al.:Three-dimensional microstructural analysis of human trabecular bone in relation to its mechanical properties. Bone 25:487-491, 1999
  pubmed

• 19) lto, M.:Symposium of The Bone Architecture and the Competence of Bone. Montry, USA May7, 2000

• 20) Majumdar, S., Genant, H. K.:Assessment of trabecular structure using high resolution magnetic resonance imaging. Stud. Health Technol. Inform. 40:81-96, 1997
  pubmed

• 21) Sharp, J. C., Copps, J. C., Liu, Q. et al.:Analysis of ovariectomy and estrogen effects on body composition in rats by X-ray and magnetic resonance imaging techniques. J. Bone Miner. Res. 15:138-146, 2000
  pubmed

• 22) Peyrin, F., Salome, M., Cloetens, P. et al.:Micro-CT examinations of trabecular bone samples at different resolutions:14, 7 and 2 micron level. Technol. Health Care 6:391-401, 1998
  pubmed

• 23) Gomez, S., Rizzo, R., Pozzi-Mucelli, M. et al.:Zinc mapping in bone tissue by histochemistry and synchrotron radiation-induced X-ray emission:Correlation with the distribution of alkaline phosphatase. Bone 25:33-38, 1999
  pubmed

P.376 掲載の参考文献

• 1) Lajeunesse, D., Frondoza, C., Schoffield, B. et al.:Osteocalcin secretion by the human osteosarcoma cell line MG-63. J. Bone Miner. Res. 5:915-922, 1990
  pubmed

• 2) Garnero, P., Grimaux, M., Seguin, P. et al.:Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J. Bone Miner. Res. 9:255-264, 1994
  pubmed

• 3) Hosoda, K., Eguchi, H., Nakamoto, T. et al.:Sandwich immunoassay for intact human osteocalcin. Clin. Chem. 38:2223-2338, 1992

• 4) Takahashi, M.:Investigation of the performance of ELISA for N-terminal mid-fragment of osteocalcin. J. Bone Miner. Metab. 15:132, 1997

• 5) Vergnaud, P., Garnero, P., Meunier, P. J. et al.:Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women:The EPIDOS Study. J. Clin. Endocrinol. Metab. 82:719-724, 1997
  pubmed

• 6) Kanzaki, S., Hosoda, K., Moriwake, T. et al.:Serum propeptide and intact molecular osteocalcin in normal children and children with growth hormone (GH) deficiency:A potential marker of bone growth and response to GH therapy. J. Clin. Endocrinol. Metab. 75:1104-1109, 1992
  pubmed

• 7) Ducy, P., Desbois, C., Boyce, B. et al.:Increased bone formation in osteocalcin-deficient mice. Nature 382:448-452, 1996
  pubmed

• 8) Boskey, A. L., Gadaleta, S., Gundberg, C. et al.:Fourier transform infrared microspectroscopic analysis of bones of osteocalcin-deficient mice provides insight into the function of osteocalcin. Bone 23:187-196, 1998
  pubmed

• 9) Knoll, B. J., Rothblum, K. N., Longley, M..:Nucleotide sequence of human placental alkaline phosphatase gene. Evolution of the 5' flanking region by deletion/substitution. J. Biol. Chem. 263:12020-12027, 1988
  pubmed

• 10) Stein, G. S., Lian, J. B., Owen, T. A.:Relationship of cell growth to the regulation of tissue-specific gene espression during osteoblast differentiation. Faseb. J. 4:3111-3123, 1990

• 11) Ohlsson, C., Isgaard, J., Tornell, T. et al.:Endocrine regulation of longitudinal bone growth. Acta Paediatr. Suppl. 82(Suppl. 391):33-40, 1993

• 12) Garnero, P., delmas, P. D.:Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J. Clin. Endocrinol. Metab. 77:1046-1053, 1993
  pubmed

• 13) Hata, K., Tokuhiro, H., Nakatsuka, K. et al.:Measurement of bone-specific alkaline phosphatase by an immunoselective enzyme assay method. . Ann. Clin. Biochem.33:127-133, 1996
  pubmed

• 14) Tobiume, H., Kanzaki, S., Hida, S. et al.:Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone (GH) deficiency:A potential marker for bone formation and response to GH therapy. J. Clin. Endocrinol. Metab. 82:2056-2061, 1997
  pubmed

• 15) Stepan, J. J., Tesarova, A., Harvanek, T. et al.:Age and sex dependency of the biochemical indices of bone remodelling. Clin. Chim. Acta 151:273-283, 1985

• 16) Moss, D. W., Eaton, R. H., Smith, J. K. et al.:Association of inorganic-pyrophjosphatase activity with human alkaline phosphatase preparations. Biochem. J. 102:53-57, 1967
  pubmed

• 17) Prockop, D. J., Kivirikko, K. I., Tuderman, L. et al.:The biosynthesis of collagen and its disorders. N. Engl. J. Med. 301:13-23, 1979
  pubmed

• 18) Melkko, J., Niemi, S., Risteli, L. et al.:Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin. Chem. 36:1328-1332, 1990
  pubmed

• 19) Kubo, T., Tanaka, H., Inoue, M. et al.:Serum levels of carboxyterminal propeptide of type I procollagen and pyridinoline crosslinked telopeptide of type I collagen in normal children and children and children with growth hormone (GH) deficiency during GH therapy. Bone 17:397-401, 1995
  pubmed

• 20) Garnero, P., Shih, W. J., Gineyts, E. et al.:Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J. Clin. Endcrinol. Metab. 79:1693-1700, 1994

P.388 掲載の参考文献

• 1) Minkin, C.:Bone acid phosphatase:Tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif. Tissue Int. 34:285-290, 1982
  pubmed

• 2) de la Piedra, C., Torre, R., Rapado, A. et al.:Serum tartrate-resistant acid phosphatase and bone mineral content in postmenopausal osteoporosis. Calcif Tissue Int. 45:58-60, 1989

• 3) Stepan, J. J., Pospichal, J., Presl, J. et al.:Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone 8:279-284, 1987
  pubmed

• 4) Kraenzlin, M. E, Lau, K.-H. W., Liang, L. et al:Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase. J. Clin. Endocrinol. Metab. 71:442-451, 1990

• 5) Calvo, M. S., Eyre, D. R., Gundberg, C. M.:Molecular basis and Clinical application of biological markers of bone turnover. Endocr. Rev. 17:333-368, 1996
  pubmed

• 6) Ebeling, P. R., Peterson, J. M., Riggs, B. L:Utility of type I procollagen propeptide assay for assessing abnormalities in metabolic bone diseases. J. Bone Miner. Res. 7:1243-1250, 1992
  pubmed

• 7) Smedsrod, B., Melkko, J., Risteli, J. et al.:Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem. J. 271:345-350, 1990
  pubmed

• 8) Atley, L. M., Mot, J. S., Lalumiere, M. et al.:Proteolysis of human bone collagen by cathepsin K:Characterization of the cleavage sites generative the cross-linked N-telopeptide neoepitope. Bone 26:241-247, 2000

• 9) Eyre, D.:Collagen cross-linking amino acids. Methods Enzymology 144:115-139, 1987

• 10) Seyedin, S. M., Kung, V. T., Daniloff, Y. N. et al.:Immunoassay for urinary pyridinoline:The new marker of bone resorption. J. Bone Miner. Res. 8:635-641, 1993
  pubmed

• 11) Black, D., Duncan, A., Robins, S.:Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reverse-phase high-performance liquid chromatography. Anal. Biochem. 169:197-203, 1988
  pubmed

• 12) Robins, S. P., Duncan, A., Riggs, B. L.:Direct measurement of free hydroxypyridinium crosslinks of collagen in urine as a new marker of bone resorption in osteoporosis. Osteoporosis. (Christiansen, C., Overgaad, K. eds.) Osteoporosis Aps, Copenhagen, 1990, p.465-468

• 13) Hanson, D. A., Weis, M. A., Bollen, A.-M. et al.:A specific immunoassay for monitoring human bone resorption:Quantitation of type I collagen crosslinked N-telopeptides in urine. J. Bone Miner. Res. 7:1251-1258, 1992
  pubmed

• 14) Beardsworth, L. J., Eyre, D. R., Dickson, I. R.:Changes with age in the urinary excretion of lysyl and hydroxylysyl-pyridinoline, two new markers of bone collagen turnover. J. Bone Miner. Res. 5:671-676, 1990
  pubmed

• 15) Delmas, P. D., Schelemmer, A., Gineyts, E. et al.:Urinary excretion of pyridinoline crosslinks correlated with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J. Bone Miner. Res. 6:639-644, 1991

• 16) Eriksen, E. F., Charles, P., Melsen, F. et al.:Serum markers of type I collagen formation and degradation in metabolic bone disease:Correlation with bone histomorphometry. J. Bone Miner. Res. 8:127-132, 1993
  pubmed

• 17) Uebelhart, D., Schlemmer, A., Johansen, J. S. et al.:Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium crosslinks. J. Clin. Endocrinol. Metab. 72:367-373, 1991
  pubmed

• 18) Seibel, M. J., Woitge, H., Scheidt-Nave, C. et al.:Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis:Results of a pilot study. J. Bone Miner. Res. 9:1433-1440, 1994
  pubmed

• 19) McLaren, A. M., Hordon, L. D., Bird, H. A. et al.:Urinary excretion of pyridinium crosslinks of collagen in patients with osteoporosis and the effects of bone fracture. Ann. Rheum. Dis. 51:648-651, 1992
  pubmed

• 20) Akesson, K., Vergnaud, P., Gineyts, E. et al.:Impairment of bone turnover in elderly women with hip fracture. Calcif. Tissue Int. 53:162-169, 1993
  pubmed

• 21) Civitelli, R., Gonnelli, S., Zacchei, F. et al.:Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J. Clin. Invest. 82:1268-1274, 1988
  pubmed

• 22) Rossini, M., Gatti, D., Zamberlan, N. et al.:Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J. Bone Miner. Res. 9:1833-1837, 1994
  pubmed

• 23) Prestwood, K. M., Pilbeam, C. C., Burleson, J. A. et al.:The short term effects of conjugated estrogen on bone turnover in older women. J. Clin. Endocrinol. Metab. 79:366-371, 1994

• 24) Hassager, C., Jensen, L. T., Podenphant, J. et al.:The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption:The effect of nandrolone decanoate and hormone replacement therapy. Calcif. Tissue Int. 54:30-33, 1994
  pubmed

• 25) Harris, S. T., Gertz, B. J., Genant, H. K. et al.:The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J. Clin. Endocrinol. .Metab. 76:1399-1406, 1993
  pubmed

• 26) Chesnut, III. C. H., McClung, M. R., Ensrud, K. E. et al.:Alendronate treatment of the postmenopausal osteoporotic women:Effect of multiple dosages on bone mass and bone remodeling. Am. J. Med. 99:144-151, 1995

• 27) Garnero, P., Shin, W. J., Gineyts, E. et al.:Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J. Clin. Endocrinol. Metab. 79:1693-1700, 1994

• 28) Garnero, P., Gineyts, E., Arbault, P. et al.:Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J. Bone Miner. Res. 10:641-649, 1995

• 29) Mallinak, N. J. S., Chemens, J. D.:Cross-linked N-telopeptides of bone collagen:A marker of bone resorption. J. Clin. Ligand Assay 21:111-117, 1998

• 30) Woitge, H., Pecherstorfer, M, Li, Y. et al.:Novel serum markers of bone resorption:Clinical assessment and comparison with established urinary indices. J. Bone Miner. Res. 14:792-801, 1999
  pubmed

• 31) Eastell, R., Mallinak, N., Weiss, S. et al.:Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J. Bone Miner. Res. 15:594-598, 2000
  pubmed

• 32) Sone, T., Miyake, M., Takeda, N. et al.:Urinary excretion of type I collagen crosslinked N-telopeptides in healthy Japanese adults:Age-and sex-related changes and reference limits. Bone 17:335-339, 1995
  pubmed

• 33) Chesnut, III. C. H., Bell, N. H., Chark, G. S. et al.:Hormone replacement therapy in postmenopausal women:Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am. J. Med. 102:29-37, 1997

• 34) Greenspan, S. L., Parker, R. A., Ferguson, L. et al:Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women:A randamized Clinical trial. J. Bone Miner. Res. 13:1431-1438, 1998

• 35) Bauer, D. C., Sklarin, P. M., Stone, K. L. et al:Biochemical markers of bone turnover an prediction of hip bone loss in older women:The study of osteoporotic fractures. J. Bone Miner. Res. 14:1404-1410, 1999

• 36) Bonde, M., Qvist, P., Fledelius, C. et al.:Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin. Chem. 40:2022-2025, 1994
  pubmed

• 37) Garnero, P., Gineyts, E., Riou, J. P. et al:Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J. Clin. Endocrinol. Metab. 79:780-785, 1994
  pubmed

• 38) Bonde, M., Qvist, P., Fledelius, C. et al.:Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps):Follow-up on hormone replacement therapy and osteoporosis risk assessment. J. Clin. Endocrinol. Metab. 80:864-868, 1995
  pubmed

• 39) Garnero, P., Hausherr, E, Chapuy, M.-C. et al.:Markers of bone resorption predict hip fracture in elderly women:The EPIDOS study. J. Bone Miner. Res. 11:1531-1538, 1996
  pubmed

• 40) Garnero, P., Dargent-Molina, P., Hans, D. et al.:Do markers of bone resorption add to bone mineral density and ultrasonographic heal measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporosis Int. 8:563-569, 1998

• 41) Fledelius, C., Johnsen, A. H., Cloos, P. A. C. et al.:Characterization of urinary degradation products derived from type I collagen:Identification of aβ-isomerized Asp-Gly sequence within the C-terminal telopeptide (α1) region. J. Biol. Chem. 272:9755-9763, 1997

• 42) Cloos, P. A. C., Fledelius, C.:Collagen fragments in urine derived from bone resorption are highly racemized and isomerized:A biological clock of protein aging with Clinical potential. Biochem. J. 345:473-480, 2000

• 43) Hoshino, H., Takahashi, M., Kushida, K. et al.:The relationships between the degree of β-isomerization of type I collagen degradation products in the urine and aging, menopause and osteoporosis with fractures. Osteoporosis Int. 9:405-409, 1999

• 44) Bonde, M., Garnero, P., Fledelius, C. et al.:Measurement of bone degradation products in serum using antibodies reactive with a isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J. Bone Miner. Res. 12:1028-1034, 1997

• 45) Risteli, J., Elomaa, I., Niemi, S. et al.:Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen:A new serum marker of bone collagen degradation. Clin. Chem. 39:635-640, 1995

• 46) 清原 剛, 黒江謙治, 秩父賢司ほか:RIA法による血中ICTP(l型コラーゲン-C-テロペプチド)の測定. ホルモンと臨床42:1189-1193, 1994

• 47) Takahashi, M., Kushida, K., Kawana, K. et al.:Discrimination ability of pyridinoline crosslinks related markers for bone resorption in post-menopause and osteoporosis. Endocr. Res. 21:105-117, 1997

• 48) Guerrero, R., Martin, M. A. D., Diaz Diego, E. M. et al.:New biochemical markers of bone resorption derived from collagen . breakdown in the study of postmenopausal osteoporosis. Osteoporosis Int. 6:297-302, 1996

• 49) Kushida, K., Takahashi, M., Kawana, K. et al.:Comparison of markers for bone formation and resorption in pre-menopausal subjects, and osteoporotic patients. J. Clin. Endocrinol. Metab. 80:2447-2450, 1995

• 50) Elomaa, I., Virkkunen, L, Risteli, L. et al.:Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br. J. Cancer 66:337-341, 1992

• 51) Koizumi, M., Yamada, Y., Takiguchi, T. et al.:Bone metabolic markers in bone metastases. J. Cancer Res. Clin. Oncol. 121:542-548, 1995
  pubmed

• 52) Maeda, H., Koizumi, M., Yoshimura, K. et al.:Correlation between bone metabolic markers and bone scan in prostatic cancer. J. Urology 157:539-543, 1997
  pubmed

• 53) Aruga, A., Koizumi, M., Hotta, R. et al.:Usefulness of bone metaboic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br. J. Caner 76:760-764, 1997

• 54) Nishi, Y., Atley, L., Eyre, d. E. et al.:determination of bone markers in pycnodysostosis:Effects of cathepsin K deficiency on bone matrix degradation. J. Bone Miner. Res. 14:1902-1908, 1999

P.399 掲載の参考文献

• 1) Kanis, J. A., Melton, L. J. III., Christiansen, C. et al.:The diagnosis of osteoporosis. J. Bone Miner. Res. 9:1137-1141, 1994

• 2) Pocock, N. A., Eisman, J. A., Hopper, J. L. et al.:Genetic determinants of bone mass in adults. A twin study. J. Clin. Invest. 80:706-710, 1987
  pubmed

• 3) Slemenda, C. W., Christian, J. C., Williams, C. J. et al.:Genetic determinants of bone mass in adult women:areevaluation of the twin model and the potential importance of gene interaction on heritability estimates. J. Bone Miner. Res. 6:561-567, 1991

• 4) 折茂 肇, 杉岡洋-ほか:原発性骨粗鬆症の診断基準 (1996年改訂版) . Osteoporosis Jpn. 4:643-652, 1996

• 5) Giguere, Y., Rousseau, F.:The genetics of osteoporosis:`complexities and difficulties:. Clin. Genet. 57:161-169, 2000
  pubmed

• 6) O'Donovan, M. C., Oefner, P. J., Roberts, S. C. et al.:Blind analysis of denaturing high performance liquid chromatography as a tool for mutation detection. Genomics 52:44-49, 1998
  pubmed

• 7) Morrison, N. A., Qi, J. C., Tokita, A. et al.:Prediction of bone density from vitamin D receptor alleles. . Nature 367:284-287, 1994
  pubmed

• 8) Nguyen, T. A., Morrison, N. A., Sambrook, P. N. et al.:vitamin D receptor gene and osteoporosis. J Clin. Endocrinol. Metab. 81:1674-1675, 1996

• 9) Eisman, J. A.:vitamin D receptor gene alleles and osteoporosis:an affirmative view. J. Bone Miner. Res. 10:1289-1293, 1995

• 10) Peacock, M.:vitamin D receptor gene alleles and osteoporosis:acontrasting view. J. Bone Miner. Res. 10:1294-1297, 1995

• 11) Cooper, G. S., Umbach, d. M.:Are vitamin D receptor polymorphisms associated with bone mineral density ? A meta-analysis. J. Bone Miner. Res. 11:1841-1849, 1996
  pubmed

• 12) Gross, C., Eccleshall, T. R., Malloy, P. J. et al.:The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-Amarican women. J. Bone Miner. Res. 11:1850-1855, 1996

• 13) Arai, H., Miyamoto, K., Taketani, Y. et al.:Avitamin D receptor gene polymorphism in the translation initiation codon:effect on protein activity and relation to bone mineral density in Japanese women. J. Bone Miner. Res. 12:915-921, 1997

• 14) Harris, S. S., Eccleshall, T. R., Gross, C. et al.:The vitamin D receptor start codon polymorphism (Fok1) and bone mineral density in premenopausal American black and white women. J. Bone Miner. Res. 12:1043-1048, 1997

• 15) Sano, M., Inoue, S., Hosoi, T. et al:Association of estrogen receptor dinucleotide repeat polyinorphism with osteoporosis. Biochem. Biophys. Res. Commun. 217:378-383, 1995
  pubmed

• 16) Kobayashi, S., Inoue, S., Hosoi, T. et al.:Association of bone mineral density with polymorphism of the estrogen receptor gene. J. Bone Miner. Res. 11:306-311, 1996

• 17) Mizunuma, H., Hosoi, T., Okano, II. et al.:Estrogen receptor gene polymorphism and bone mineral density at the lumbar spine of pre-and postmenopausal women. Bone 21:379-383, 1997

• 18) Shiraki, M., Shiraki, Y., Aoki, C. et al.:Association of bone mineral density with apolipoprotein E phenotype. J. Bone Miner. Res. 12:1438-1445, 1997
  pubmed

• 19) Hosoi, T., Miyao, M., Inoue, S. et al.:Association study of parathyroid hormone gene polymorphism and bone mineral density in Japanese postmenopausal women. Calcif. Tissue Int. 64:205-208, 1999
  pubmed

• 20) Miyao, M., Hosoi, T., Emi, M. et al.:Association of bone mineral density with a dinucleotide repeat polymorphism at the calcitonin (CT) locus. J. Human Genetics (in press)

• 21) Tsukamoto, K., Orimo, H., Hosoi, T. et al:Association of bone mineral density with polymorphism of the human matrix Gla protein locus in elderly women. J. Bone Miner. Metab. 18:27-30, 2000
  pubmed

• 22) Langdahl, B. L, Knudsen, J. Y., Jensen, H. K. et al.:A sequence variation:713-8delC in thetransforming growth factor-β1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women. Bone 20:289-294, 1997

• 23) Yamada, Y., Hosoi, T., Makimoto, F. et al.:Transforming growth factor β-l gene polymorphism and bone mineral density in Japanese adolescents. Am. J. Med. 106:477-479, 1999

• 24) Miyao, M., Morita, H., Hosoi, T. et al.:Association of methylenetrahydrofolate reductase (MTHFR) polymorphism with bone mineral density in postmenopausal Japanese women. Calcif. Tissue Int. 66:190-194, 2000

• 25) Utterlinden, A. G., Burger, H., Huang, Q. et al.:Relation of alleles of the collagen type I α 1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women. N. Engl J.:Med. 338:1016-1021, 1998

• 26) Nakajima, T., Ota, N., Shirai, Y. et al.:Ethnic difference in contribution of Sp 1 site variation of COLIA 1 gene in genetic predisposition to osteoporosis. Calcif. Tissue Int. 65:352-353, 1999

• 27) Han, K. O., Moon, I. G., Hwang, C. S. et al.:Lack of an intronic Sp 1 binding-site polymorphism at the collagen type I alpha 1 gene in healthy Korean women. Bone 24:135-137, 1999

• 28) Ota, N., Hunt, S. C., Nakajima, T. et al.:Linkage of interleukin glocus to human osteopenia by sibling pair analysis. Hum. Genet. 105:253-257, 1999

• 29) Ota, N., Hunt, S. C., Nakajima, T. et al.:Linkage of human tumor necrosis factor-alpha to human osteoporosis by sib-pair analysis Genes. and Immunity 1:261-265, 2000

• 30) Koller, d. L., Econs, M. J., Morin, P. A. et al.:Genome screen for QTLs contributing to normal variation in bone mineral density and osteoporosis. J. Clin. Endocrinol. Metab. 85:3116-3120, 2000

第4章 骨粗鬆症治療薬の作用機序と効果

P.414 掲載の参考文献

• 1) Polatti, F., Capuzzo, E., Viazzo, F. et al.:Bone mineral density during and after lactation Obstet. Gynecol. 94:52-56, 1999
  pubmed

• 2) Chiv, K. M., Ju, J., Mayes, d. et al.:Changes in bone resorption during the menstrual cycle. J. Bone Miner. Res. 14:609-615, 1999

• 3) Smith, E. P., Boyd, J., Frank, G. P. et al:Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. N. Engl. J. Med. 331:1056-1061, 1994

• 4) Gillberg, P., Johansson, A. G., Ljunghall, S.:decreased estradiol level and free androgen and elevated sex hormone binding globulin levels in male idiopathic osteoporosis. Calcif Tissue Int. 64:209-213, 1999
  pubmed

• 5) Riggs, B. L., Khosla, S., Melton, L. IIL:Aunitary model for involutional osteoporosis.:Estrogen deficiency causes both type I and type II osteoporosis in post-menopausal women and contributes to bone loss in aging men. J. Bone Miner. Res. 13:763-773, 1998

• 6) Vanderschueren, D., Van Herck, E., Nijs, J. et al.:Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats. Bone 21:49-56, 1997

• 7) Bertelloni, S., Baroncelli, G. I., Sorrentino, M. C. et al.:Androgen-receptor blockade does not impair bone mineral density in adolescent females. Calcif. Tissue Int. 61:1-5, 1997

• 8) Hansen, M. A., Overgaad, K., Christiansen, C.:Spontaneous postmenopausal bone loss in different skeletal areas-Follow up for 15 years. J. Bone Miner. .Res. 10:205-210, 1995

• 9) Mazzuoli, G., Acca, M., Pisani, d . et al.:Annual skeletal balance and metabolic bone marker changes in healthy early postmenopausal women:Results of a prospective study. Bone 26:381-386, 2000
  pubmed

• 10) Melton, L. J. III., Atkinson, E. J., O'Connor, M. K. et al.:determinants of bone loss from the femoral neck in women of different ages. J Bone Miner. Res. 15:24-31, 2000

• 11) Gennari, C., Agnusdei, D., Civitelli, R. et al.:Effects of estrogens on vitamin D in metabolism in postmenopausal osteoporotic women. Postmenopausal hormone therapy:benefits and risks. (Fioretti, P. et al. ed. ) Raven Press, New York, 1987, p. 243-253

• 12) Gallagher, J. C., Nordin, B. E. C.:Oestrogen and calcium metabolisnl. Aging and estrogens. vol. 2. Frontiers of Hormone Research. (Van Keep, P. A., Lauritzen, C. K. eds. ) 1973, p. 98-117

• 13) Liel, Y., Shany, S., Smimoff, P. et al:Estrogen increases 1,25-dihydroxyvitamin D receptors expression and bioresponse in the rat duodenal mucosa. Endocrinology 140:280-285, 1999
  pubmed

• 14) Schulz, S. R., Morris, II. A.:Ionized calcium and bone turnover in the estrogen-deficient rat. Calcif. Tissue Int. 65:78-82, 1999

• 15) Colin, E. M., Vand, B. G., Van Aken, M. et al.:Evidence for involvement of 17 beta-estradiol in intestinal calcium absorptioll independent of 1,25-dihydroxyvitamin D3 level in the rat. J. Bone Miner. Res. 14:57-64, 1999

• 16) Arts, J., Kuiper, G. G., Janssen, J. M. et al.:differential expression of estrogen receptors α and β mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology 138:5067-5070, 1997

• 17) Onoe, Y., Miyaura, C., Ohta, H. et al.:Expression of estrogen receptor β in rat bone. Endocrinology 138:4509-4512, 1997

• 18) Lim, S. K., Won, Y. J., Lee, H. C. et al.:APCR analysis of ER alpha and ER beta mRNA abundance in rats and the effect of ovariectomy. J.Bone Miner. Res. 14:1189-1196, 1999

• 19) Hoyland, J. A., Baris, C., Wood, L. et al.:Effect of ovarian steroid deficiency on oestrogen receptor alpha expression in bone. J. Pa thol. 188:294-303, 1999

• 20) Pan, L. C., Ke, H. Z., Simmons, H. A. et al.:Estrogen receptor-alpha knockout (ERKO) mice lose trabecular and cortical bone following ovariectomy. J. Bone Miner. Res. 12:S134, 1997

• 21) Windel, S. H., Vidal, O., Andersson, G. et al.:Increased cortical bone mineral content but unchanged trabecular bone density in female ER beta (-/-) mice. J. Clin.Invest. 104:895-901, 1999

• 22) Pacifici, R., Rifas, L, McCracken, R. et al:Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. Proc. Natl. Acad. Sci. USA 86:2398-2402, 1989
  pubmed

• 23) Jilka, R. L., Hangoc, C., Girasole, G. et al.:Increased osteoclast development after estrogen Ioss:Mediation by interleukin-6. Science 257:88-91, 1992

• 24) Ishimi, Y., Miyaura, C., Jim, C. et al.:IL-6 is produced by osteoblasts and induces bone resorption. J.Immunol. 145:3297-3303, 1990

• 25) Girasole, G., Givliani, N., Modena, A. B. et al.:Oestrogens prevent the increase of human serum soluble interleukin-6 receptor induced by ovariectomy in vivo and decrease its release in human osteoblastic cells in vitro. Clin. Endocrinol. 51:801-807, 1999
  pubmed

• 26) Tamura, T., Udagawa, N., Takahashi, N. et al.:Soluble interleukin-6 receptor trigger osteoclast formation by interleukin-6. Proc. Natl. Acad. Sci. USA 490:11924-11928, 1993

• 27) Lewis, d. B., Liggitt, H. D., Effman, E. L. et al:Osteoporosis induced in mice by overproduction of interleukin-4 Proc. Natl. Acad. Sci. USA 90:11618-11622, 1993

• 28) Girasole, G., Paseri, G., Knutson, S. et al.:A distinct and hierarchically central role of interleukin-11 among other cytokines in osteoclast development. J. Bone Miner. Res. 8:117-123, 1993

• 29) Kimble, R. B., Srivastava, S., Ross, F. P. et al.:Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1 and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J. Biol. Chem. 271:28890-28897, 1996
  pubmed

• 30) Wimalawansa, S. J.:Restoration of ovariectomy-induced osteopenia by nitroglycerin. Calcif.Tissue Int. 66:56-60, 2000
  pubmed

• 31) Armour, K. E., Ralston, S. H.:Estrogen upregulates endothelial constitutive nitric oxide synthase expression in human osteoblast-like cells. Endocrinology 139:799-802, 1998
  pubmed

• 32) Hughes, d. E., dai, A., Triffee, J. C. et al.:Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nature Med. 2:1132-1136, 1996

• 33) Tompkinson, A., Gevers, E. F., Wit, J. M. et al:The role of estrogen in the control of rat osteocyte apoptosis. J. Bone. Miner. Res. 13:1243-1250, 1998

• 34) Powers, M. S., Schenkel, L, darley, P. E. et al.:Pharmacokinetics and pharmacodynamics of transdermal dosage form of 17β-estradiol:comparison with conventional oral estrogens used for hormone replacement. Am. J. Obstet. Gynecol. 152:1099-1106, 1985

• 35) Persson, I., Adami, H. O., Bergkvist, L. et al.:Risk of endometrial cancer after treatment with estrogens alone or in conjunction with progestogens:results of a prospective study. . Br. Med. J. 298:147-151, 1989
  pubmed

• 36) Minaguchi, H., Uemura, T., Shirasu, K. et al.:Effect of estriol on bone loss in postmenopausal Japanese women:Amulticenter prospective open study. J. Obstet. Gynecol. Res. 22:259-265, 1996

• 37) Ettinger, B., Genant, H. K., Steigen, P. et al:Low dosage micronized 17β-estradiol prevents bone loss in postmenopausal women. Am. J. Obstet. Gynecol. 166:479-488, 1992

• 38) O'sullivan, A. J., Cramptor, L. J., Frend, J. et al.:The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J. Clin. Invest. 102:1035-1040, 1998

• 39) Stevenson, J. C., Cust, M. P., Ganger, K. F. et al:Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 336:265-269, 1990

• 40) PEPI Study Group:Effects of hormone replacement therapy on bone mineral density:results from the postmenopausal. estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA 276:1389-1396, 1996

• 41) Munk Jensen, N., Nielsen, S. P., Obel, E. P. et al:Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen:adouble blind placebo controlled study. Br. Med. J. 296:1150-1152, 1988

• 42) Ettinger, B., Genant, H. K., Cann, C. E.:Long term oestrogen replacement therapy prevents bone loss and fractures. Ann. Intern. Med. 102:319-324, 1985
  pubmed

• 43) Bone, H. G, Greenspan, S. L, McKeever, C. et al.:Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J. Clin. Endocrinol. Metab. 85:720-726, 2000
  pubmed

P.432 掲載の参考文献

• 1) Jones, C. D., Blaszczak, L. C., Goettel, M. E. et al.:Antiestrogens. 3. Estrogen receptor affinities and antiproliferative effects in MCF-7 cells of phenolic analogues of trioxifene, [3, 4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl) ethoxy]-phenyl] methanone. J. Med. Chem. 35 (5):931-938, 1992
  pubmed

• 2) Brzozowski, A. M., Pike, A. C., dauter, Z. et al:Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (6652):753-758, 1997
  pubmed

• 3) Sato, M., Grese, T:. A., Dodge, J. A. et al.:Emerging therapies for the prevention or treatment of postmenopausal osteoporosis. J. Med. Chem. 42 (1):1-24, 1999
  pubmed

• 4) Sato, M., McClintock, C., Kim, J. et al.:dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J. Bone Miner. Res. 9 (5):715-724, 1994
  pubmed

• 5) Sato, M., Bryant, H. U.:Raloxifene efficacy in nonreproductive and reproductive tissues in rat models in vivo and in vitro. In Vitro Biology of Sex Steroid Hormones Action. (Kuramoto, H., Gurpide, E. eds. ) Livingstone, Tokyo, Churchill, 1996, p. 406-421

• 6) Sato, M.:Comparative x-ray densitometry of bones from ovariectomized rats. Bone 17 (4 Suppl):157S-162S, 1995

• 7) Turuer, C. H., Sato, M., Bryant, H. U.:Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 135 (5):2001-2005, 1994

• 8) Sato, M., Kim, J., Short, L. L. et al.:Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. J. Pharmcol Exp. Ther. 272:1252-1259, 1995

• 9) Bryant, H. U., Turner, C. H., Frolik, C. A. et al.:Long-term effects of raloxifene on bone, cholesterol alld uterus in ovariectomized rats. Bone 16 (Suppl):116S, 1995

• 10) Onoe, Y., Miyaura, C., Ito, M. et al:Comparative effects of estrogen alld raloxifene on B lymphopoiesis and bone loss induced by sex steroid deficiency in mice. J. Bone Miner. Res. 15 (3):541-549, 2000

• 11) Yang, N. N., Bryant, H. U., Hardikar, S. et al:Estrogen and raloxifene stimulate transforming growth factor-β3 gene expression in rat bone:apotential mechanism for estrogen-or raloxifene-mediated bone maintenance. Endocrinology 137 (5):2075-2084, 1996

• 12) Yang, N. N., Venugopalan, M., Hardikar, S. et al:Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene [see comments][published erratum appears in Science 275 (5304):1249, 19971 Science 273:1222-1225, 1996

• 13) Frolik, C. A., Bryant, H. U., Black, E. C. et al.:Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats:Effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. Bone 18 (6):621-627, 1996
  pubmed

• 14) Sato, M., Bryant, H. U., Iversen, P. et al:Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats. J.Pharmacol. Exp. Ther. 279 (1):298-305, 1996
  pubmed

• 15) Turner, A. S., Hannan, M. K., Bouxsein, M. L. et al.:Effects of raloxifene on bone density and bone strength in aged, ovariectomized ewes. 45th Annual Orthopaedic Research Society Program Proceedings 230, 1999

• 16) Jerome, C. P., Lees, C. J., Register, T. C. et al.:lliac and lumbar vertebral histomorphometry, bone densitometry and bone biomarker data from raloxifene-treated macaques-ASBMR 19th Annual Meeting. J. Bone Miner. Res. 12 (1):347, 1997

• 17) Delmas, P. D., Bjarnason, N. H., Mitlak, B. H. et al.:Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337 (23):1641-1647, 1997

• 18) Delmas, P. D., Bjarnason, N., Mitlak, B. H. et al.:Raloxifene HCl prevents bone loss and lowers serum cholesterol without endometrial stimulation in early postmenopausal women. The Endocrine Society 79th annual meeting program. 67, 1999

• 19) Prestwood, K. M., Gunness, M., Muchmore, d. B. et al.:A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J. Clin. Endocrinol. Metab. 85 (6):2197-2202, 2000

• 20) Evans, G., Bryant, H. U., Magee, d. et al.:The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 134 (5):2283-2288, 1994
  pubmed

• 21) Ettinger, B., Black, d. M., Mitlak, B. H. et al:Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene:Results from a 3-year randomized Clinical trial. J. Am. Med. Assoc. 282 (7):637-645, 1999

• 22) Melton, L. J., Khosla, S., Atkinson, E. J. et al.:Relationship of bone turnover to bone density and fractures. J. Bone Miner. Res. 12 (7):1083-1091, 1997
  pubmed

• 23) Black, L. J., Sato, M., Rowley, E. R. et al.:Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest. 93 (1):63-69, 1994
  pubmed

• 24) Kauffman, R. F, Bensch, W. R., Roudebush, R. E. et al:Hypocholesterolemic activity of raloxifene (LY13948d:pharmacological characterization as a selective estrogen receptor modulator. J. Pharmacol. Exp. Ther. 280 (1):146-153, 1997
  pubmed

• 25) Bjarnason, N. H., Haarbo, J., Byrjalsen, I. et al.:Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 96 (6):1964-1969, 1997
  pubmed

• 26) Clarkson, T. B., Anthony, M. S., Jerome, C. P.:Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J. Clin. Endocrinol. Metab. 83 (3):721-726, 1998
  pubmed

• 27) Zuckerman, S. H., Bryan, N.:Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HC1) . Atherosclerosis 126 (1):65-75, 1996

• 28) Wiernicki, T., Glasebrook, A., Phillips, d. L. et al:Estrogen and a novel tissue selective estrogen receptor modulator raloxifene directly modulate vascular smooth muscle cell functions:Implications in the cardioprotective mechanism of estrogen. Circulation 94 (8 suppl. d:1278, 1996

• 29) Rahimian, R., Laher, I., Dube, G. et al.:Estrogen and selective estrogen receptor modulator LY117018 enhance release of nitric oxide in rat aorta. J. Pharmacol. Exp. Ther. 283 (1):116-122, 1997
  pubmed

• 30) Simoncini, T., de Caterina, R., Genazzani, A. R.:Selective estrogen receptor modulators:different actions on vascular cell adhesion molecule-1 (VCAM-d expression in human endothelial cells. J. Clin. . Endocrinol. Metab. 84 (2):815-818, 1999

• 31) Zoma, W. D., Baker, R. S., Clark, K. E.:Coronary and uterine vascular responses to raloxifene in the sheep. Am. J. Obstet. Gynecol. 182 (3):521-528, 2000
  pubmed

• 32) Walsh, B., Paul, S., Wild, R. A. d. R. et al.:Effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in postmenopausal women:a randomized, controlled trial J. Endocrinol. Metab. 85 (1):214-218, 2000

• 33) Walsh, B. W., Kuller, L. H., Wild, R. A. et al.:Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J. Am. Med. Assoc. 279 (18):1445-1451, 1998

• 34) Hulley, S., Grady, D., Bush, T. et al.:Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J. Am. Med. Assoc. 280 (7):605-613, 1998

• 35) Press Release of the Women's Health Initiative (WHI) Study. Hormone replacement study finds slight rise in heart problems. The Washington Post via DowVision A Section, The. Washington Post Co. A08, 2000

• 36) Barrett-Connor, E., Wenger, N. K., Grady, d. et al.:Coronary heart disease in women, randomized Clinical trials, HERS and RUTH. Maturitas 31(1):l-7, 1998

• 37) Black, L. J., Jones, C. D., Falcone, J. F.:Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci. 32 (9):1031-1036, 1983
  pubmed

• 38) Fuchs-Young, R., Magee, d. E., Cole, H. W. et al.:Raloxifene is a tissue specific antiestrogen that blocks tamoxifen or estrogen stimulated uterogenic effects. Endocrinology 136:37, 1995

• 39) Bryant, H. U., Wilson, P. K., Adrian, M. d. et al.:Selective estrogen receptor modulators:Pharmacological profile in the rat uterus. J. Soc. Gynecol. Invest. 3 (2):152, 1996

• 40) Sato, M., Rippy, M. K., Bryant, H. U.:Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 10:905-912, 1996
  pubmed

• 41) Swisher, d. K., Tague, R. M., Seyler, d. E.:Effect of the selective estrogen receptor modulator raloxifene on explanted uterine growth in rats. drug d ev. .Res. 36:43-45, 1995

• 42) Fanning, P. M., Kuehl, T. J., Lee, R. et al.:Video mapping to assess efficacy of an antiestrogen (raloxifene) on spontaneous endometriosis in the rhesus monkey. Fertility and Sterility 67 (5 Suppl. ):38, 1997

• 43) Porter, K. B., Tsibris, J. C. M., Porter, G. W. et al.:Effects of raloxifene in a guinea pig model for leiomyomas. Am. J. Obstet. Gynecol. 179 (5):1283-1287, 1998

• 44) PEPI Trial Writing Group:Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. J. Am. Med. .Assoc. 275 (5):370-375, 1996

• 45) Grady, D., Gebretsadik, T., Kerlikowske, K. et al:Hormone replacement therapy and endometrial cancer risk:ameta-analysis. Obstet. Gynecol 85 (2):304-313, 1995

• 46) Hahn, R. G.:Compliance considerations with estrogen replacement:withdrawal bleeding and other factors. Am. J. Obstet. Gynecol. 161 (6 Pt 2):1854-1858, 1989

• 47) Cummings, S., Eckert, S., Krueger, K. et al.:The effect of raloxifene on risk of breast cancer in postmenopausal women. J.Am. Med. Assoc. 281 (23):2189-2197, 1999

• 48) Goldstein, S. R., Scheele, W. H., Rajagopalan, S. K. et al.:A12-month comparative study of raloxifene, estrogen, and placebo (m the postmenopausal endometrium. Obstet. Gynecol. 95:95-103, 2000

• 49) Fugere, P., Scheele, W. H., Shah, A. et al:Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmellopausal women. Am. J. Obstet. Gynecol. 182 (3):568-574, 2000
  pubmed

• 50) Cohen, F. J., Watts, S., Shah, A. et al.:Uterine effects of three-year raloxifene therapy in postmenopausal women under age 60. Obstet. Gynecol. 95:104-110, 2000

• 51) Sato, M., Glasebrook, A. L., Bryant, H. U.:Raloxifene:aselective estrogen receptor modulator. J. Bone Miner. Metab. 12:9-20, 1994

• 52) Schairer, C., Lubin, J., Troisi, R. et al:Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J. Am. Med. Assoc. 283:485-491, 2000

• 53) Barrett-Connor, E.:Hormone replacement and cancer. Br. Med. Bull. 48:345-355, 1992
  pubmed

• 54) Fuchs-Young, R., Iversen, P., Shelton, P. et al.:PreClinical demonstration of specific and potent inhibition of mammary tumor growth by new selective estrogen receptor modulators (SERMs)-88th Annual Meeting. Proc. Am. Assoc. Cancer Res. 38:573, 1997

• 55) Clemens, J. A., Bennett, D. R., Black, L. J. et al.:Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci. 32:2869-2875, 1983
  pubmed

• 56) Daniel, C. W., Silberstein, G. B., Strickland, P.:direct action of 17β-estradiol on mouse mammary ducts analyzed by sustained release implants and steroid autoradiography. Cancer Res. 47 (22):6052-6057, 1987

• 57) Short, L. L., Glasebrook, A. L., Adrian, M. d. et al.:distinct effects of selective estrogen receptor modulators on estrogen dependent and estrogen independent human breast cancer cell proliferation. J. Bone Miner. Res. 11(1):S482, 1996

• 58) Thompson, E. W., Reich, R., Shima, T. B. et al.:differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res. 48 (23):6764-6768, 1988
  pubmed

• 59) Labrie, F, Veilleux, R., Fournier, A.:Glucocorticoids stimulate the growth of mouse mammary carcinoma shionigi cells in culture. Mol. Cell Endocrinol. 58 (2-3):207-211, 1988

• 60) Anzano, M. A., Peer, C. W., Smith, J. M. et al:Chemoprevention of mammary carcinogenesis in the rat:combined use of raloxifene and 9-cis-retinoic acid. J. Natl. Cancer.Inst. 88:123-125, 1996
  pubmed

• 61) Cauley, J. A., Lucas, F. L, Kuller, L. H. et al.:Elevated serum estradiol and testosteron concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann. Intern. Med. 130:270-277, 1999

• 62) Collaborative Group on Hormonal Factors in Breast Cancer:Breast cancer and hormone replacement therapy:collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 350:1047-1059, 1997

• 63) Lufkin, E. G., Whitaker, M. D., Nickelsen, T. et al.:Treatment of established postmenopausa osteoporosis with raloxifene:arandomized trial. J. Bone Miner. Res. 13(11):1747-1754, 1998

• 64) Draper, M. W., Flowers, d. E., Huster, W. J. et al.:Acontrolled trial of raloxifene (LY13948d HCI) impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone Miner. Res. 11:835-842, 1996

• 65) Polo-Kantola, P., Portin, R., Polo, O. et al.:The effect of short-term estrogen replacement therapy on cognition:a randomized, double-blind, cross-over trial in postmenopausal women. Obstet. Gynecol. 91 (3):459-466, 1998
  pubmed

• 66) Merchenthaler, I., Lane, L. V., Shughrue, P. J.:The comparative distribution of estrogen receptor (and) mRNA-expressing neurons in the rat central nervous system:An in situ hybridization study. Soc. Neurosci. Abstr. 23:1683, 1997

• 67) Simard, J., Labrie, F.:Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs. Mol. Cell. Endocrinol. 39:141-144, 1985
  pubmed

• 68) Wu, X., Glinn, M., Su, Y. et al.:Raloxifene increases hippocampal cholineacetyltransferase activity in ovariectomized rats. So6. Neurosci. Abstr. 24 (1):732, 1998

• 69) Wu, X., Glinn, MA, Ostrowski, N. L. et al.:Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats. Brain Res. 847:98-104, 1999
  pubmed

• 70) Kawas, C., Resnick, S., Morrison, A. et al.:A prospective study of estrogen replacement therapy and the risk of developing Alzheimer:s disease:the Baltimore Longitudinal Study of Aging [published erratum appears in Neurology 51 (2):654, 1998]. Neurology 48 (6):1517-1521, 1997

• 71) Brenner, d. E., Kukull, W. A., Stergachis, A. et al.:Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease:a population-based case-control study. Am. J. Epidemiol. 140 (3):262-267, 1994
  pubmed

• 72) Haskell, S. G., Richardson, E. D., Horwitz, R. I. et al.:The effect of estrogen replacement therapy on cognitive function in women:a critical review of the literature. J. Clin. Epidemiol. 50 (1):1249-1264, 1997

• 73) Yaffe, K., Sawaya, G., Lieberburg, I. et al.:Estrogen therapy in postmenopausal women:effects on cognitive function and dementia. J. Am. Med. Assoc. 279 (9):688-695, 1998

• 74) Lakshmanan, M., Bryant, H. U., Paul, S. M. et al.:Central nervous system effects of raloxifene:evidence from animal models and controlled Clinical trials in postmenopausal women. Climacteric 2 (Suppl. 1):331, 1999

• 75) Nickelsen, T., Lufkin, E. G., Riggs, B. L. et al.:Raloxifene hydrochloride, a selective estrogen receptor modulator:safety assessment of effects on cognitive function and mood in postmenopausal women. Psychonezaroendocrinology 24:115-128, 1999
  pubmed

• 76) Fleisch, H.:Bisphosphonates in Bone disease:From the Laboratory to the Patient. Partheonon Publishing, 1997

• 77) Liberman, U. A., Weiss, S. R., Broll, J. et al.:Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N. Engl. J. Med. 333:1437-1443, 1995

• 78) Rodan, G. A., Fleisch, H. A.:Bisphosphonates:mechanisms of action. J. Clin. Invest. 97 (12):2692-2696, 1996
  pubmed

• 79) Pizzani, E., Valenzuela, G.:Esophagitis associated with alendronate sodium. Va. Med. Q. 124 (3):181-182, 1997
  pubmed

• 80) Gertz, B. J., Holland, S. D., Kline, W. F. et al.:Clinical pharmacology of alendronate sodium. Osteoporos. Int. 3:13-16, 1993

• 81) Chavassieux, P. M., Arlot, M. E., Reda, C. et al.:Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J. Clin. Invest. 100:1475-1480, 1997

• 82) Burr, d. B., Forwood, M. R., Fyhrie, d. P. et al.:Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J. Bone Miner. Res. 12 (1):6-15, 1997
  pubmed

• 83) Fisher, B., Costantino, J. P., Wickerham, d. L. et al.:Tamoxifen for prevention of breast cancer:report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90 (18):1371-1388, 1998
  pubmed

• 84) Hemminki, K., Rajaniemi, H., Lindahl, B. et al.:Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res. 56 (19):4374-4377, 1996

• 85) Bauer, d. C., Black, D., Ensrud, K. et al.:Upper gastrointestinal tract safety profile of alendronate:the fracture intervention trial. Arch. Intern. Med. 160:517-525, 2000
  pubmed

• 86) Ettinger, B., Pressman, A. R., Schein, J. et al.:Alendronate use among 812 women:prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J. Managed Care Pharm. 4:488-492, 1998

• 87) 中澤隆弘, Bryant, H. U.:ラロキシフェン:骨への選択的作用とそのメカニズム. The Bone 11(1):89-102, 1997

• 88) Davies, G. C., Huster, W. J., Lu, Y. et al:Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet. Gynecol. 93 (4):558-565, 1999
  pubmed

• 89) Umland, E. M., Rinaldi, C., Parks, S. M. et al.:The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers. Ann. Pharmacother. 33:1315-1328, 1999
  pubmed

• 90) Love, R. R., Wiebe, d. A., Newcomb, P. A. et al.:Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann. Intern. Med. 115:860-864, 1991
  pubmed

• 91) Yang, N. N., Bryant, H. U., 中澤隆弘:ラロキシフェンの組織特異的作用の分子機構. Mol. Med. 35 (4):520-526, 1998

• 92) Bryant, H. U., 福山隆子, 中澤隆弘:ラロキシフェンとエストロゲンの骨作用における類似性. 蛋白質核酸酵素45 (6):1102-1108, 2000

P.443 掲載の参考文献

• 1) Copp, d. H., Cameron, E. C., Cheney, B. A. et al:Evidence for calcitonin-a new hormone from the parathyroid that lowers blood calcium. Endocrinology 70:638-649, 1962
  pubmed

• 2) Rosenfeld, M. G., Mermod, J. J., Amara, S. G. et al.:Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 304:129-135, 1983
  pubmed

• 3) Brown, E. M., Gamba, G., Riccardi, d. et al.:Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature 366:575-580, 1993
  pubmed

• 4) Garrett, J. E., Tamir, H., Kifor, O. et al.:Calcitonin-secreting cells of the thyroid express an extracellular calcium receptor gene. Endocrinology 136:5202-5211, 1995
  pubmed

• 5) Freichel, M., Zink-Lorenz, A., Holloschi, A. et al.:Expression of a calcium-sensing receptor in a human medullary thyroid carcinoma cell line and its contribution to calcitonin secretion Endocrinology 137:3842-3848, 1996

• 6) Naveh-Many, T., Raue F, Grauer, A. et al:Regulation of calcitonin gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J. Bone Miner. Res. 7:1233-1237, 1992

• 7) Lin, H. Y., Harris, T. L, Flannery, M. S. et al.:Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science 254:1022-1024, 1991
  pubmed

• 8) Segre, G. V., Goldring, S. R.:Receptors for secretin, calcitonin, parathyroid hormone/PTH-related peptide, vasoactive intestinal peptide, glucagon-like peptide 1, growth hormone-releasing hormone and glucagon belong to a newly discovered G-protein linked receptor family. 7 Trends Endocrinol. Metabtab. 4:309-314, 1993

• 9) Gorn, A. H., Lin, H. Y., Yamin, M. et al.:Cloning, characterization, and expression of a human calcitonin receptor from an ovarian carcinoma cell line. J. Clin. .rnvest. 90:1726-1735, 1992

• 10) Gorn, A. H., Rudolph, S. M., Flannery, M. R. et al.:Expression of two human skeletal calcitonin receptor isoforms cloned from a giant cell tumor of bone. The first intracellular domain modulates ligand binding and signal transduction. J. Clin. Invest. 95:2680-2691, 1995
  pubmed

• 11) Lee, S. K., Galson, d. L. et al.:Calcitonin downregulates calcitonin receptor mRNA expression in osteoclast-like cells (OLC) generated from hematopoietic stem cell lines. J. Bone Miner. Res. 11:S277, 1996

• 12) Ikegame, M., Rakopoulos, M., Martin, T. J. et al.:Effects of continuous calcitonin treatment on osteoclast-like cell development and calcitonin receptor expression in mouse bone marrow cultures. J. Bone Miner. Res 11:456-465, 1996
  pubmed

• 13) Takahashi, S., Goldring, S., Katz, M. et al:down regulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J. Clin. Invest. 95:167-171, 1995
  pubmed

• 14) Wada, S., Martin, T. J., Findlay, d. M.:Homologous regulation of the calcitonin receptor in mouse osteoclast-like cells and human breast cancer T47D cells. Endocrinology 136:2611-2621, 1995
  pubmed

• 15) Orcel, P., Takahashi, K. et al.:Identification and characterization of two Gs protein-coupling sequences in the porcine calcitonin.Bone 16(Suppl. 1):87S, 1995

• 16) Teti, A., Paniccia, R., Goldring, S. R.:Calcitonin increases cytosolic free calcium concentration via capacitative calcium influx. J. Biol. Chem. 270:16666-16670, 1995
  pubmed

• 17) Ikegame, M., Ejiri, S., Ozawa, H.:Histochemical and autoradiographic studies on elcatonin internalization and intracellular movement in osteoclasts. J. Bone Miner. Res. 9:25-37, 1994
  pubmed

• 18) Suda, T., Nakamura, N., Jimi, E. et al.:Regulation of osteoclast function. J. Bone Miner. Res. 12:869-879, 1997

• 19) Clementi, G., Amico-Roxas, M., Rapisarda, E. et al.:The analgesic activity of calcitonin and the central serotonergic system. Eur. J. Pharmacol. 108:71-75, 1985
  pubmed

• 20) Rico, H., Revilla, M., Hernandez, E. R. et al:Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin:aprospective study. Calcif Tissue Int. 56:181-185, 1995

• 21) Mazzuoli, G. F., Passeri, M., Gennari, C. et al.:Effects of salmon calcitonin in postmenopausal osteoporosis:acontrolled double-blind Clinical study. Calcif. Tissue Int. 38:3-8, 1986

• 22) Reginster, J. Y., denis, D., deroisy, R. et al.:1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 2:1481-1483, 1987
  pubmed

• 23) Reginster, J. Y., deroisy, R., Lecart, M. P. et al.:Adouble-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am. J. Med. 98:452-458, 1995

• 24) Overgaard, K., Riis, B. J., Christiansen, C. et al:Effect of salcatonin given intranasally on early postmenopausal bone loss. B. M. J. 299:477-479, 1989

• 25) Overgaard, K., Riis, B. J., Christiansen, C. et al.:Nasal calcitonin for treatment of established osteoporosis. Clin. Endocrinol. 30:435-442, 1989
  pubmed

• 26) Overgaard, K.:Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women:adose-response study. Calcif. Tissue In t. 55:82-86, 1994

• 27) Orimo, H., Morii, H., Inoue, T. et al.:Effect of elcatonin on involutional osteoporosis. J. Bone Miner. Metab. 14:73-78, 1996

• 28) 藤田拓男, 井上哲郎ほか:骨粗鬆症に対するエルカトニンの効果:プラセボを対照薬とした多施設二重盲検比較試験. 医学のあゆみ152:261-282, 1990

• 29) Kanis, J. A., delmas, P., Burckhardt, P. et al.:Guidelines for diagnosis and management of osteoporosis. Osteoporosis Int. 7:390-406, 1997
  pubmed

• 30) 三浦隆行, 井上哲郎ほか:骨粗鬆症に伴う腰背痛に対するエルカトニン長期投与の臨床効果. 診断と新薬 32:110-131, 1995

• 31) Fujita, T., Fukase, M., Shimada, T. et al:Treatment of established osteoporosis with la (OH) vitamin D3 and low dose intermittent elcatonin (eel calcitonin derivative) . J. Bone Miner. Metab. 10:37-40, 1992

P.456 掲載の参考文献

• 1) Gural, R. P., Chungi, V. S., Shewsbury, R. P. et al:dose-dependent absorption of disodium etidronate. J. Pharm. 37:443-445, 1985

• 2) Gertz, B. J., Holland, S. D., Kline, W. F. et al:Studies of the oral bioavailability of alendronate. Clin. Pharmacol. Ther. 58:288-298, 1995
  pubmed

• 3) Kasting, G. B., Francis, M. d.:Retention of etidronate in human, dog and rat. J. Bone Miner. Res. 7:513-522, 1992

• 4) Sato, M., Grasser, W., Endo, N. et al.:Alendronate localization in rat bone and effects on osteoclast structure. J. Clin. Invest. 88:2095-2105, 1991

• 5) Shinoda, H., Adamek, G., Felix, R. et al.:Structure-activity relationships of various bisphosphonates. Calcif. Tissue Int. 35:87-99, 1983
  pubmed

• 6) Flanagan, A. M., Chambers, T. J.:dichloromethylenebisphosphonate (CI2MBP) inhibits bone resorption through injury to osteoclasts that resorb C12MBP-coated bone. Bone Miner. 6:33-43, 1989

• 7) Flanagan, A. M., Chambers, T. J.:Inhibition of bone resorption by bisphosphonates:interactions between bisphosphonates, osteoclasts, and bone. Calcif. Tissue Int. 49:407-415, 1991
  pubmed

• 8) Murakami, H., Takahashi, N., Sasaki, T. et al.:A possible mechanism of the specific action of bisphosphonates on osteoclasts:tildronate preferentially affects polarized osteoclasts having ruffled borders. Bone 17:137-144, 1995

• 9) Hughes, d. E., Macdonald, B. R., Russell, R. G. G. et al.:Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J. Clin. Invest. 83:1930-1935, 1989

• 10) Skorey, K., Ly, H. D., Kelly, J. et al.:How does alendronate inhibit protein-tyrosine phosphatases? J. Biol. Chem. 272:22472-22480, 1997
  pubmed

• 11) Schmidt, A., Rutledge, S. J., Endo, N. et al.:Protein-tyrosine phosphatase activity regulate osteoclast formation and function:inhibition by alendronate. Proc. Natl.Acad. Sci. 93:3068-3073, 1996
  pubmed

• 12) Murakami, H., Takahashi, N., Tanaka, S. et al.:Tiludronate inhibits protein tyrosine phosphatase activity in osteoclast. Bone 20:399-404, 1997
  pubmed

• 13) Opas, E. E., Rutledeg, S. J., Golub, E. et al.:Alendronate inhibition of protein-tyrosine phosphatase-megl. Biochem. Pharm. 54:721-727, 1997

• 14) Soriano, P., Montgomery, C., Geske, R. et al.:Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64:693-702, 1991

• 15) Hughes, d. E., Wright, K. R., Uy, H. L. et al.:Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 10:1478-1487, 1995
  Medical*Online
  pubmed

• 16) Luckman, S. P., Hughes, d. E., Coxon, F. P. et al.:Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13:581-589, 1998

• 17) Zhang, F. L., Casey, P. J.:Protein prenylation:Molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65:241-269, 1996
  pubmed

• 18) van Beek, E., Pieterman, E., Cohen, L. et al.:Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. 264:108-lll, 1999
  pubmed

• 19) Bergstrom, J. D., Bostedor, R. G., Masarachia, P. J. et al.:Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys. 373:231-241, 2000
  pubmed

• 20) van beek, E., Lowik, C., van der Pluijm, G. et al.:The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro:Aclue to the mechanism of action of nitrogen-containing bisphosphonates. J. Bone Miner. Res. 14:722-729, 1999

• 21) Benford, H. L, Frith, J. C., Auriola, S. et al:Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates:biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol. Pharmacol. 56:131-140, 1999
  pubmed

• 22) Rogers, M. J., Brown, R. J., Hodkin, V. et al.:Bisphosphonates are incorporated into adenine nucleotides by human amino-acyl-tRNA synthetase enzymes. Biochem. Biophys. Res. Commun. 224:863-869, 1996
  pubmed

• 23) Frith, J. C., Monkkonen, J., Blackburn, G. M. et al.:Clodronate and lioposome-encapsulated clodronate are metabolized to a toxic ATP analog, Adenosine 5:-β, γ-dichloromethylene triphosphate, by mammalian cells in vitro. J. Bone Miner. Res. 12:1358-1367, 1997

• 24) david, P., Nguyen, H., Barbier, A. et al.:The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H (+)-ATPase. J. Bone Miner. Res. 11:1498-1507, 1996

• 25) 藤田拓男, 折茂 肇, 井上哲郎ほか:退行期骨粗鬆症に対するアルファカルシドールを対照としたエチドロン酸二ナトリウム(EHDP)の二重盲検比較試験. Clin. Eval. 20:261-302, 1993

• 26) Storm, T., Kollerup, G., Thamsborg, G. et al.:Five years of Clinical experience with intermittent cyclical etidronate for post menopausal osteoporosis. J. Rheumatol. 23:1560-1564, 1996
  pubmed

• 27) Lufkin, E. G., Argueta, R., Whitaker, M. d. et al.:Pamidronate:An unrecognized problem in gastro intestinal tolerability. Osteoporosis Int. 4:320-322, 1994

• 28) Black, d. M., Cunnings, S. R., Karpf, d. B. et al.:Randamized trial of effect of alendronate on risk of fracture in women existing vertebral fractures. Lancet 348:1535-1541, 1996

• 29) Schweitzer, d. H., Oostendorp-van de Ruit, M., Van der Pluijm, G. et al:Interleukin-6 and the acute phase response during treatment of patient with Paget:disease with the nitrogen-containing bisphosphonate dimethylamino hydroxypropylidene bisphosphonate. J. Bone Miner. Res. 10:956-962, 1995

• 30) Bounameaux, H. M., Schfferli, J., Montani, J. P. et al.:Renal failure associated with intravenous bisphosphonates. Lancet 1:471, 1983

• 31) dumon, J. C., Magritte, A., Body, J. J.:Efficacy and safety of the bisphophonate tiludronate for the treatment of tumor associated hypercalcemia. Bone Miner. 15:257-266, 1991

• 32) Francis, M. D., Slough, C.:Acute intravenous infusion of disodium dihydrogen (1-hydroxy-ethylidene) diphosphonate:Mechanism of cytotoxicity. J. Pharm. Sci. 73:1097-1100, 1983

• 33) Fleisch, H.:Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. drugs 42:919-944, 1991
  pubmed

• 34) Pecherstorfer, M., Ludwig, H., Schlosser, K. et al.:Administration of the bisphosphonate ibandronate (BM21. 0955) by intravenous bolus injection. J. Bone Miner. Res. 11:587-593, 1996
  pubmed

• 35) Watts, N. B., Harris, S. T., Genant, H. K. et al.:Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl. J. Med. 323:73-79, 1990
  pubmed

• 36) libermann, U. A., Weiss, S. R., Broll, J. et al.:Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 333:1437-1443, 1995

• 37) Pols, H. A. P., Felsenberg, D., Hanley, d. A. et al.:Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass:results of FOSIT study. Osteoporosis Int. 9:461-468, 1999

• 38) Cummings, S. R., Black, d. M., Thompson, d. E. et al.:Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280:2077-2082, 1998
  pubmed

P.469 掲載の参考文献

• 1) Reid, I.:vitamin D and its metabolites in the management of osteoporosis, in Osteoporosis. (Marcus, R., Feldman, D., Kelsey, J. eds. ), Academic Press, San diego, London, Boston, New York, Sydney, Tokyo, Toront, 1996, p. 1169-1190

• 2) Rosen, C.:vitamin D and bone health in adults and the elderly, in vitamin D:Physiology, molecular biology, and Clinical applications. (Holick, M. ed. ) Humana Press, Totowa, 1999, p. 287-305

• 3) 板橋 明:原発性骨粗鬆症. 病態生理. 最新内科学体系73 骨疾患. (坂根 剛, 森井浩世 編)中山書店, 東京, 1995, p. 146-154

• 4) 板橋 明:骨粗鬆症と骨軟化症. 内科学. (黒川 清, 松澤佑次 編) 文光堂, 東京, 1999, p. 1195-1199

• 5) Holick, M.:Evolution, Biologic functions, and recommend and dietary allowances for vitamin D, in vitamin D:Physiology, molecular biology, and Clinical applications. (Holick, M. ed. ) Humana Press, Totowa, 1999, p. l-16

• 6) Utiger, R.:The Need for More vitamin D. N. Engl. J. Med. 338:828-829, 1998
  pubmed

• 7) Holick, M., Matsuoka, L., Wortsman, J.:Age, vitamin D, and solar ultraviolet radiation. Lancet 4:1104-1105, 1989

• 8) Tsai, K.-S., Heath, HI, H., Kumar, R. et al.:Impaired vitamin D Metabolism with Aging in women. Possible Role in Pathogenesis of Senile osteoporosis. J. Clin. Invest. 73:1668-1672, 1984

• 9) Ebeling, P., Sandgren, M., diMagno, E. et al.:Evidence of an age-related decrease in intestinal responsiveness to vitamin D:Relationship between serum 125-dihydroxyvitamin D3 and intestinal vitamin D receptor concentrations in normal women. J. Clin. Endocrinol. Metab. 75:176-182, 1992

• 10) Vieth, R.:vitamin D supplementation, 25-hydrovitamin D concentrations, and safety. Am. J. Clin. Nutr. 69:842-856, 1999

• 11) Andersson, S., davis, D., dahlback, H. et al.:Cloning, Structure, and Expression of the Mitochondrial Cytochrome P-450 Sterol 26-Hydroxylase, a Bile Acid Biosynthetic Enzyme. J. Biol. Chem 2. 264:8222-8229, 1989

• 12) Usui, E., Noshiro, M., Okuda, K.:Molecular cloning of cdNA for vitamin D 25-hydroxylase from rat liver mitochondria. FEBS Lett. 262:135-138, 1990

• 13) Slovik, D., Adams, J., Neer, R. et al.:deficient production of 1,25-dihydroxyvitamin D in elderly osteoporotic Patients. N. Engl. J. Med. 305:372-374, 1981
  pubmed

• 14) Kinyamu, H., Gallagher, J., Prahl, J. et al.:Association between intestinal vitamin D receptor, calcium absorption, and serum 1,25-dihydroxyvitamin D ip normal young and elderly women. J. Bone Miner. Res. 12:922-928, 1997

• 15) Horst, R., Goff, J., Reinhardt, T.:Advancing age results in reduction of intestinal and bone 1,25dihydroxyvitamin D receptor. Endocrinology 126:1053-1057, 1990
  pubmed

• 16) Armbrecht, H., Boltz, M., Christakos, S. et al.:Capacity of 1, 25dihydroxyvitamin D to stimulate expression of calbindin d changes with age in the rat. Arch. Biochem. Biophys. 352:159-164, 1998
  pubmed

• 17) Optimal calcium intake. NIH consensus development panel on optimal calcium intake. JAMA 272:1942-1948, 1994
  pubmed

• 18) dawson-Hughes, B., Dallal, G., Krall, E. et al.:Acontrolled trial of the effect of calcium supplementation on bone density in postmenopausal women. N. Engl. J. Med. 323:878-883, 1990

• 19) Reid, I., Ames, R., Evans, M. et al.:Effect of calcium supplementation on bone loss in postmenopausal women. N. Engl. J. Med. 328:460-464, 1993

• 20) Riggs, B., O'Fallon, W., Muhs, J. et al.:Longterm effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women.J. Bone Miner. Res. 13:168-174, 1998
  pubmed

• 21) Chapuy, M., Arlot, M., Duboeuf, F. et al.:vitamin D3 and calcium to prevent hip fracture in elderly women. N. Engl. J. Med. 327:1637-1642, 1992
  pubmed

• 22) dawson-Hughes, B., Harris, S., Krall, E. et al.:Effect of calcium and vitamin D supplementation on bone density in men and women 65years of age or older. N. Engl. J. Med. 337:670-676, 1997
  pubmed

• 23) Heikinheimo, R., Inkovarra, J., Harju, E. et al.:Annual injection of vitamin D and ractures of aged bones. Calcif. Tissue Int. 51:105-110, 1992

• 24) Lips, P., Graafmans, W., Ooms, M. et al.:vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled Clinical trial. Ann. Int. Med. 124:400-406, 1996

• 25) Meunier, P.:Calcium and vitamin D are effective in preventing fractures in elderly people by reversing senile secondary hyperparathyroidism. Osteoporosis Int. 8 (Suppl 2):S1-S2, 1998

• 26) Gallagher, J., Riggs, B., Eisman, J. et al:Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients. J. Clin. Invest. 64:729-736, 1979
  pubmed

• 27) Francis, R., Boyle, L, Moniz, C. et al:Acomparison of the effects of alfacalcidol treatment and vitamin D2 supplementation on calcium absorption in elderly women with vertebral fractures. Osteoporosis In t. 6:284-290, 1996

• 28) Christiansen, C., Christensen, M., Rodbro, P. et al.:Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis. Ezar. J. Clin. Invest. 11:305-309, 1981
  pubmed

• 29) Falch, J., odegaard, O., Finnanger, A. et al.:Postmenopausal osteoporosis:No effect of three years treatment with 1,25-dihydroxycholecalciferol. Acta Med. Scand. 221:199-204, 1987
  pubmed

• 30) Ott, S., Chesnut, C.:Calciteriol treatment is not effective in postmenopausal osteoporosis. Ann. Int. Med. 110:267-274, 1989

• 31) Aloia, J., Vaswani, A., Yeh, J. et al.:Calciteriol in the treatment of postmenopausal osteoporosis. Am. J. Med. 8:401-408, 1988
  pubmed

• 32) Gallagher, J., Goldgar, d.:Treatment of postmenopausal osteoporosis with high doses of synthetic calciteriol. Ann. Int. Med. 113:649-655, 1990
  pubmed

• 33) Tilyard, M., Spears, G., Thompson, J. et al.:Treatment of postmenopausal osteoporosis with alciteriol or calcium. N. Engl. J. Med. 326:357-362, 1992
  pubmed

• 34) Christiansen, C., Christensen, M., Mcnair, P. et al:Prevention of early postmenopausal bone loss:controlled 2-year study in 315 normal females. Eur. J. Clin. Invest. 10:273-279, 1980
  pubmed

• 35) 伊丹康人, 藤田拓男, 井上哲郎ほか:アルファカルシドールの骨粗鬆症に対する効果. 医学のあゆみ123:958-973, 1982

• 36) Orimo, H., Shiraki, M., Hayashi, Y. et al.:Effects of 1α-hydroxyvitamin D on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif. Tissue Int. 54:370-376, 1994

• 37) Nakamura, T.:The importance of genetic and nutritional factors in response to vitamin D and its analogs in osteoporotic patients. Calcif. Tissue Int. 60:119-123, 1997
  pubmed

• 38) Gardiner, E., Baldock, P., Thomas, G. et al.:Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage. FASEB J. 14:1908-1916, 2000
  pubmed

• 39) Shiraishi, A. ;Higashi, S., Ohkawa, H. et al.:The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif. Tissue.Int. 65:311-316, 1999
  pubmed

• 40) lchikawa, F., Sato, K., Nanjo, M. et al.:Mouse primary osteoblasts express vitamin D325-hydroxylase mRNA and convert 1α-hydroxylvitamin D3 into 1α, 25-dihydroxyvitamin D3. Bone 16:129-135, 1995

• 41) Shiraishi, A., Takeda, S., Masaki, T. et al.:Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis:distinct actions from estrogen. J. Bone Miner. Res. 15:770-779, 2000

• 42) Chen, J., Shiraki, M., Hasumi, K. et al.:1-α-hydroxyvitamin D3 treatment decreases bone turnover and modulates calcium-regulating hormones in early postmenopausal women. Bone 20:557-562, 1997

• 43) 西井易穂:活性型ビタミンD誘導体の開発, 特にカルシウム作用と分化誘導作用の分離. ビタミン72:461-467, 1998

• 44) Bouillon, R., Okamura, W., Norman, A.:Structure-function relationship in the vitamin D endocrine system. Endocr. Rev. 16:200-257, 1995
  pubmed

• 45) Abe, E., Miyaura, C., Sakagami, H. et al.:differentiation of mouse myeloid leukemiac cells induced by 1α, 25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. USA 78:4990-4994, 1981

• 46) Kubodera, N., Sato, K., Nishii, Y.:Characteristics of 22-Oxacalcitriol (OCT) and 2β-(3-hydroxypropoxy) calciteriol (Ed-7d . (Feldman, D., Glorieux, F., Pike, J. eds. ) Academic Press, San diego, London, Boston, New York, Sydney, Tokyo, Toront, 1997, p. 1071-1086

• 47) Tsurukami, H., Nakamura, T., Suzuki, K. et al.:Anovel synthetic vitamin D analogue, 2β-(3-hydroxypropoxy) 1α, 25-dihydroxyvitamin D3 (Ed-7d, increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Calcif. Tissue.Int. 54:142-149, 1994

• 48) Ikeda, K., Ogata, E.:The ecffect of vitamin D on osteoblasts and osteoclasts. Curr. Opin. Orthop. 10:339-343, 1999

P.480 掲載の参考文献

• 1) Consensus development Conference:diagnosis, prophylaxis and treatment of osteoporosis. Am. J. Med. 94:646-650, 1994

• 2) 日本骨代謝学会, 骨粗鬆症診断基準委員会:原発性骨粗鬆症の診断基準(1996年改訂版). Osteoporosis Jpn. 4:643-652, 1996

• 3) 岩永貞昭ほか 監:ビタミンK-医学生物学領域における新展開. メディカルジャーナル社, 1994

• 4) Bouckaert, J. H., Said, A. H.:Fracture Healing by vitamin K. Nature 185:849, 1960
  pubmed

• 5) Pettifor, J. M., Benson, R.:Congenital malformations associated with the administration of oral anticoagulants during Pregnancy. J. Pediatr. 86:459-462, 1975
  pubmed

• 6) Price, P. A., Otsuka, A. S., Poser, J. W. et al:Characterization of a γ carboxyglutamic acidcontaining protein from bone. Proc. Natl. Acad. Sci. USA 73:1447-1451, 1976

• 7) Hauschka, P. V., Reid, M. L:Vitamin K dependence of a calcium-binding protein containing γ carboxyglutamic acid in chicken bone. J. Biol. Chem. 253:9063-9068, 1978

• 8) Price, P. A., Williamson, M. K.:Primary structure of bovine matrix Gla protein, a new vitamin K-dependent bone protein. J. Biol. Chem. 260:14971-14975, 1985

• 9) Maillard, C., Berruyer, M., Serre, C. M. et al.:Protein S, a vitamin K-dependent protein, is a bone matrix component synthesized and secreted by osteoblasts. Endocrinology 130:1599--1604, 1992

• 10) Hart, J. P., Shearer, M. J., Klenerman, L. et al.:Electrochemical detection of depressed circulating levels of vitamin K. in osteoporosis. J. Clin. Endocrinol. Metab. 60:1268-1269, 1985

• 11) Hodges, S. J., Akesson, K., Vergnaud, P. et al.:Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture. J. Bone Miner. Res. 8:1241-1245, 1993
  pubmed

• 12) Feskanich, D., Weber, P., Wilet, W. C. et al.:Vitamin K intake and hip fractures in women;a prospective study. Am. J. Clin. Nutr. 69:74-79, 1999

• 13) 金木正夫, 水野有三, 細井孝之ほか:退行期骨粗鬆症における血清ビタミンK濃度の検討. 日老医誌32:195-211, 1995

• 14) Plantalech, L, Guillaumont, M., Philippe, V. et al:Impairment of γ calboxylation of circulating osteocalcin (bone gla protein) in elderly women. J. Bone Miner. Res. 6:1211-1216, 1991

• 15) Szulc, P., Arlot, M., Chapuy, M.-C. et al.:Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J. Bone Miner. Res. 9:1591-1595, 1994
  pubmed

• 16) Szulc, P., Chapuy, M.-C., Meunier, P. J. et al:Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J. Clin. Invest. 91:1769-1774, 1993
  pubmed

• 17) Vergnaud, P., Garnero, P., Meunier, P. J. et al.:Undercalboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women:The EPIDOS Study. J. Clin. Endocrinol. Metab. 82:719-724, 1997

• 18) Plantalech, L., Chapuy, M. C., Guillaumont, M. et al.:Impaired calboxylation of serum osteocalcin in elderly women. Osteoporosis. Effects ot vitamin K1 treatment. (Cristiansen, C., Overgaard, K. eds. ) 1990, p. 345-347

• 19) Shiraki, M., Shiraki, Y., Aoki, C. et al.:Vitamin K2 (Menatetorenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporois. J. Bone Miner. Res. 15:515-521, 2000

• 20) Luo, G., Ducy, P., McKee, M. d. et al.:Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386:78-81, 1997
  pubmed

• 21) Vermeer, C., Knapen, M. H., Schurgers, L. J.:Vitamin K and metabolic bone disease. J. Clin. Pathol. 51:424-426, 1998
  pubmed

• 22) Knapen, M. H. J., Hamulyak, K., Vermeer, C.:The effect of vitamin K supplementation on circulating osteocalcin (bone Gla-protein) and urinary calcium excretion. Ann. Intern. Med. 111:1001-1005, 1989

• 23) Kiyama, Y., Hara, K., Ohkawa, I. et al.:Effects of menatetrenone on bone loss induced by ovariectomy in rats. Jpn. J. Pharmacol. 62:145-153, 1993

• 24) Hara, K., Akiyama, Y., Ohkawa, I. et al.:Effects of menatetrenone on predonisolone-induced bone loss in rat. Bone 14:813-818, 1993

• 25) 折茂 肇, 藤田拓男, 小野村敏信ほか:骨粗鬆症に対する Ea-0167(Menatetrenone)の臨床評価. 臨床評価 20:45-100, 1992

• 26) Koshihara, K., Hoshi, K., Ishibashi, H. et al.:Vitamin K2 promote 1,25 (OH) 2 vitamin D3-induced mineralization in human periosteal osteoblasts. Calcif. Tissue Int. 59:466-473, 1996

• 27) Koshihara, Y., Hoshi, K.:Vitamin K2 enhances osteocalcin accumulation in the extracellular matrix of human osteoblasts in vitro. J. Bone Miner. Res. 12:431-438, 1997
  pubmed

• 28) Koshihara, Y., Hoshi, K., Shiraki, M.:Vitamin K2 (menatetrenone) inhibits prostaglandin synthesis in cultured human osteoblast-like periosteal cells by inhibiting prostaglandin H synthase activity. Biochem. Pharmacol. 46:1355-1362, 1993
  pubmed

• 29) Hara, K., Akiyama, Y., Tajima, T. et al.:Menatetrenone inhibits bone resorption partly through inhibition of PGE2 synthesis in vitro. J. Bone Miner. Res. 8:535-542, 1993
  pubmed

• 30) Hara, K., Akiyama, Y., Nakamura, T. et al.:The inhibitory effect of vitamin K2 (menatetrenone) on bone resorption may be related to its side chain. Bone 16:179-184, 1995

• 31) Kameda, T., Miyazawa, K., Mori, Y. et al:Vitamin K sub 2 inhibits osteoclastic bone resorption by inducing osteoclast apoptosis. Biochem. Biophys. Res. Commun. 220:515-519, 1996

• 32) Nakamura, Y. S., Hakeda, Y., Takakura, N. et al:Tyro 3 receptor tyrosine kinase and its ligand, Gas6, stimulate the function of osteoclasts. Stem. Cells. 16:229-238, 1998
  pubmed

• 33) Fiore, C. E., Tamburino, C., Foti, R. et al.:Reduced bone mineral content in patients taking an oral anticoagulant. South Med. J. 83:538-542, 1990
  pubmed

• 34) Resch, H., Pietschmann, P., Krexner, E. et al.:decreased peripheral bone mineral content in patlents under anticaglant therapy with phenproumon. Ezar. Heart J. 14:439-441, 1991

• 35) Caraballo, P. J., Heit, J. A., Atkinson, E. J. et al.:Long-term use of oral anticoagulants and the risk of fracture. Arch. Intern. Med. 159:1750-1756, 1999
  pubmed

P.490 掲載の参考文献

• 1) Suda, T., Takahashi, N., Udagawa, N. et al:Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20:345-357, 1999
  pubmed

• 2) Kanatani, M., Sugimoto, T., Takahashi, Y. et al.:Estrogen via the estrogen receptor blocks cAMP-mediated parathyroid hormone (PTH)-stimulated osteoclast formation. J. Bone Miner. Res. 13:854-862, 1998
  pubmed

• 3) Lindsay, R., Nieves, J., Formica, C. et al.:Randomized controlled study of effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women on estrogen with osteoporosis. Lancet 350:550-555, 1997
  pubmed

• 4) Cosman, F., Nieves, J., Woelfert, L. et al.:Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J. Bone Miner. Res. 13:1051-1055, 1998
  pubmed

• 5) Podbesek, R., Edourard, C.:Effect of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds. Endocrinology 112:1000-1006, 1983

• 6) Zhang, L., Takahashi, H. E., Inoue, J. et al.:Effects of intermittent administration of low dose human PTH (1-34) on cancellous and cortical bone of lumber vertebral bodies in adult beagles. Bone 21:501-506, 1997

• 7) Hock, J. M., Gera, I.:Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to PTH. J. Bone Miner. Res. 7:65-72, 1992
  pubmed

• 8) Mitlak, B. H., Burdette-Miller, P.:Sequential effects of chronic human PTH (1-84) treatment of estrogen deficiency osteopenia in the rat. J. Bone Miner. Res. 11:430-439, 1996

• 9) Meng, X. W., Liang, X. G., Birchman, R. et al.:Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J. Bone Miner. Res. 11:421-429, 1996
  pubmed

• 10) Okimoto, N, Tsurukami, H., Okazaki, Y. et al.:Effects of a weekly injection of human parathyroid hormone (1-34) and withdrawal on bone mass, strength, and turnover in mature ovariectomized rats. Bone 22:523-531, 1998

• 11) Hock, J. M., Hummert, J. R., Boyce, R. et al.:Resorption is not essential for the stimulation of bone growth by hPTH-(1-34) in rats in vivo. J. Bone Miner. Res. 4:449-458, 1989

• 12) delmas, P. D., Vergnaud, P., Ariot, M. E. et al.:The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16:603-610, 1995

• 13) Yamamoto, N., Takahashi, H. E., Tanizawa, T. et al.:Maintenance of bone mass by physical exercise after discontinuation of intermittent hPTH (1-34) administration. Bone-Miner. 23:333-342, 1993
  pubmed

• 14) Zhang, L., Takahashi, H. E., Tanizawa, T. et al.:Maintenance of bone mineral density of femoral cortex in ovariectomized rats after withdrawal of concurrent administration of human parathyroid hormone (1-34) and incadronate disodium (YM175) . J. Bone Miner. Metab. 15:206-212, 1997

• 15) Isogai, Y., Akatsu, T., Ishizuya, T. et al.:Parathyroid hormone regulates osteoblast differentiation positively or negatively depending on the differentiation stages. J. Bone Miner. Res. 11:1384-1393, 1996
  pubmed

• 16) Hollnagel, A., Ahrens, M., Gross, G.:Parathyroid hormone enhances early and suppresses late stages of osteogenic and chondrogenic development in a BMP-dependent mesenchymal differentiation system (C3H10T1/2) . J. Bone Miner. Res. 12:1993-2004, 1997

• 17) Ishizuya, T., Uzawa, T., Takao, R. et al.:Parathyroid hormone inhibits differentiation of bon marrow adipocytes. J. Bone Miner. Res. 14:S209, 1999

• 18) Nishida, S., Yamaguchi, A., Tanizawa, T. et al.:Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone 15:717-723, 1994

• 19) Kostenuik, P. J., Harris, J., Halloran, B. P. et al.:Skeletal unloading causes resistance of osteoprogenitor cells to parathyroid hormone and to insulin-like growth factor-1. J. Bone Miner. Res. 14:21-31, 1999
  pubmed

• 20) Onishi, T., Zhang, W., Cao, X. et al.:The mitogenic effect of parathyroid hormone is associated with E2F-dependent activation of cyClin-dependent kinase (cdc2) in osteoblast precursors. J. Bone Miner. Res. 12:1596-1605, 1997
  pubmed

• 21) Jilka, R. L., Weinstein R. S., Bellido, T. et al.:Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. .Invest. 104:439-446, 1999
  pubmed

• 22) Ishizuya, T., Yokose, S., Hori, M. et al:Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J. Clin. Invest. 99:2961-2970, 1997

• 23) Canalis, E., Cehtrella, M., Burch, W. et al.:Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J. Clin. Invest. 83:60-65, 1989

• 24) Hock, J. M., Fonseca, J.:Anabolic effect of human synthetic parathyroid hormone-(1-34) depends on growth hormone. Endocrinology 127:1804-1810, 1990
  pubmed

• 25) Andress, d. L, Birnbaum, J.:Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. J. Biol. Chem. 267:22467-22472, 1992

• 26) Nasu, M., Sugimoto, T., Chihara, K.:Stimulatory effects of parathyroid hormone and 1,25-dihydroxyvitamin D3 on insulin-like growth factor-binding protein-5 mRNA expression in osteoblastic cells:the difference between transient and continuous treatments .FEBS Lett. 409:63-66, 1997
  pubmed

• 27) Linkhart, T. A., Mohan, S.:Parathyroid hormone stimulates release of insulin-like growth factor-I (IGF-1) and IGF-II from neonatal mouse calvaria in organ culture. Endocrinology 125:1484-1491, 1989
  pubmed

• 28) Pfeilschifter, J., Mundy, G. R.:Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc. Natl. Acad. Sci. USA 84:2024-2028, 1987
  pubmed

• 29) Klein-Nulend J., Pilbeam, C. C., Harrison, J. R. et al.:Mechanism of regulation of prostaglandin production by parathyroid hormone, interleukin-11 and cortisol in cultured mouse parietal bones. Endocrinology 128:2503-2510, 1991

• 30) Centrella, M., McCarthy, T. L, Canalis, E.:Parathyroid hormone modulates transforming growth factor β activity and binding in osteoblast-enriched cell cultures from fetal rat parietal bone. Endocrinology 85:5889-5893, 1988

• 31) drake, M. T., Baldassare, J. J., McConkey C. L. et al.:Parathyroid hormone increases the expression of receptors for epidermal growth factor in UMR 106-01 cells. Endocrinology 134:1733-1737, 1994
  pubmed

• 32) Chow, J. W. M., Fox, S., Jagger, C. J. et al.:Role for parathyroid hormone in mechanica responsiveness of rat bone. Am. J. .Physiol. 274:E146-E156, 1998

• 33) Ma, Y., Jee, W. S. S., Yuan, Z. et al.:Parathyroid hormone and mechanical usage have a synergistic effect in rat tibial diaphyseal cortical bone. J. Bone Miner. Res. 14:439-448, 1999

• 34) Kano, J., Sugimoto, T., Kanatani, M. et al.:Second messenger signaling of c-fos gene induction by parathyroid hormone (PTH) and PTH-related peptide in osteoblastic osteosarcoma cells:its role in osteoblast proliferation and osteoclast-like cell formation. J. Am. Physiol. 161:358-366, 1994

• 35) Mosekilde, L., Sogaard, C. H., danielsen, C. C. et al.:The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biochemical testing:Acomparison study between hPTH-(1-34) and hPTH-(1-84) . Epidemiology 129:421-428, 1991

• 36) Nasu, M., Sugimoto, T., Kano, J. et al:Carboxyl-terminal parathyroid hormone fragments stimulate type-Iprocollagen and insulin-like growth factor-bindillg protein-5 mRNA expression in osteoblastic UMR-106 cells. Endocr. J. 45:229-234, 1998

• 37) Nakaoka, D., Sugimoto, T., Kobayashi, T. et al.:Prediction of bone mass change after parathyroidectomy in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 85:1901-1907, 2000
  pubmed

• 38) Reeve, J., Meunier, P. J., Parsons, J. A. et al.:Anabolic effect of human PTH on trabecular bone in involutional osteoporosis:amulticenter trial. Br. Med. J. 280:1340-1344, 1980

• 39) Sone, T., Fukunaga, M., Ono, S. et al.:A small dose of human parathyroid hormone (1-34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis. Miner. Electrolyte Metab. 21:232-235, 1995

• 40) Fujita, T., Inoue, T., Morii, H. et al:Effect of intermittent weekly dose of a human parathyroid hormone (1-34) on osteoporosis. a randomized double-masked prospective study using three dose levels. Osteoporos. Int. 9:296-306, 1999
  pubmed

• 41) Finkelstein, J. S., Klibanski, A., Arnold, A. L. et al:Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34) . J. Am. Med. Associat. 280:1067-1073, 1998

• 42) Lane, N. E., Sanchez, S., Modin, G. W. et al.:Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis:Results of a randomized controlled Clinical trial. J. Clin. Invest. 102:1627-1633, 1998
  pubmed

• 43) Slovik, d. M., Rosenthal, D. I., Doppelt, S. H. et al.:Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 125-dihydroxyvitamin D. J. Bone Miner. Res. 1:377-381, 1986

• 44) Hodsman, A. B., Fraher, LJ., Watson, P. H. et al.:A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequehtial calcitonin to improve bone mass in post-menopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 82:620-628, 1997

P.505 掲載の参考文献

• 1) Marcelli, C., Yates, A. J., Mundy, G. R.:In vivo effects of human recombinant transforming growth factor beta on bone turnover in normal mice. J. Bone. Miner. Res. 5:1087-1096, 1990

• 2) dunstan, C. R., Boyce, R., Boyce, B. F. et al.:Systemic administration of acidic fibroblast growth factor (FGF-d prevents bone loss and increases new born formation in ovariectomized rats. J. Bone Miner. Res. 14:953-959, 1999

• 3) Harris, S. E., Bonewald, L. F., Harris, M. A. et al.:Effects of transforming growth factor beta on bone nodule formation and expression of bone morphogenetic protein 2, Osteocalcin, osteopontin alkaline phosphatase, and type I collagen mRNA in long-term cultures of fetal rat calvarial osteoblasts. J. Bone Miner. Res. 9:855-863, 1994

• 4) Chen, D., Harris, M. A., Rossini, G. et al.:Bone morphogenetic protein 2 (BMP-2) enhances BM-3, BMP-4, and bone cell differentiation marker gene expression during the induction of mineralized bone matrix formation in cultures of fetal rat calvarial osteoblasts. Calcif. Tissue Int. 60:283-290, 1997

• 5) Harris, S. E.:Recombinant bone morphogenetic protein 2 accelerates bone cell differentiation and stimulation BMP 2 mRNA expression and BMP 2 promoter activity in primary fetal rat calvarial osteoblast cultures. Mol. Cell. Diff. 3:137-155, 1997

• 6) Ghosh-Choudhury, N., Windle, J. J., Koop, B. A. et al.:Immortalized murine osteoblasts derived from BMP2-T-antigen expressing transgenic mice. Endocrinology 137:331-339, 1996
  pubmed

• 7) Rossouw, J. E., Lewis, B., Rifkind, B. M.:The value of lowering cholesterol after myocardial infarction. N. Engl. J. Med. 323:1112-1119, 1990
  pubmed

• 8) Law, M. R., Wald, N. J., Thompson, S. G.:By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Brit. Med. J. 308:367-372, 1994
  pubmed

• 9) Mundy, G., Garrett, R., Harris, S. et al.:Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-1949, 1999
  pubmed

• 10) Fisher, J. E., Rogers, M. J., Halasy, J. M. et al.:Alendronate mechanism of action:geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. Sci. USA 96:133-138, 1999
  pubmed

• 11) Russell, R. G. G., Rogers, M. J.:Bisphosphonates:From the laboratory to the Clinic and back again. Bone 25:97-106, 1999

• 12) Garrett, I. R., Escobedo, A., Mundy, G. R.:N2-containing bisphosphonates risedronate and ibandronate stimulate bone formation in organ culture. J. Bone Miner. Res. 14 (Suppl. 1):S525, 1999